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ACTH   adrenocorticotropic hormone 
ANOVA  analysis of variance 
AUC   area under curve 
a    the apparent first order distribution rate constant for two compartment model 
*a   factor of significance in Friedman’s non parametric test 
BDP    beclomethasone dipropionate 
BMD   bone mineral density  
BMI   body mass index 
BUA   broadband ultrasound attenuation 
BUD    budesonide 
ß    the apparent first order elimination rate constant for two compartment model 
Ce   concentration in the effect compartment 
COPD   chronic obstructive pulmonary disease 
CS(’s)   corticosteroid(s)  
CV   coefficient of variation 
D   dosis 
DEXA   dexamethasone 
DXA   dual energy X-ray absorptiometry  
E0  the effect value in the hypothetical situation that neither exogenous nor 
endogenous GC is present 
EC50   steady state plasma concentration at which 50% of Emax is achieved  
ECP   eosinophilic cationic protein 
EDTA   edetic acid  
Emax    maximal possible effect of a drug 
FEV1   forced expiratory volume in 1 second 
FLU    flunisolide 
FP    fluticasone propionate 
GABA   gamma amino butyric acid 
GC(’s)  glucocorticoid(s) 
G-CSF   granulocyte colony stimulating factor  
GM-CSF   granulocyte macrophage colony stimulating factor  
GRE’s   glucocorticoid-responsive-elements  
HC   hydrocortisone 
HECM   human epithelial cell conditioned media  
11 b-HSD   11 b-hydroxysteroid-dehydrogenase  
HPLC   high-performance liquid-chromatography  
5-HPETE   5-hydro-peroxy-eicosa-tetraenoic-acid 
IC50    concentration causing 50% survival inhibition 
ICS    inhaled corticosteroids  
Inf   infusion 
IL    interleukin   
IV  intravenously 
Ka   absorption rate constant 
Kel    elimination rate constant 
Kelcort   elimination rate constant for cortisol 
KelcortD   elimination rate constant for cortisol after administration of DEXA 
KelcortP  elimination rate constant for cortisol after administration of PRED 
LAßA  long acting ß2 agonist(s) 
LT    leukotrienes  
MS    mineralocorticoid  
nM    nanomolair  
OC    osteocalcin 
p   factor for statistical significance   
PAF    platelet aggregating factor  
PD    pharmacodynamic(s)   
PFT  pulmonary function test 
PHA    phytohemagglutinin    
PK    pharmacokinetic(s)  
PRED   prednisolone 
QUS    quantitative ultrasound  
RD   coefficient of determination for DEXA 
ROC    receiver operator characteristics 
RP   coefficient of determination for PRED 
RV   residual volume 
SAßA   short acting ß2 agonist(s) 
SD   standard deviation 
SRS-A   slow reacting substance of anaphylaxis  
SOS   speed of sound 
t ½    time in which the plasma concentration is diminished to 50% 
TAA    triamcinolone acetonide   
TAT    tyrosine-a-ketoglutarate-transaminase 
Thcell   T lymphocyte helper cell  
TGFß    transforming growth factor beta    
Tlag   lag time 
TLC   total lung capacity 
TNFa    tumour necrosis factor alpha 
V   volume 
VD   volume of distribution 
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Introduction 
 
Historical milestones 
In the nineteen thirties, researchers discovered the effects of hormones produced in the cortex of 
the adrenal gland. Extracts were firstly isolated in 1927 by the groups of Hartman, Hartman and 
Mc Arthur and Rogoff and Stewart in cats and dogs1,2. In 1932 Fineman described the use of this 
cortisol containing extract in the clinical management of bronchial asthma3. After the second 
world war, physicians started treatments with ACTH, later on followed by purified cortisone4,5. 
From 1951, various aerosolized glucocorticoid (GC) formulations were introduced, but with 
undesired systemic adverse effects. In 1972 Morrow, Brown, et al.. described the selective GC 
aerosol formulation beclomethasone dipropionate, with less systemic side effects when 
administered in a locally appropriate dose6. GC’s both inhaled and systemically administered, 
are at present well accepted as one of the core treatments for asthma and exacerbations of 
Chronic Obstructive Pulmonary Disease (COPD).  
 
Genomic and non genomic mechanisms of glucocorticoids (GC’s)  
Along with many other effects, GC’s encompass anti- inflammatory properties probably 
related to effects towards micro-vasculature and cells7,8,9. GC’s alter biological behaviour of 
T- lymphocytes involved in inflammatory cascades. Corticosteroids (CS) in general exhibit 
their pharmacological effects via genomic and non-genomic mechanisms. In accordance with 
the hypothesis of the genomic mechanism, lipophilic GC’s are believed to cross the cell 
membrane and to bind to the cytosolic GC-receptor, after which event two “heat shock” 
proteins are released. The GC-receptor-complex then passes through the nuclear membrane 
and binds to the glucocorticoid-responsive-elements (GRE’s) of the genomic DNA, followed 
by interaction with a nuclear transcription factor10,11,12. The duration of the aforementioned 
processes varies from 30 minutes to several hours. However, a number of pharmacological 
responses on GC’s and other CS’s are observed within seconds to minutes, which exclude 
genomic action and is therefore referred to as a nongenomic action. Non-genomic 
mechanisms are believed to take place through two modes of actions: interaction of CS’s with 
specific receptors or with non-specific proteins and/or membrane lipids. In addition, 
interactions have also been described between genomic and nongenomic mechanisms, thereby 
controlling genomic mechanisms through nongenomic mechanisms13.  
 
Influences of GC’s on inflammatory mediators in asthma 
 
Cytokines 
Many mediators of inflammation have been recognised to be involved in the pathophysiology of 
different inflammatory diseases involving the lung. Th2 lymphocyte expression, characterized by 
cytokine production appears to be predominantly present in asthma. To illustrate, cytokines are 
cellular proteins, involved in the regulation of cell function. The typical cytokine is a 
glycosylated protein, transiently secreted by a stimulated effector cell. Cytokine effects originate 
from binding to specific receptors on target tissues14. GC’s inhibit cytokine production of cells 
involved in the inflammatory cascade of asthma.  
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Leukotrienes 
Leukotrienes (cystenyl leukotrienes) are another series of peptides that are considered as 
inflammatory mediators in asthma. In 1938, Feldberg and Kellaway discovered a biological 
activity generated by the interaction between cobra venom and guinea pig lung tissue15. This 
biological activity was described initially as slow reacting substance of anaphylaxis (SRS-A), 
and was characterized later on in 1979 as: SRS-A = LTC4 + LTD4 + LTE416. 
GC’s inhibit the eosinophilic granulocyte in the production of LTC4 and PAF, through inhibition 
of of IL3, IL5 and GM-CSF production by T-lymfocytes, macrophages and endothelial cells
17. 
Direct inhibition by GC’s regarding arachidonic acid cascade has not been clearly 
demonstrated18,19.  
 
Current views on the clinical potencies of glucocorticoids  
 
Historical concepts 
Clinical potencies of GC’s and mineralocorticoids (MC) have been difficult to assess although 
classical approaches were accepted in clinical practice. The citation in Table 1.1  is an 
example of one of the historical concepts, extracted from one of the various textbooks20. Table 
1.1  shows the difference between GC’s and MC’s and suggests that clinical effectiveness of a 
GC is reflected by its potency to suppress cortisol production. By its differentiation of CS’s in 
GC and MC, already then the suggestion is made that different CS’s may have a different 
potency per target, however within the classification of GC or MC this difference in potency per 
target was not addressed. 
 
 
Drug 
 
Estimated 
potencies1 
 
Equivalent 'anti-
inflammatory' 
'effectiveness' 
(per nearest whole tablet) 
 
Daily Dose above which HPA 
axis suppression possible2 
 
(mg) 
 
Approx. 
plasma 
half-life 
(min) 
 
Biological 
half-life  
 
(hrs) 
 Gluco- 
corticoid 
Mineralo- 
corticoid  male female   
Cortisol 
(hydrocortisone)   1 1 20 mg 20-30 15-25 90 8-12 
Cortisone  0.8 0.8 25 mg 25-35 20-30 90 8-12 
Prednisolone 4 0.25 5 mg 7,5-10 7,5 200 or> 18-36 
Prednisone 4 0.25 5 mg 7,5-10 7,5 200 or> 18-36 
Methylprednisolone 5 +/- 4 mg 7,5-10 7,5 200 or> 18-36 
Triamcinolone 5 +/- 4 mg 7,5-10 7,5 200 or> 18-36 
Paramethasone 10 +/- 2 mg 7,5-10 7,5 300 or> 36-54 
Dexamethasone 25 +/- 0,8mg 1-1,5 2,5-5 300 or> 36-54 
Betamethasone 25-30 +/- 0,6mg 1-1,5 1-1,5 300 or> 36-54 
Aldosterone 0.3 400 - - - 30  
Fludrocortisone 
(flu-hydrocortisone) 10 300 - - - 200 or> 18-36 
 
Table 1.1.  Characteristics of some adrenocorticosteroid preparations 
1 Relative milligram comparisons to cortisol, setting the glucocorticoid and mineralocorticoid properties of 
cortisol as 1. Sodium retention is insignificant with usually employed doses of methylprednisolone, triamcinolone, 
dexamethasone and betamethasone. 
2 Intended as a guide only. The dose in an individual depends on total body surface area. The figures quoted are 
those which apply in general. (Adapted from Avery GS, Drug Treatment, 2nd edition, Churchill Livingsone, Eds. 
Edinburgh and London, p.530) 
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Assessment of potencies using various methods 
The potency of systemic effects of GC’s is frequently expressed as the ability to suppress 
cortisol production. Apart from this, another effect of GC’s, i.e. the suppression of 
inflammation, is not easily quantified. In clinical studies anti inflammatory efficacy of GC’s 
towards several target tissues and cells have been substituted by clinical outcome while 
laboratory studies, focussing at the potencies of GC’s, were expressed as influences on cellular 
biological processes and surrogate markers. A few examples are discussed below. 
 
In vitro studies 
  
Inhibition of PHA stimulated lymphocytes 
Cantrill et al. published a paper in 1975 were the potencies of three corticosteroids were 
compared21. CS concentrations, necessary to inhibit PHA stimulated lymphocyte transformation 
by 50%, were measured. Potencies of hydrocortisone (set as 1.00), prednisolone, and 
dexamethasone were determined in 16 patients and were 1.00, 2.43, and 24.7, respectively.  
   Langhoff et al. used a similar method, comparing methylprednisolone, betamethasone, 
dexamethasone, hydrocortisone, prednisolone, and aldosterone22. Three classes of potencies were 
distinguished i.e. very potent: methylprednisolone and betamethasone; intermediate potent: 
dexamethasone and prednisolone, and low potent: hydrocortisone and aldosteron. 
 
Competitive protein- binding radioassays 
Angeli et al. used competitive protein-binding radioassays in various species and at different 
dilutions of transcortin-bound cortisol23. By comparing corticosterone, 11-deoxycortisol and 
prednisolone in the various species, only the binding ability of corticosterone was found to be 
particularly dependent upon the species. 
 
Inhibition of cytokine production 
Snijdewint et al. investigated whether effects of GCs could be classified according to their 
distinct in-vitro effects on T lymphocytes classes by studying Th1- and Th2-type cytokine 
production24. In the assay used, GC’s concentrations in the range of 10-9 to 10-4M induced a 
class- and dose-dependent-inhibition of the production of both IFN-gamma and IL4.  
 
Eosinophilic granulocyte survival in supernatant  
Mullol et al. discovered that supernatants from epithelial cell cultures enhance eosinophil 
survival in vitro25. This effect could be abrogated by foregoing incubation of peripheral blood 
eosinophils with GC’s. Dexamethasone, methylprednisolone, deflazacort, and budesonide were 
tested in human epithelial cell conditioned media (HECM) obtained from healthy nasal mucosa- 
and polyp- cultures. Inhibitory potencies of the four steroids on the eosinophil survival index was 
compared using the concentration of each steroid that caused 50% survival inhibition (IC50). 
Methylprednisolone was the least potent (IC50 = 536nM), followed by deflazacort (IC50= 264nM) 
and budesonide and dexamethasone (both IC50=58nM), respectively. Notably, using the 
supernatant of nasal polyps revealed different steroid potencies i.e. methylprednisolone 
(IC50=546nM), deflazacort (IC50=390nM), dexamethasone (IC50=76nM), and budesonide 
(IC50=78nM). 
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In-vivo studies 
 
Skin-blanching test  
The most well known in-vivo test to determine the relative potencies of GC’s (Table 1.2) was 
the so called skin-blanching test by Mackenzie and Stoughton, which described 
vasoconstriction due to local application of GC’s26. The test correlated with human CS 
receptor half- life and binding-affinities27,28. Notably, a number of previously reported clinical 
trials have suggested that this skin-blanching test correlated fairly with various clinical 
efficacies (Table 1.2). However these studies did not address concentration-effect 
relationships29,30,31,32,33. Moreover, a more recent study disputed the correlation between the 
skin-blanching test and the effects on airway and systemic hyper-responsiveness of inhaled 
corticosteroids34. 
 
Drug Topical potency 
skin-blanching 
 (minutes) 
CS-receptor binding 
half-life  
(hours) 
CS-receptor binding 
affinity  
(hours) 
Beclomethasone dipropionate (BDP)  
Budesonide (BUD)  
Flunisolide (FLU)  
Fluticasone propionate (FP)  
Triamcinolone acetonide (TAA)  
600 
980 
330 
1200 
330 
7.5  
5.1  
3.5  
10.5  
3.9 
13.5  
9.4  
1.8  
18  
3.6 
 
Table 1.2.  Relative potencies of various GC’s according to the skin-blanching test compared to the receptor 
binding expressed as half life and affinity hours. Numbers are assigned in reference to dexamethasone, which 
has a value of "1" in the MacKenzie test.  
 
 
 
Suppression of cortisol production 
Downie et al.. performed a single-dose study to investigate the relative potency of predni-
solone and betamethasone in suppressing adreno-cortical function35. Betamethasone produced 
a more profound suppression of plasma cortisol than a supposed equivalent anti- inflammatory 
dose of prednisolone. 
 
Simultaneous determinations of systemic and topical effects  
In a study of McCubbin et al. local as well as systemic effects of inhaled beclomethasone-
dipropionate (50µg/puff), triamcinolone-acetonide (100µg/puff), and flunisolide (250µg/puff) 
were investigated, looking at inhaled allergen suppression and urinary cortisol excretion36. All 
three inhaled corticosteroids (ICS) were described ‘equipotent’ in the doses administered 
towards local and systemic effects. Notably these findings were not sustained by data revealing 
concentration effect relationships and would have been different after correction for first pass 
effects of ICS in the liver37. Pharmacodynamic and pharmacokinetic (PK/PD) modelling studies 
of inhaled ICS are needed to overcome obvious confounders. 
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Ex vivo studies 
Distinct actions of CS on different effector organ systems have been previously reported. 
Monder et al. investigated 11b-hydroxysteroid-dehydrogenases (11 b-HSD) production in 
Leydig cells in rat, dictating local GC’s concentrations, which are related to testosterone 
secretion38. This group reported a half-maximal inhibition of testosterone production for 1.5nM 
dexamethasone and for 0.4µM corticosterone. Notably, several compounds (i.e. glycyrrhetinic 
acid and mifeprestone) exhibit distinct inhibitory actions on local cortisol concentrations via the 
11 b-HSD-system. It appeared, therefore, that the state of activation of local factors is of 
considerable importance to understand differential CS’s potencies. 
 
Outline of the studies in this thesis 
 
In this thesis, pharmacological (part 1) and clinical effects (part 2) of CS’s or more explicitly 
GC’s are explored. In part one, PK/PD-modelling studies were performed to illustrate some 
genuine genomic actions and differential potencies of GC’s towards different targets and 
human studies were conducted to illustrate differential clinical effects of GC’s towards 
different endpoints (surrogate markers). In part two, studies in humans were conducted 
showing clinical outcome of various glucocorticoid treatment regimens and an alternative 
method of detection of (glucocorticoid induced) osteoporosis was investigated. 
 
In Chapter II, effects of hydrocortisone on the plasma tyrosine concentrations and 
lymphocyte counts (both genomic targets for GC’s) were studied in healthy subjects, in order 
to test the hypothesis, that plasma tyrosine can be used as a marker for GC concentration 
effect relationships, e.g. clinical potency.  
In Chapter III, a clinical model for inflammation was applied using GCSF-stimulated 
Eosinophilic Cationic Protein (ECP) concentrations in healthy men. This model was used to 
compare the biological effects of different CS’s, in assumed equipotent doses towards adrenal 
suppression, on the concentrations of surrogate markers of adrenal function, bone metabolism 
and inflammation. The hypothesis that GC’s in assumed equipotent doses might act differently 
towards these biological targets, was tested. 
In Chapter IV, pharmacokinetic (PK) and pharmacodynamic (PD) modelling studies were 
performed to show that different CS’s, in classically accepted equipotent doses, display 
different concentration-effect relationships against different targets.  
In Chapter V, a cross-sectional study was conducted among healthy men and pre-menopausal 
women, analyzing the relationships between the cumulative dose of this, infusion resembling, 
administration of methylprednisolone (repetitive depots epidurally) with that of bone mineral 
density (BMD) outcomes. We tested the hypothesis that GC induced osteoporosis is not 
correlated with the cumulative dose in case of a long lasting continuously low-dose 
administration. 
In Chapter VI, a case-finding strategy for the detection of osteoporosis with heel quantitative 
ultrasound (QUS) in pre- and postmenopausal women visiting the outpatient clinic for 
pulmonary diseases, was studied. Correlations of QUS and BMD outcomes were compared in 
women before and after menopause. We tested the hypothesis that an easy accessible and 
reliable diagnostic method for detecting osteoporosis compared to the golden standard is thus 
far not available. 
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In Chapter VII, bone densitometry measurements of a group of male COPD patients after 
treatment with different GC’s regimens, were compared. The results were expressed as BMD 
adjusted for age, disease, and the total cumulative GC’s dosis previously administered. We 
tested the hypothesis that the cumulative dose of GC’s in the development of GC induced 
osteoporosis is regimen-dependent. 
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Abstract 
 
Objective: During steroid therapy, plasma tyrosine concentrations are lowered due to 
induction of tyrosine amino transferase. Lymphocytopenia is considered to be a nongenomic 
effect of corticosteroids. The objective of this study was to test the hypothesis that both 
genomic and nongenomic effects of Hydrocortisone (HC) can be described by essentially the 
same physiologic model by pharmacokinetic-pharmacodynamic (PK/PD) modelling. 
Methods: Seven healthy subjects were studied for two 24-hours period during which they 
received either no drug or 300mg HC orally. 
Results: Plasma tyrosine decreased by a mean maximum 15% on the control day and by 50% 
on the test (HC) day. Lymphocyte counts decreased by a mean maximum of 30% on the 
control day and by 75% on the test day. Tyrosine nadirs were seen on average, two hours later 
than those of lymphocyte counts. The mean estimated plasma concentration of HC that gives 
50% of the maximal attainable drug effect (EC50) was 378±186mg/L for increased plasma 
tyrosine levels. The plasma concentration giving 50% lymphocyte inhibition (IC50) was 
142±42mg/L. The effects on the control day could be fitted to essentially the same 
physiological model, with identical parameter values, as on the HC day. 
Conclusions: Spontaneous diurnal variations in levels of plasma tyrosine and lymphocyte 
counts under controlled conditions can be described by fluctuations in endogenous levels of 
HC. These effects may be used as an indicator of the actions of exogenous corticosteroids, 
which may allow the study of concentration dependencies of genomic and nongenomic effects 
for a variety of corticosteroids. 
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Introduction 
 
Corticosteroids have a wide range of physiological and pharmacological effects. Their 
mechanisms of action can be divided into two types: genomic (gene-mediated effects or so 
called indirect effects) and nongenomic effects (non-gene-mediated or so called direct 
effects).  Decreases of plasma tyrosine and blood lymphocyte levels after administration of 
corticosteroids are respective examples1-3. The principal objective of this study was to test the 
hypothesis that hydrocortisone (HC) concentration-effect relationships for both genomic and 
nongenomic effects can be estimated using the same physiologic model by pharmacokinetic-
pharmacodynamic (PK/PD) modelling. 
   The level of tyrosine in plasma is an easily accessible and measurable marker of 
corticosteroid action4. This aromatic amino acid is either synthesized from phenylalanine or 
absorbed after food intake in humans. Tyrosine is a precursor of thyroxine, and hydroxylation 
of tyrosine is the first step in the formation of either DOPA, which is converted to adrenaline 
(via dopamine) and noradrenaline or melanin. However, tyrosine is mainly degraded to 
fumarate and acetoacetate. The first step of this degradation pathway is the transamination of 
tyrosine in p-hydroxyphenylpyruvate by the tyrosine amino transferase enzyme tyrosine-a-
ketoglutarate- transaminase (TAT)5. In addition to auto- induction by its substrate, this enzyme 
is induced by cortisol.  
   Tyrosine amino transferase and the influence of corticosteroids on its activity has been 
studied extensively (mainly in rats). PK/PD modelling of this effect of corticosteroids has 
been carried out in rat, with results of ex vivo measurements in rats3. In one study, the 
relationship between cortisone and tyrosine was investigated in humans1. Cortisone 300mg 
administered in divided doses over 24 hours reduced plasma tyrosine levels within 24 hours 
of administration. These results were compatible with corticosteroid-mediated induction of an 
enzyme (most probably tyrosine aminotransferase)6,7. Corticosteroid- induced lymphopenia is 
regarded as a direct effect, although the precise mechanism of action is not known8. It should 
also be noted that both plasma tyrosine levels and lymphocyte counts show diurnal rhythm9,10. 
   Corticosteroids are widely used in the treatment of inflammatory disease, with rapid onset 
of therapeutic effect in many instances [within hours (e.g. anaphylactic reactions) to days (e.g. 
systemic lupus erythematodus)]. Adverse reactions, however, tend to become apparent much 
later (e.g. osteopenia). The identification of quantifiable markers of activity early in long-term 
treatment regimens could be useful in the identification of the lowest effective dose or in the 
optimization of dosage schedules when corticosteroids are combined with other drugs (e.g. 
with ß2 agonists in  asthma11) in order to minimize the risk of late adverse reactions. 
   In vivo studies on kinetics and action of corticosteroids with the help of PK/PD modelling 
techniques have provided insight into many aspects of the effects of this class of drugs, with 
the disappearance of lymphocytes or other leukocytes from the blood being predominantly 
used12,13. The direct concentration dependency of these effects indicated that they are most 
likely not gene-mediated13,14. We are not aware of studies carried out in vivo of gene-
mediated effects of corticosteroids in humans with linkage of pharmacokinetics and 
pharmacodynamics. The physiological model of Jusko describes the action of corticosteroids 
by the kinetics of the corticosteroid receptor and its ligand in the nucleus and resulting 
changes in TAT concentrations15,16. Various other indirect response models allow 
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quantification of the effects of corticosteroids17,18. HC was chosen as the test drug in this 
study, because this particular glucocorticoid is identical to the endogenous hormone cortisol 
(and therefore has the same kinetic and dynamic behavior). This facilitates the linking of 
observed effects with plasma concentrations corticosteroid, because concentrations of 
endogenous and exogenous compound in the plasma can simply be added to give a single 
result that can be used to determine concentration-effect relationships. 
 
Methods 
 
Participants 
Seven healthy Caucasian male students (age range 19-21 years) with no medical history of 
note participated in the study. The participants were asked to avoid strenuous exercise the day 
before the test and to maintain a normal sleep pattern the week before the study.  
   Inclusion criteria were no abnormal findings after routine physical examination or routine 
blood testing (full blood count and blood levels of glucose, sodium, potassium, AST, ALT 
and creatinine), and an uneventful history. Exclusion criteria were the use of medication or an 
acute medical problem in the preceding 3 months, and a history of illness or symptoms that 
were judged to be relevant. Smoking and alcohol other than for social use were also exclusion 
criteria. Written informed consent was obtained from all participants.  
 
Study design 
The study had an open, randomized, crossover design. On the test day 300mg hydrocortisone 
was administered as a single oral dose. On the control day no drug was given. The 2 days 
were at least 1 week apart. The participants drank only tap water from the night before until 
the end of the experimental day, and also refrained from eating during that period.  
 
Study procedures 
The study was approved by the Institutional Review Board. The participants arrived at the 
department of Clinical Pharmacology at 5.45 am. Participants remained comfortably seated by 
day and slept in the research unit of the department at night.  A green VenflonÒ cannula was 
inserted in the forearm from which baseline and subsequent  plasma samples were obtained. 
The cannula was kept patent with a 10 U/ml heparin solution and the experimental period 
lasted until 6:30 the next morning. On one of the two days at 6:30 am 15 tablets of HC 20mg 
were swallowed with 2 glasses of water at 6:30 am, and blood samples were drawn 0.25, 0.50, 
1, 1.5, 2, 3, 4.5, 5.5, 7, 8, 9, 11, 12.5, 14, 16, 18, 20, 22, 24 hours after the drug intake 
ingestion. Samples of 3 ml in edetic acid (EDTA) were used for lymphocytes measurement, 
and 10 ml samples were collected in heparin for tyrosine and HC measurements. EDTA 
samples were forwarded immediately to the clinical chemistry laboratory of the hospital; the 
heparinised samples were centrifuged and the plasma stored at -200C immediately after 
collection. HC and tyrosine determinations were carried out by the department of clinical 
pharmacology.  
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HC assay 
Hydrocortisone was assayed by high-performance liquid-chromatography (HPLC) with UV 
detection (method as published by Rose and Jusko19 with the modifications as described by 
Oosterhuis et al.20. Intra- and inter-assay coefficients of variation were approximately 7%. 
The lower limit of detection was 20ng per ml of serum. 
 
Tyrosine assay 
The tyrosine was assayed by HPLC with electro-chemical detection as described by Edwards 
et al.21. The intra- and inter-assay coefficients of variation were approximately 2%. The lower 
limit of detection was 1mg per ml of serum. 
 
Data analysis 
A model based on that of Koopmans et al. was used to describe the kinetics of HC22. This 
model has been shown to describe accurately the time course of plasma concentrations of 
exogenous HC after administration. The plasma corticosteroid concentrations versus time 
curves on the control day were fitted to a polynomial function. The results obtained were used 
as the basis of the concentration - effect model, for which the 'link' was made for both effects 
(lymphocyte lowering and tyrosine lowering as a result of hydrocortisone) by in essentially 
the same physiological model (as previously published by Jusko et al.15). Briefly, this model 
describes the influence of a drug on either an input (the zero-order constant for production of 
the response variable) or output rate (the loss of the response variable) of an effect parameter, 
or both. This influence can either be an inhibition or an increase of the rate.  
   The relationship of the plasma drug concentration and the rate constant was empirically 
described with an Emax formula. Control day and experimental day data were fitted 
concurrently, using common parameter values. Goodness of fits was judged by correlation 
coefficients and visual inspection. 
 
Pharmacokinetics 
 
Hydrocortisone on experimental day 
The exogenous HC data were modelled with a one compartment linear pharmacokinetic 
model with lagtime (Tlag) [h] for a single oral dose (Equation   2.1).  
 
HCexo = (Dose*Ka) / [Volume/f*(Ka-Kel)]*[ e
- Kel* (T-Tlag) – e-Ka* (T-Tlag)]         Equation  2.1 
where Ka (h
-1) is the absorption rate constant; f is the fraction of the dose that is available 
systemically, and Kel (h
-1) is the elimination rate constant22. Volume of distribution (L) 
incorporates f, giving V/f instead of V. Endogenous HC production was assumed to cease at 
the time of absorption  (T=Tlag) of the exogenous compound, immediately after which 
endogenous HC is eliminated at the same rate as estimated: 
 
If T < Tlag: HCendo 1 = HCT=0  
 
If T > Tlag: HCendo 1 = HCT=0 *e –Kel*(T-Tlag)                    Equation  2.2 
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Cortisol only returns to its baseline production rate when the exogenous administered 
hormone has been almost entirely eliminated23. The reappearance of endogenous HC 
approximately 24 h after administration was modelled as an intravenous infusion that started 
at Tstart. In most participants, HC could be detected again only in the last blood sample. Tstart 
was therefore estimated by fitting the kinetic and dynamic data together to find the time that 
resulted in the best fit (Equation  2.3, Figure 2.1.).  
 
     endo HC 
        (Tlag – Tstart) 
    infusion   
     exoHC     
Ka     Kel 
 
Figure 2.1. Hydrocortisone plasma concentration (HC) as a result of input of exogenous and endogenous 
hydrocortisone (exo HC and endo HC) and elimination. Exo HC= administered dose of  hydrocortisone; Ka= 
absorption rate constant of exo HC; endo HC= endogenous hydrocortisone; infuse= infusion rate constant with 
which endo HC appears in the circulation; Tlag= lagtime, i.e. time between drug administration and the start of 
drug absorption; Tstart= time at which the infusion of endo HC is switched on again. 
 
If T > Tstart: HCendo 2 = Infusion/(Volume * Kel)(1-e
-Kel (T-Tstart ))              Equation  2.3 
The total measured plasma concentration of HC was the sum of 3 HC time curves given in 
Equation 2.4. The parameters were estimated by the nonlinear fitting program ScientistÒ24 for 
exogenous HC (Equation 2.2.).  
 
HC = HCendo 1 + HCendo 2 + HCexo                  Equation  2.4 
Hydrocortisone on control day 
The curve of endogenous HC concentration versus time on the control day, when variations in 
concentrations are caused by a variable but unknown production rate, was described by a 
polynomial equation (Equation  2.5). The order necessary to describe the data was found by 
visual inspection. 
 
HC = C + C1 * T + C2 * T
2 + C3 * T
3  and so on.               Equation  2.5 
  
HC 
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Pharmacodynamics 
 
Lymphocyte and tyrosine depletion were expressed with differential equations describing 
models in which the influx and output rate constants are influenced by HC concentration 
according to a sigmoid Emax formula. These models are based on physiologic models as 
described by Jusko25. We have introduced a modification to allow rate constants to be 
influenced directly by HC concentrations according to an Emax formula. The data were fitted 
to the models with the nonlinear fitting program ScientistÒ24. Common dynamic parameter 
values were used (except for tyrosine input rates and baseline values for lymphocyte levels) 
for both study days. For each person the time courses of the two effects were fitted 
simultaneously. 
   Differences between EC50 (HC concentration in steady-state that results in 50% of the 
maximal inducible effect) values for the effect of HC on disappearance of tyrosine or IC50 
(HC concentration in steady-state that results in 50% of the maximal obtainable inhibition) 
values for lymphocyte appearance and the elimination rate constant values for tyrosine (Kdis 
and KdisHC) and the linear efflux rate constant (Keff) for lymphocytes were tested with the 2-
sided t-test for paired data. Correlation coefficients were compared with the Wilcoxon non 
parametric test. 
 
Lymphocytes 
It was assumed that lymphocytes are being lost from the circulation with a linear rate constant 
and that the constant influx is controlled by HC concentration2,25,26. Thus, the lymphocyte 
count (L-1) was described by Keff (h
-1), and a constant influx (Inmax), that was controlled by 
HC concentration according to Equation  2.6.  
 
 
Lymphocyte¢ = Inmax * { 1 – [HCN / ( IC50N + HCN)]} – Keff * Lymphocyte       Equation  2.6 
At T=0: E=E0 on the HC day; E= E0 control on the control day   
 
The influx, Inmax, is influenced by HC according to a sigmoidal Emax formula, with IC50 
(mg/L) being the plasma concentration that gives 50% drug effect (inhibition) and with a 
maximal influx with zero HC concentration and no influx with high HC concentration. N is 
the sigmoidicity factor that determines the steepness of the concentration versus effect curve. 
The baseline values E0 (lymphocyte count at the time of drug administration) for the 
lymphocytes at T=0 were estimated by ScientistÒ as a parameter. E0 was estimated separately 
for the control day (E0control) and the hydrocortisone day (E0).  (Figure 2.2) 
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[1-HCN / (IC50N + HCN)] 
 
 
          Inmax         Keff 
 
Figure 2.2. Lymphocyte count in plasma (LYMFOCYTE) as a result of influx and efflux of cells. 
Inmax= influx rate of lymphocytes, which is controlled by the hydrocortisone plasma concentration (HC) via an 
Emax formula; N= sigmoidicity parameter; IC50= HC concentration in steady-state that results in 50% of the 
maximal obtainable inhibition; Keff= rate constant of the decrease of lymphocyte count. 
    
Tyrosine 
As there was no dietary intake, it was assumed that tyrosine was being formed at a constant 
rate before exogenous HC administration, and that its disappearance was controlled by HC 
concentration as described previously.1,27 We did not observe a time delay between an 
increase of HC in the circulating HC and the start of the decline in levels of tyrosine. An 
immediate but slow modulation of the tyrosine disappearance rate described the data 
satisfactorily.  
  Plasma tyrosine levels were described by a constant influx, Input (h-1), a constant linear 
efflux rate, Kdis (h
-1), and an efflux rate, KdisHC (h
-1), that was influenced by HC according to 
a sigmoidal Emax formula; EC50 (mg/L) is the plasma HC concentration giving 50% of the 
maximum drug effect. N is the sigmoidicity factor that determines the steepness of the drug 
concentration versus the effect curve. Zero drug concentration gives no drug induced efflux 
and high HC concentration maximal induced efflux (Equation  2.7).  
 
Tyrosine' = Input - Tyrosine * {Kdis + [KdisHC * HC
N / (EC50
N + HCN)]}           Equation  2.7 
At T=0: Tyrosine = Input / Kdis. On the control day Input is denoted by Inputcontr. 
In contrast to the lymphocyte counts, tyrosine at the start of each day (Tyr0) was not based on 
the measured baseline value. This was because the tyrosine measurements showed larger 
variations than lymphocyte determinations. In view of the low endogenous HC concentrations 
in the preceding period and a delayed response, tyrosine at T=0 was assumed to be at steady 
state, and therefore equal to the ratio of input rate and efflux rate (disregarding the amount of 
endogenous cortisol present at that time). The baseline values for the tyrosine, Tyr0, were thus 
calculated by ScientistÒ as Input divided by the Kdis. Input was estimated separately for the 
control day (Inputcontr) and the HC day (Input) (Figure 2.3). 
 
  LYMPHOCYTE 
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             HCN / (EC50 + HC
N) 
 
 
    Input      KdisHC 
 
 
          Kdis 
 
Fig 2.3. Tyrosine plasma concentration (TYRO) as a result of production and degradation of tyrosine. 
Input= the production rate of tyrosine; Kdis= degradation rate of tyrosine, which is independent of hydrocortisone 
(HC); KdisHC = degradation rate of tyrosine, which is controlled by HC via an Emax formula; N= sigmoidicity 
parameter; E50= HC concentration in steady-state that results in 50% of the maximal inducible effect. 
 
Statistics 
 
Comparisons between parameters were carried out with the Wilcoxon signed rank test. A 
value of p£0.05 was used to show statistically significant differences. No power calculation 
was done in order to find the number of participants necessary to show certain effects, as this 
was a hypothesis testing study only. 
 
 Results 
 
Although the experimental procedure on the test days was somewhat demanding for the 
participants, no untoward events were reported.  
  The order of the polynomial function necessary to describe the HC data on the control day 
varied for the seven subjects from 6 to 9. The coefficients of correlation as indicators of the 
goodness of fit were similar under these conditions and not statistically significantly different 
(p>0.05) from those on the HC day. 
   The pharmacokinetic parameters for HC as estimated on the HC day by using Equation  2.4 
are given in Table 2.1 together with the correlation coefficients for both days. The measured 
concentrations and the fitted curves of hydrocortisone on the control and HC day of a 
representative participant (p.3) are shown in Figure 2.4. 
   The plasma tyrosine level at the start of each day (Tyr0) was not  based on the measured 
baseline value, but was assumed to be at steady state, and therefore equal to the ratio of input 
rate and efflux rate (disregarding the amount of endogenous cortisol, present at that time). 
Calculating Tyr0 while taking into account the assumed effect of cortisol, did not lead to 
better fits, but resulted in an underestimation of the measured tyrosine concentrations at T=0 
and in EC50 values, that were un-physiologically high, and made it impossible to fit the 
tyrosine of the control and HC days with common parameters. 
   Pharmacodynamic parameters for the effect of hydrocortisone on lymphocyte counts are 
TYRO 
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given in Table 2.2 With the same parameters for both days, the goodness of fit was similar 
(p>0.05). A representative curve is presented for p.3 in Figure 2.5. 
   Pharmacodynamic parameters for the effect of hydrocortisone on plasma tyrosine con-
centrations are given in Table 2.3 With the same parameters for both days the goodness of fit 
was less than on the HC day (p<0.02). A representative curve is presented for p.3 in Figure 
2.6. 
   The EC50 for the effect of HC on plasma tyrosine level differed from IC50 value for the 
effect on lymphocyte counts (p=0.02). For the effect on tyrosine the Input differed from the 
Inputcontr (p=0.01), i.e. the baseline values were different. The mean measured baseline values 
for tyrosine were 12.4mg/L on the experimental (HC) day and 11.3mg/L on the control day 
(p=0.15). The mean time at which the first blood samples were taken on the HC and the 
control days were 6:29 am and 6:49 am respectively (p=0.18). The estimated baseline 
lymphocyte count for the HC day (E0) did not differ from that for the control day (E0pl) 
(p=0.46). 
   The measured effect points and the fitted effect versus t and tyrosine levels on the control 
and HC days are shown for a representative participant (p.3.) in Figure 2.5 and Figure 2.6, 
respectively. The steady-state concentration-effect relationships for both effects, calculated 
with mean parameter values from all participants are shown in Figure 2.7. 
   The comparisons of the goodness of fit for the lymphocyte counts and for the tyrosine levels 
were different in the HC and the control day. On the control day, the correlations for the 
lymphocyte count curves and the tyrosine level curves were similar (p>0.05). On the HC day, 
the correlation for the tyrosine level curves for the various individuals were less than the 
correlations for the lymphocyte count curves (p<0.05). 
 
Discussion 
 
Although we did not include possible underlying physiological processes (e.g. modulation of 
GC receptors 3,16,18) our models described the dynamic data adequately. 
   In variations in lymphocyte counts and the plasma tyrosine levels on the control day could 
be linked to the plasma cortisol concentration. The good fits of the two effects on both days 
using identical effect models with common parameter values support the premise that all 
observed responses can be attributed to plasma HC concentrations. The concentration-effect 
relationships suggest that steady-state HC blood concentrations above 2000mg/L give only 
minimal increases in measured responses. 
   Plasma HC concentrations on the control day showed somewhat variable plasma 
concentrations that were not described well by a polynomial equation as plasma HC 
concentrations on the test day by a one compartment pharmacokinetic model. Both the 
spurious concentration-time course and the low concentrations in the range of the EC50 values 
will have contributed to the fact that the fits of the effects on the cortisol day were less good. 
A placebo was not used on the control day as we did not expect a placebo to influence our 
hypothesis testing, nor did we expect it to have a large (if any) effect on the objective 
parameters. 
   The so called indirect model that we used, which is based on certain physiological 
assumptions, appeared to be capable of describing both genomic and presumably nongenomic 
corticosteroid effects. In the model HC inhibits the input of lymphocytes in the blood and the 
disappearance of tyrosine from the blood. The output of the lymphocytes, the input of tyrosine 
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and the HC-independent disappearance of tyrosine were assumed to be constant. Since the 
participants had not eaten for at least 7 hours, it was assumed that only a steady baseline 
endogenous tyrosine production remained. The less important route of degradation of tyrosine 
that does not use the amino transferase enzyme (which is influenced by HC) was also thought 
to stay unchanged. 
   In addition to diurnal variation in lymphocyte levels and the lymphocytopenia observed 
after exogenous corticosteroid administration, transient lymphocytopenia is known to occur as 
a result of increased corticosteroid plasma levels in stressful situations and in acute infections. 
If such a response had occurred during our study, then this would have been partly 
incorporated in our model, as the altered cortisol pattern would have been fitted. Absolute 
lymphocytosis is often observed as part of the immune response in association with viral and 
other infections. 
   In contrast to lymphocyte counts, tyrosine at the start of each day (Tyr0) was not based on 
the measured baseline value because tyrosine measurements showed a greater variation than 
lymphocyte counts (as shown by the data on the control day). This was because Tyrosine at 
T=0 was assumed to be at steady-state and an imprecise tyrosine concentration at T=0 could 
have had an unacceptable large influence on the rate constants.  
   The assumption that tyrosine at T=0 was at stead-state and thus equal to the ratio of input 
rate and efflux rate while not accounting for the amount of endogenous cortisol, present is 
justified by the low endogenous HC concentrations in the preceding period and a delayed 
response. The assumption that the same HC concentrations at T=0 were present in the 
preceding period would result in an overestimation. These assumptions were further justified 
by the fact that calculation of Tyr0, taking into account the assumed effect of cortisol, did not 
lead to better fits, but resulted in under estimation of the measured tyrosine levels at T=0 and 
excessive EC50 values, and made it impossible to fit the tyrosine of the control day and the 
HC day with common parameters. 
   Furthermore, during the first one and an half hour after administration, the mean curve for 
all participants showed very little change in plasma tyrosine levels both on the control and the 
HC days.  
   From this study it is not possible to tell if both effects indeed differ with respect to the 
mechanism of action of corticosteroids. From studies in rats in which the relation between 
TAT in liver biopsies and tyrosine plasma concentrations were described, it may be expected 
that the tyrosine change we observed is also a DNA mediated (genomic) effect. Efficiency of 
TAT induction has been shown in rat to be more closely related to corticosteroid receptor 
occupancy than to plasma corticosteroid concentrations, and to the time required for mRNA 
and the TAT enzyme to readjust to baseline conditions28,29. From the observed tyrosine data, 
it appears that plasma tyrosine levels decrease rapidly after HC concentration increase. The 
maximum tyrosine effect was reached on average 8 hours after the HC concentration peak. 
The lymphocyte effect which also seems to start directly after HC administration, but is more 
rapid than the tyrosine effect, had its nadir 2 hours earlier on average. The mechanism behind 
decreased lymphocyte counts is not known, but is thought to be a direct effect. 
   It would be useful to know whether the efficacy of corticosteroids can be studied by two 
effects that supposedly represent the mechanisms of action of these agents and their role in the 
treatment of diseases. If so, these effects could serve as surrogate markers of efficacy, and 
differences in potency between corticosteroids could be studied. Plasma tyrosine levels can be 
used as a surrogate marker of presumably indirect effects of corticosteroids. It has been 
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suggested that free blood tyrosine levels reflex the whole body glucocorticoid activity at the 
cellular level (in a manner similar to blood glucose levels in relation to insulin)30. Since 
tyrosine is a marker of metabolism, influenced by protein and glucose uptake, strict fasting 
must be observed for reliable parameter estimation in the acute studies, while during long-
term follow-up, an overnight fast might be sufficient for effects to be monitored. This marker 
can also be used in studies in healthy volunteers. 
   The metabolism and plasma level of tyrosine are dependent  on several factors. Plasma 
levels of tyrosine vary directly with dietary content9,31. Insulin, and (indirectly) glucose 
interfere with the reduction in tyrosine plasma levels, which show diurnal rhythm with a 
trough occurring around 3 p.m. in humans9. Tyrosine monitoring is potentially useful the 
design of corticosteroid dosage regimens in patients, especially in long-term treatment in 
which markers of outcome of disease are often difficult to establish. 
Chapter II: PK/PD modelling of cortisol effects 
 34 
 
 
 
 
 
Table 2.1. Estimated pharmacokinetic parameters for HC. Contr corr.= correlation coefficient of fit of hydrocortisone 
concentration on control day; f= fraction of dose available systemically; Geomn= geometric mean; HC corr.= correlation 
coefficient of fit of hydrocortisone on experimental day; HCt = 0 = hydrocortisone plasma concentration at time of drug 
administration; Infus= infusion rate of endogenous hydrocortisone;Ka= absorption rate coinstant; Kel= elimination rate 
constant; SD= standard deviation; Tlag = lagtime; Tstart= start time. 
Participant 1 2 3 4 5 6 7 mean SD geomn 
Ka  (h -1) 2.44 2.42 9.57 5.72 1.53 2.78 8.37 4.69 3.22 3.80 
Kel  (h -1) 0.42 0.39 0.33 0.42 0.36 0.43 0.52 0.41 0.06 0.41 
Volume/f (L) 44 67 104 67 60 91 46 69 22 66 
Tlag (h) 0.23 0.40 0.24 0.05 0.11 0.01 0.38 0.20 0.15 0.12 
HCt=0 (mg/L) 85 207 229 146 245 168 231 187 58 178 
Infus (mg/h) 1902 4367 10777 2293 3528 3053 4951 4410 3006 3776 
Tstart (a.m.) 5.2 5.3 5.4 4.8 5.5 4.9 4.6 5.1 0.4 5.1 
HC corr. 0.98 0.99 0.93 0.97 1.00 0.94 0.82 0.95 0.06  
Contr corr. 0.60 0.86 0.86 0.91 0.96 0.91 0.90 0.86 0.12  
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Participant 1 2 3 4 5 6 7 mean SD geomn 
E0 (109/L) 2.3 3.4 2.1 2.9 2.0 2.4 2.0 2.4 0.5 2.4 
E0 control(109/L) 1.8 3.7 2.4 3.4 2.0 2.4 2.0 2.5 0.8 2.5 
Inmax (h -1) 0.64 1.45 0.81 1.06 0.67 0.88 1.05 0.94 0.28 0.90 
Keff (h -1) 0.26 0.44 0.33 0.36 0.27 0.37 0.33 0.34 0.06 0.33 
IC50 (mg/L) 115 104 155 153 189 194 86 142 42 137 
N 3.0 1.6 1.6 0.9 1.8 1.7 1.2 1.7 0.7 1.6 
HC corr. 0.97 0.99 0.99 0.99 0.98 0.96 0.99 0.98 0.01  
Contr corr. 0.94 0.94 0.93 0.93 0.68 0.74 0.84 0.86 0.11  
 
Table 2.2.  Estimated dynamic parameters for HC induced lymphocytopenia. E0: lymphocyte count at t=0 on the HC day; 
E0control: lymphocyte count at t=0 on the control day; Inmax: constant lymphocyte influx controlled by HC concentration; Keff: 
efflux rate constant of lymphocytes. IC50: HC concentration in steady-state that results in 50% of the maximal obtainable 
inhibition; N: sigmoidicity factor that determines the steepness of the concentration versus effect curve; HC corr. and contr 
corr.: correlation coefficient of fit on the HC day and the control day, respectively. 
 
 
 
Participant 1 2 3 4 5 6 7 mean SD geomn 
Input (h -1) 4.56 6.01 0.88 0.71 1.99 1.28 2.64 2.58 2.00 1.97 
Inputcontr (mg/L)  4.07 5.95 0.63 0.67 1.59 1.16 2.36 2.36 1.98 1.74 
Kdis (h -1) 0.46 0.40 0.07 0.06 0.20 0.10 0.15 0.21 0.16 0.15 
KdisHC (h -1) 0.18 0.23 0.16 0.09 0.05 0.08 0.25 0.15 0.08 0.13 
EC50 (mg/L) 450 32 392 268 486 395 620 378 186 292 
N 1.4 0.6 1.3 1.9 0.4 0.4 0.4 0.9 0.6 0.7 
HC corr. 0.74 0.85 0.99 0.93 0.70 0.87 0.98 0.87 0.11  
contr corr. 0.57 0.69 0.87 0.61 0.69 0.85 0.85 0.73 0.12  
 
Table 2.3.   Estimated dynamic parameters for tyrosine lowering effect of HC. Input and Inputcontr : constant influx of 
tyrosine on HC day and control day, respectively; Kdis: constant linear efflux rate of tyrosine; KdisHC: constant linear efflux 
rate of tyrosine influences by HC; EC50: plasma HC concentration giving 50% of the maximum drug effect; N: sigmoidicity 
factor that determines the steepness of the drug concentration versus the effect curve; HC corr. and contr corr.: correlation 
coefficient of fit on the HC day and the control day, respectively. 
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Figure 2.4.  Representative fits of hydrocortisone plasma concentrations (ng/l) on the experimental 
(solid squares) and on the control day (open circles). (P.3)
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Figure 2.5.   Representative fits of lymphocytopenia on the experimental (solid squares) and on the 
control day (open circles) . (P.3) 
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Figure 2.6.  Representative fits of tyrosine variation on the experimental (solid squares) and  on 
the control day (open circles). (P.3) 
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         Figure 2.7. The mean concentration-effect relationships in steady state from all subjects for lymphocyte  
              count (dotted line) and tyrosine plasma concentration (solid line). 
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Abstract  
 
Objective: To study the effects of prednisolone (PRED) and dexamethasone (DEXA) in 
assumed clinically equivalent doses towards the lowering of cortisol, osteocalcin (OC), and 
the stimulated-rise of eosinophilic cationic protein (ECP) by granulocyte colony stimulating 
factor (G-CSF). 
Methods: At four separate sessions of 25 hours each, saline IV alone, G-CSF SC alone or in 
combination with either 12.5mg PRED IV or 2.0mg DEXA IV, were randomly administered 
in eight healthy male subjects. 
Results: All subjects had equal lowering of cortisol after DEXA and PRED at 10 hours, 
whereas a sustained suppression at 25 hours persisted only after administration of DEXA. 
Between four to ten hours after administration of DEXA and PRED, (?AUC4-10) of OC 
became 24.4% and 2.3% lower, respectively (p<0.0001). After 25 hours, this effect persisted 
for DEXA. ? AUC5-10 of the G-CSF-stimulated ECP response decreased by a mean of 76.8% 
after PRED compared to DEXA and to controls (p<0.02), and this difference had disappeared 
at 25 hours. DEXA did not elicit any effect towards the G-CSF-stimulated ECP response.  
Conclusion: PRED and DEXA in formerly assumed clinically equivalent doses induced a 
similar suppression towards cortisol within the first 10 hours, but had different actions 
towards blood concentrations of OC and ECP following G-CSF-stimulation, in healthy male 
subjects.  
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Introduction  
 
For decades, different glucocorticoids (GCs) have been prescribed as anti- inflammatory 
drugs. Their dose selection has been based ma inly upon ‘equipotency’ towards the human 
adrenal cortical function. The rationale for this has been further supported by several other in-
vivo and in-vitro tests1. Equipotent doses refer to doses of different GCs resulting in an equal 
response. According to this traditional classification, the ratio of equipotency of prednisolone 
(PRED) and dexamethasone (DEXA) is 25:41. 
   Comparisons of different GC actions against different biological targets revealed 
unexpected differences. In a previous study comparing PRED and deflazacort, authors 
reported a suppression ratio of 2.27 for cortisol, 1.54 for osteocalcin and 2.77 for lymphocyte 
count (expressed as mg deflazacort versus mg PRED)2. In another study, differences in 
potencies were also found toward several aspects of bone biology. Apart from a more 
pronounced effect towards serum OC, PRED elicited larger amounts of trabecular bone loss 
when compared to deflazacort in assumed equipotent doses3,4. Thus far, no data have been 
reported comparing clinical dose equivalence of effects of different GCs with markers of 
inflammation. In this respect, a marker of interest is eosinophilic cationic protein (ECP), 
which has shown a correlation with instability of asthma, e.g. an exacerbation is precluded by 
a rise in ECP concentrations5. Notably, granulocyte colony stimulating factor (G-CSF) has 
been recognized as a stimulant in the inflammation cascade of asthma and has been linked 
directly with the rise of ECP concentrations6. 
   Based on the studies aforementioned, we hypothesized that assumed clinically equivalent 
dosages of PRED and DEXA would act differently towards other biological targets. In other 
words, dose equivalence of two GC’s towards cortisol may not reflect equivalence with 
regard to bone metabolism or inflammation. In the current study we considered the effects of 
PRED and DEXA on cortisol, OC, and ECP concentrations after amplification with G-CSF, 
in healthy men.  
 
 Subjects and methods  
 
Subjects 
Eight healthy male Caucasian subjects participated in the study, after written informed 
consent was obtained. The subjects were all none smokers and were recruited from the 
hospital staff. The Medical Ethical Committee of the hospital Reinier de Graaf Groep 
approved the study. 
 
Study design and methods 
An open- label,  controlled study was conducted, consisting of four randomized sessions. 
Effect parameters were monitored by serially blood sampling over 25 hours. All subjects 
received saline, granulocyte colony stimulating factor (G-CSF) and G-CSF in combination 
with either prednisolone (PRED) or dexamethasone (DEXA). Each session was separated by 
a period of seven to nine days. 
  
Effect parameters 
The effects on circadian cortisol secretion were used as a marker of exogenous steroid 
potency against adrenal gland activity in-vivo1.  
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   Osteocalcin (OC), which mainly reflects osteoblast activity, is suppressed by GCs7,8. OC is 
a non-collagenous protein secreted by osteoblasts that become incorporated in the bone matrix 
and its surplus is released into the circulation during bone formation. Hence it reflects a 
marker of both bone formation and resorption9,10,11. To determine the influence of endogenous 
cortisol production against OC, concentrations were determined during a saline session in 
healthy subjects12,13,14,15,16. In order to rule out any influence of G-CSF against OC, 
concentrations were also determined during a G-CSF session, which revealed no differences.  
   In the asthmatic inflammatory cascade, granulocyte colony stimulating factor (G-CSF) is 
believed to be involved. In humans, it is recognized as a mediator produced by endothelial 
cells and macrophages17.  
   Eosinophilic cationic protein (ECP) is a pro-inflammatory cytokine in asthma and atopy18,19. 
ECP levels, determined in healthy subjects and stable atopic asthmatic patients are usually 
low, with a narrow signal to noise range20,21. Therefore, definite conclusions cannot be drawn 
from minor changes in ECP levels after exogenous GCs. Exogenous G-CSF administration 
provokes a significant rise of ECP. Hence, G-CSF as stimulus for ECP enhancement was used 
in this study as model of inflammation6.  
 
Blood sampling and analysis 
During each session, an indwelling catheter was inserted into the cubital vein and flushed 
every thirty minutes with saline. Blood samples were drawn at 0, 15, 30 minutes, 1, 2, 3, 4, 5, 
6, 7, 8, 9, 10 and 25 hours, and collected in plain, 143 USP lithium-heparin medium and gel 
clotting tubes. The plain and the lithium-heparin containing tubes (for the determination of 
OC) were immediately processed i.e. serum was separated after centrifugation and frozen at 
-20°C. The gel clotting tubes were used for ECP determinations. After sampling, these tubes 
were left untouched in upright position for 90 minutes before further processing. 
   A single experienced laboratory technician performed all determinations. Cortisol, OC, and 
ECP were assayed with an ELISA (Imulite®) purchased from Diagnostic Products 
Corporation, USA. The intra- and inter- assay variation coefficient (CV) of cortisol, OC and 
ECP were 7.6% and 10.2%, 3.2% and 4.7%, and 6.9% and 9.7%, respectively. The assay, 
which was used for OC measurements, determines the complete molecule22. 
    At the start of each sessions (except following saline), 1 ml G-CSF (Granocyteâ, filgastrim, 
33.6 million U/ml = 263 microgram + 1 ml solvent) was administered SC (i.e. 50% of the 
recommended therapeutic dose), in the upper arm solely or in combination with either 12.5mg 
PRED or 2.0mg DEXA IV. The PRED and DEXA doses were considered to be 
pharmacologically equipotent towards cortisol suppression1. 
 
Statistical analysis 
 
To rule out any possible effects of G-CSF on cortisol and OC, concentrations of these were 
compared after administration of G-CSF and saline. GC effects towards cortisol and OC 
concentrations were compared using mixed-model analysis of variance (ANOVA) followed 
by two-sided unpaired Student t-tests. GC effects towards the values of G-CSF-stimulated-
ECP were also compared using ANOVA followed by two-sided unpaired Student t-tests after 
data pooling within similar time intervals. AUC was accounted for the same intervals and 
Simpson’s rule was applied. p-values<0.05 were considered statistically significant. Data are 
presented as mean±SEM.  
Chapter III: Distinct actions of prednisolone and dexamethasone 
 48 
 
Results  
 
Eight subjects included in the study were (mean±1SD): 35±8 years of age (range: 28-46) with 
Body Mass Index (BMI) of 24.6±3.7kg/m2.  
   G-CSF-stimulated-ECP occurred five hours after G-CSF administration in all subjects up to 
a mean of 165.9% (p<0.0001). Cortisol and osteocalcin (OC) concentrations were not 
influenced by G-CSF. 
 
Cortisol 
Effects of PRED and DEXA towards cortisol are shown in Figure 3.1. There was a significant 
difference between treatments (ANOVA: p<0.05). The cortisol concentrations ten hours after 
administration of PRED and DEXA were (mean±SEM): 66.9±3.0 and 39.6±1.3nmol/l, 
respectively. At 25 hours, both GCs acted differently which resulted in a sustained cortisol 
suppression after DEXA but not after PRED (mean±SEM): 32.2±1.3 and 358.9±13.0nmol/l, 
respectively. 
 
Osteocalcin 
Effects of PRED and DEXA towards OC are demonstrated in Figure 3.2. ?AUC4-10 of OC 
after PRED did not change compared to controls, while ?AUC4-10 of OC after DEXA 
decreased to a mean of 75.6% (p<0.0001), which effect persisted at 25 hours.  
 
Eosinophilic Cationic Protein 
Effects of PRED and DEXA towards the G-CSF-stimulated ECP response are demonstrated 
in Figure 3.3. ?AUC5-10 of this ECP response decreased to a mean of 76.8% after PRED 
(p<0.02), whereas ?AUC5-10 after DEXA was similar to that of the controls. The ECP 
response after PRED and DEXA were similar at 25 hours. 
 
Discussion  
 
In the present study, the effects of prednisolone (PRED) and dexamethasone (DEXA) towards 
cortisol, osteocalcin (OC), and eosinophilic cationic protein (ECP), a marker of inflammation, 
were compared with doses that are generally considered to be clinically equivalent. The 
current data confirmed the equivalence of the 12.5mg DAF and 2.0mg DEXA IV bolus in 
terms of cortisol suppression within the first 10 hours after steroid administration1. At 25 
hours, however, near maximal cortisol suppression persisted after DEXA but not after PRED. 
Notably, administration of DEXA, revealed also a suppression of OC persisting at 25 hours, 
whereas no such effect was observed after PRED. Prolonged suppressive effects of DEXA on 
cortisol production by the adrenal glands have been described previously23,24. In a 
pharmacokinetic study in horses, DEXA, PRED (prednisolone sodium succinate), and PA 
(prednisolone acetate) suppression of cortisol has been reported. In this particular study, it 
was demonstrated that cortisol levels returned to baseline concentrations within 24 hours after 
PRED and PA, whereas it remained suppressed up to three to four days after DEXA25. In the 
current study, PRED elicited no suppression of OC and a 23.2% suppression of G-CSF-
stimulated ECP after five to ten hours (p<0.005), whereas DEXA did not induce any effect 
towards this ECP response but did suppress OC by a mean of 75.6% (p<0.0001). These 
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differences in response after DAF or DEXA support our hypothesis that cortisol suppression 
after GCs do not reflect the effects towards other targets, in particular those towards cytokines 
involved in the cascade of inflammation. 
   The current study bares several limitations. Firstly, we did not address issues concerning 
concentration-effect-time relationships. For this, pharmacokinetic (PK) and pharmaco-
dynamic (PD) modelling work is planned in the nearby future, since concentration-effect-time 
relationships are needed to calculate residual cortisol concentrations in the effect compartment 
and to extrapolate whether the presence of concentrations would interfere with the exogenous 
GCs-target- interactions. In other words, to test whether assumed equipotencies of exogenous 
GC’s concentrations reflect a ratio, independently of the administered doses. G-CSF-
stimulated ECP as an inflammation model has so far not been described. In all subjects, the 
data showed a similar and statistically significant rise in ECP. These observations made us to 
adopt this method as a useful tool to mimic inflammation. 
 
In summary  
The current study questioned whether classical predictions of dosage equivalence of PRED 
and DEXA were adequate towards cortisol suppression and the suppression of other targets 
e.g. bone metabolism and inflammation. Our findings support that PRED and DEXA in a 
ratio of 25:4 only elicit clinically similar actions towards cortisol suppression within the first 
ten hours after administration. Moreover, it appeared that these assumed clinically equivalent 
doses acted differently towards various biological targets, illustrated by the current data, 
showing that 12.5mg PRED is less potent in suppressing cortisol and OC, but that it is more 
potent in suppressing stimulated ECP production as compared to 2mg DEXA. More clinical 
research is needed to depict those steroids with high affinity against inflammation and low 
affinity towards targets, which may cause side effects. 
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Figure 3.1. Plotted serum cortisol concentrations in eight healthy subjects expressed as 
mean±SEM. *= significant differences of cortisol concentrations comparing prednisolone 
(PRED) and controls versus dexamethasone (DEXA) (p<0.0001). # = significant differences of 
cortisol concentrations after PRED and DEXA versus controls (p<0.0001). 
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Figure 3.2. Plotted serum osteocalcin (OC) concentrations in 8 healthy subjects expressed as 
mean±SEM. * = significant differences of OC concentrations after DEXA versus PRED and 
controls (p< 0.0001).  
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Figure 3.3. Plotted plasma G-CSF-stimulated eosinophilic cationic protein (ECP) concentrations 
in 8 healthy subjects expressed as mean±SEM. # = significant differences of ECP concentrations 
comparing G-CSF with or without PRED or DEXA versus controls (p<0.005). * = significant 
differences of ECP concentrations comparing the effects of G-CSF with or without DEXA 
versus PRED (p<0.02). 
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Abstract  
 
Objective: To compare potency and efficacy of dexamethasone (DEXA) and prednisolone 
(PRED) in assumed equipotent doses in combination with endogenous cortisol, using 
lymphocyte counts, plasma osteocalcin (OC), and eosinophilic cationic protein (ECP) as 
effect variables and to evaluate potential differences between healthy subjects and asthmatic 
patients.  
Methods: Eight healthy subjects and six asthmatic patients who had stopped taking their 
regular inhaled glucocorticosteroid treatment (ICS) for one week, were given an IV bolus of 
DEXA and PRED in assumed equipotent doses of 2.0mg and 12.5mg, respectively, on 
separate occasions, in combination with subcutaneously injected granulocyte–colony 
stimulating factor (G-CSF) as a stimulant for ECP production. Plasma levels of DEXA, 
PRED, cortisol and effect variables were determined over 25 hours and PK/PD modelling 
was performed. 
Results: Baseline cortisol concentration was lower in patients than in healthy subjects. Both 
of the exogenous glucocorticoids (GCs) diminished cortisol production. In the healthy 
subjects, the cortisol production remained suppressed for the full duration of the study day 
after DEXA but not after PRED. In the asthmatic patients though, the reappearance of the 
endogenous production of cortisol was seen after both DEXA and PRED. The Emax values for 
lymphocyte counts and OC showed that cortisol acted as partial, and DEXA and PRED as 
full agonist. The observed responses of DEXA and PRED suppressing cortisol, OC and 
lymphocyte counts were all of the same relative order of magnitude, in accordance with the 
estimated PD parameters. However, cortisol was estimated to have very little effect on ECP 
and modelling further predicted that DEXA and PRED were only partial agonists for this 
effect, without a difference between healthy and asthmatic subjects. Yet, in healthy subjects, 
AUCs indicated unexpectedly that ECP was only suppressed after PRED and not after 
DEXA, while in patients it was suppressed after both GCs. The rank order of potency on 
lymphocyte counts, OC and ECP was DEXA > PRED > cortisol, although the different 
relative potencies of the three GCs involved were not the same for all of the three effect 
variables and differences were also found between healthy and asthmatic subjects.  
Conclusion: PK/PD modelling studies of GCs demonstrated not only differences in potency 
of DEXA and PRED on the measured systemic markers, but also different potencies per 
target tissue and differences between healthy and asthmatic men. The effects caused by the 
achieved blood concentrations of DEXA and PRED, expressed as AUCs of the effect 
variables, were in accordance with their respective Emax values in case of the lymphocytes 
and OC but not for ECP.  
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Introduction 
 
Dose regimens of IV or oral glucocorticoids (GCs) are generally based on either non-human 
animal studies or empiricism. For decades, studies have been performed determining the 
potencies of different GCs in in-vivo models, such as skin blanching tests and oedema of the 
rat ear1. Although never used for dose finding purposes, other biological markers such as 
lymphocyte counts, cytokines, osteocalcin (OC), and tyrosine aminotransferase have also 
been studied2-8. 
   Osteocalcin (OC), a non-collagenous protein secreted by osteoblasts that becomes 
incorporated in the bone matrix during bone formation while its surplus is released into the 
circulation, mainly reflects osteoblast activity and is suppressed by GCs9,10. Thus, it is a 
marker of both bone formation and bone resorption11-17. To determine the influence of 
endogenous cortisol production on OC, as was also done by others18,19,20,21, OC concen-
trations were determined during a saline session in healthy subjects in one of our earlier 
studies22. In that study, it was disputed whether relative potencies of GCs on adrenal 
suppression could be extrapolated to other target tissues and whether the relative adrenal 
suppression by exogenous GCs would mirror anti- inflammatory potency as has been 
suggested9. The results demonstrated that dexamethasone (DEXA) and prednisolone (PRED) 
had distinct actions. ECP production, stimulated by Granulocyte Colony Stimulating Factor 
(G-CSF) was suppressed after PRED, but not after DEXA. G-CSF is a mediator in the 
asthmatic inflammatory cascade and induces a rise in ECP, which is also a mediator in this 
cascade and is related to the activity of this inflammation23,24,25. Without stimulation, ECP 
baseline values, especially in healthy subjects, have a low signal to noise ratio, which makes 
it impossible to use it as an outcome parameter for inflammation22. 
   The primary aim of the present study is to investigate the potency and efficacy of DEXA, 
PRED and cortisol by applying pharmacokinetic/pharmacodynamic (PK/PD) modelling. 
Effect variables were lymphocyte counts, OC and ECP. Cortisol production over time was 
estimated since endogenous cortisol interferes with the effects of exogenous GCs. In 
consequence, the effects on lymphocyte counts, OC and ECP were always the combined 
effects of changing endogenous and exogenous GC concentrations, as has been described 
earlier26. Secondary aims of the study are to compare the outcome variables per target tissue 
and to investigate whether effects of classically assumed equipotent doses differ between 
healthy subjects and asthmatic patients who had stopped their chronic treatment of inhaled 
corticosteroids (ICS) one week before each session. Results from the study mentioned above 
in healthy subjects and new data in asthmatic patients are analysed for these purposes22. 
 
Patients and methods 
 
Participants 
Eight healthy male subjects and six stable atopic male patients with mild asthma participated 
in the study after approval by the Medical Ethical Committee of the hospital Reinier de Graaf 
Groep and after written informed consent was obtained. The healthy men were recruited from 
the hospital staff and the asthmatic patients from the outpatient clinic for pulmonary diseases. 
The medical history of the asthmatic men and their previous pulmonary function tests 
confirmed stable asthma, which had been treated with ICS for at least a year, showing normal 
baseline values with a reversibility of FEV1 after salbutamol 400µg of less than 8%. The 
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patients, who were only using ICS and short acting ß2 agonists (SAßA), were asked to 
withhold their ICS for one week only, in order to avoid deterioration of their asthma and 
SAßA for at least 8 hours prior to each study session27,28.  
 
Demographics 
The mean age (SD) of the healthy men and the asthmatic patients was 35 (8) (range: 28 – 46) 
and 37 (11) (range: 20-50 years), and the mean BMI (SD) was 24.6 kg/m2 (3.7) and 
26.3kg/m2 (3.7), respectively. All of the study participants were non-smokers. As expected, 
baseline lung function values were within the normal range in the healthy men with a mean 
(SD) value for FEV1 of 3.88L (0.45) and for FEV1/VC 0.79 (0.04). All patients were, apart 
from their asthma, generally healthy and had never used systemic GCs. The daily ICS dose 
was either budesonide 400µg b.i.d. (n=4), or beclomethasone 400µg b.i.d. (n=2). Pulmonary 
function tests showed pre- and post-bronchodilator mean (SD) value for FEV1 of 3.29L 
(0.51) and 3.41L (0.50) and for FEV1/VC 0.72 (0.06) and 0.75 (0.05), respectively.  
Study design and methods 
This study included 4 randomised cross-over sessions in the healthy men and 3 randomized 
cross-over sessions in the asthmatic patients. A saline session was only performed in healthy 
subjects, in order to rule out an effect by G-CSF on any of the outcome variables other than 
ECP release / production. The effect of subcutaneously injected G-CSF on ECP was reported 
in the previous study22. Sessions were separated by a washout period of at least one-week. 
Plasma kinetics and effect markers were monitored by serially blood sampling over 25 hours.  
   Throughout each session an indwelling catheter was inserted into the cubital vein, which 
was flushed with saline every 30 minute. Blood was collected in plain and Na EDTA 
medium tubes (the latter for the determination of OC) at 0, 15, 30, 60 minutes and at 2, 3, 4, 
5, 6, 7, 8, 9, 10, and 25 hours. The tubes were immediately centrifuged and serum was 
separated and frozen at -20°C. The blood samples drawn for the determination of ECP were 
left to rest at room temperature for 90 minutes before processing.  
   At the start of each session, except for the session in the healthy subjects at which only 
saline was given, 1ml G-CSF (Granocyteâ, filgastrim, 33.6 million U/ml (=263µg)) was 
administered subcutaneously in the upper arm, either alone or concomitantly with 
intravenous DEXA 2.0mg or PRED 12.5mg, given as a slow bolus injection.  
   DEXA and PRED were analysed simultaneously with cortisol with a high performance 
liquid chromatograph method. This method as was published by Rose and Jusko, was used 
with the following modifications29. A Lichrosorb 10-Diol column (Merck, Darmstadt, 
Germany) was used for separation. Eluent composition was methylene dichloride/hexane/ 
methanol in a 73:25.5:1.5 ratio (v/v). As the internal standard, 20-beta-dihydrocortisone 
(Sigma Chemical Co., St Louis, MO) was used. The coefficient of variation was 
approximately 8% for cortisol, DEXA and PRED. The lower limit of detection for each 
steroid was about 5ng/ml. 
  Cortisol, lymphocyte counts, OC and ECP were determined at the time points mentioned 
above. Results of the effect markers lymphocyte count, OC and ECP on the GC days were 
compared to the results that were obtained from the session with G-CSF alone. 
   OC and ECP were assayed with an ELISA (Imulite®) purchased from Diagnostic Products 
Corporation, USA. The intra- and inter-assay variation coefficient (CV) for OC and ECP 
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were 3.2% and 4.7%, and 6.9% and 9.7%, respectively. The assay which was used for OC 
determination, measures the complete molecule30. 
 
Pharmacokinetics and pharmacodynamics 
 
Cortisol, OC, ECP and GC concentrations were measured at all mentioned time points, while 
lymphocyte counts were determined pre-dose and at 1, 4, 7, 10 and 25 hours. For PK/PD 
modelling, GC serum concentration-time courses and the corresponding PD responses were 
described by non- linear regression analysis (modelling) using the software programme 
Scientist for Windows, Micro Math, version 4.031. 
 
Concentration-time curves of DEXA and PRED 
Concentration-time curves of DEXA were fitted to a two-compartment model with first order 
elimination32:  
 
ConcD(t) =       
D/V   *     (K21-a) * e-(a * t)   +   (K21 - ß) * e- (ß * t)   
                                                                            
ß - a                                        a - ß 
  
Concentration-time curves of PRED were fitted to a one-compartment model with first order 
elimination:  
 
  ConcP(t) = 
D/V * e-Kel*t 
 
Conc(t): exogenous GC plasma concentration at the given time post dose (t); D: dose of the exogenous GC, V: 
volume of distribution; e: the natural logarithmic base number, Kel: elimination rate constant for one 
compartment model, K21: transfer rate constant from the peripheral to the central compartment, a: the apparent 
first order distribution rate constant for a two compartment model and ß : the apparent first order elimination rate 
constant for two compartment model. 
 
Effects on cortisol 
Time curves of endogenous cortisol were described with the same assumptions as those of a 
previously described model8,26,33,36. In the model as it is used in the present study, the 
modelled cortisol was described from 4 hours prior to the exogenous GC administration till 
25 hours on the next day by the sum of: 
 
cortisol1(t) + cortisol2(t) + cortisol3(t) + cortisol4(t). 
 
   Three of these four cortisol concentration-time curves resulted each from a different 
endogenous ‘infusion’, while one time curve (cortisol3(t)) describes the elimination of 
cortisol after the administration of the exogenous GC:  
1) a continuous basal cortisol infusion (Inf1) resulting in a steady state cortisol concentration 
and which is never affected by any exogenous GC;  
2) an infusion of cortisol (Inf2) starting at 4 a.m. of which the rate is halted or decreased at 8 
a.m., immediately after the administration of the exogenous GC resulting in cortisol4(t);  
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3) an infusion (Inf3) which is started at a time point estimated by the model. The rate of this 
infusion on day two was estimated independently from the infusion rate on day 1 (Inf2).  
Previous studies have shown that the production rate of cortisol of Inf2 after administration of 
DEXA becomes practically zero33. If this had been the case after PRED administration then 
cortisol elimination rate constants would have been expected to be identical on both 
treatment days for a given subject. However, visual inspection of the data showed 
concentration-time course differences during the period that the cortisol concentration 
declined after administration of exogenous GC. For simplicity it was nevertheless still 
assumed that Inf2 had been stopped completely after both PRED and DEXA administration 
and the disappearance of cortisol produced by Inf2 was described by different elimination 
rate constants (Kelcort D and Kelcort P ) rather than describing differentially reduced infusion 
rates after PRED and DEXA administration. Thus, three different elimination rate constants 
were used to describe the full time course of cortisol: Kelcort , Kelcort D and Kelcort P .  
   As mentioned above, Inf1 was assumed not to be affected by exogenous GC and therefore 
supposed to be identical on both treatment days. 
The following equations were used to estimate cortisol1(t), cortisol2(t), cortisol3(t) and for  
cortisol4(t) two different equations after DEXA and PRED administration, respectively. 
 
cortisol1 (t) =  
  Inf  1               (continuous basal infusion) 
                         
V*Kelcort 
 
cortisol2 (t) =  
  Inf  2      *  (1 – e-Kelcort * t)                             (on at 4 a.m., off at 8 a.m.) 
          
V*Kelcort 
 
cortisol3 (t) =  
  Inf  3           * (1 – e-Kelcort * (t-ton ))   (from switch-on time  
    
V*Kelcort             till end of observation) 
Cortisol1(t), cortisol2(t) and cortisol3(t): cortisol plasma concentrations resulting from Inf1, Inf2 and Inf3, 
respectively; Inf1, Inf2 and Inf3: apparent endogenous production of cortisol described as infusion 1, 2 and 3; V: 
volume of distribution; Kelcort : elimination rate constant; t: time, ton: time point at which Inf3 starts. 
 
Elimination of cortisol after switch-off of Inf2 at 8 a.m., 4 hours after its start, is described by 
cortisol4(t).  
 
Equation for DEXA: 
cortisol4 (t) = ( 
Inf 2       (1 – e-Kelcort * 4)) * e-KelcortD * t  (from 8 a.m. onwards) 
   V*Kelcort   
 
Equation for PRED: 
cortisol4 (t) = ( 
Inf 2       (1 – e-Kelcort * 4)) * e-KelcortP  * t  (from 8 a.m. onwards) 
   V*Kelcort   
 
It should be noted that the volume of distribution of cortisol (V) was arbitrarily set at 1 litre 
as no information was available for its estimation. Therefore, the estimates of the infusion 
rates are also virtual values.  
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Effects on lymphocyte counts, OC and ECP 
The effects of DEXA or PRED combined with cortisol on the chosen effect variables 
lymphocyte counts, OC and ECP were described by a competitive interaction model with the 
use of an effect compartment as previously described33. 
For DEXA: 
Effect =Eo   *   1 – (                 CeD * Emax D             +          CeC * Emax C                        )            
                         CeD + EC50 D +  
EC50 D * CeC         CeC + EC50 C +  
EC50 C * CeD 
                                      EC50 C              EC50 D 
 
For PRED:   
Effect =Eo   *   1 – (                 CeP * Emax P             +          CeC * Emax C                       )            
                         CeP + EC50 P +  
EC50 P * CeC        CeC + EC50 C +  
EC50 C * CeP 
                                      EC50 C           EC50 P 
 
E0: the effect value in the hypothetical situation that neither exogenous nor endogenous GC is present; 
CeC: effect-compartment concentration of cortisol; CeD: effect-compartment concentration of DEXA; Emax C: 
maximal possible effect of cortisol; Emax D: maximal possible effect of DEXA; EC50 C: steady state cortisol 
plasma concentration at which 50% of Emax C is achieved; EC50 D: steady state DEXA plasma concentration at 
which 50% of Emax D is achieved; CeP: effect-compartment concentration of PRED; Emax P : maximal possible 
effect of PRED; EC50 P : steady state PRED plasma concentration at which 50% of Emax P  is achieved. 
 
CeD and CeP  are defined by the following differential equations34,35:  
d(CeD)  =  Ke0D*(concD -CeD)      and   d(CeP)  =  Ke0P*(concP-CeP), respectively. 
d(t)      d(t) 
 
In analogy to the approach used by Braat et al., the effect-compartment concentration-time 
course of cortisol (CeC) in the effect-compartment is described as the sum of the various 
phases33: 
 
CeC1(t) + CeC2(t) + CeC3(t) + CeC4(t). 
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For Inf1: 
 
CeC1(t) =  
Inf 1
           .        
      
V * Kelcort 
 
For Inf2 from 4 until 8 a.m.: 
 
 
CeC2(t) = 
  Inf 2         *    (
 e-Kelcort*t – 1 ) *  Ke0 * e-Kelcort*t        ( e-Ke0*t – 1 ) * Kelcort * e -Ke0*t     
      
V  * 
Kelcort                         
Ke0 – Kelcort               Ke0  – Kelcort 
 
For Inf2 from 8 a.m. until ton: 
 
Equation for cortisol after DEXA administration: 
 
CeC3(t) = 
   Inf 2           *    ( 1 – e-Kelcort* 4 ) *       Ke0 * e -
KelcortD * t         KelcortD * e -Ke0*t     
     
V  * Kelcort                                         Ke0 – KelcortD               Ke0 – KelcortD 
 
Equation for cortisol after PRED administration: 
 
CeC3(t) = 
  Inf 2           *    ( 1 – e- Kelcort * 4 ) *       Ke0 * e -
KelcortP * t          Kelcort P * e -Ke0*t    
     
V  * Kelcort                                           Ke0 – Kelcort P               Ke0  – Kelcort P 
 
 
For Inf3 :  
 
CeC4(t) = 
 
 
Inf 3      
 *     (e
-Kelcort*(t-ton) – 1 )*Ke0* e-Kelcort*(t-ton)     ( e-Ke0*(t- ton) – 1 )* Kelcort * e-Ke0*(t-ton)    
V* 
Kelcort              
Ke0 – Kelcort                             Ke0  – Kelcort 
 
 
The effects of DEXA and PRED were modelled simultaneously. The pharmacodynamic 
parameters EC50, Emax and Ke0 for cortisol were assumed to be the same for each effect on the 
two days. 
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Calculation of effects on ECP 
In order to reduce variability, the following ‘normalisation’ procedure was applied for the 
effects on ECP. The effects of exogenous GCs for each individual were expressed as the 
differences between the mean ECP values after G-CSF stimulation without exogenous GCs 
and the measured ECP values at the various time points after administration of G-CSF and 
the exogenous GC. That is to say that: 
 
?ECP = mean ECPG-CSF – individual ECPG-CSF + GC 
 
These ?ECP values were used as the effect parameter which was fitted to the dynamic 
model, and the estimated Emax is the maximal absolute suppression of the exogenous 
glucocorticoid on the G-CSF induced ECP elevation. In the pharmacodynamic model for 
?ECP, E0 was not fixed at zero but was estimated to allow for variability. 
 
Statistical analysis 
The effects of exogenous GCs on cortisol, OC, lymphocytes and G-CSF-stimulated ECP 
concentrations were compared within and between the two populations of healthy subjects 
and asthmatic patients, respectively, using two-sided unpaired and paired Wilcoxon rank 
tests; p-values<0.05 were considered statistically significant. Mean ± standard deviation was 
used. To compare the effects of cortisol with DEXA and PRED on the various parameters 
Friedman’s non parametric test was used and a of less than 0.05 were considered statistically 
significant. 
 
Results 
 
No adverse events occurred in any of the participants during the study and the follow-up 
period and all participants completed the study.  
   Pharmacokinetic data of DEXA and PRED administered as slow IV bolus are summarized 
in Table 4.1. The mean coefficients of determination (SD) for DEXA in healthy subjects and 
asthmatic patients were respectively 0.99 (0.08) and 0.97 (0.05) and for PRED 0.93 (0.05) 
and 0.94 (0.06). 
   Pharmacokinetic data related to cortisol after DEXA and PRED are listed in Table 4.2. In 
contrast to the observations after PRED, the switch-on of Inf3 was absent after DEXA except 
in two asthmatic patients. The Inf1 of endogenous cortisol was estimated as a common 
parameter on the days with DEXA and PRED. 
   The mean basic values (SD) at t0 (8 a.m.) for cortisol were 541ng/ml (72) and 399ng/ml 
(87) for healthy and asthmatic men respectively (p<0.01, student t-test, 2 sided, unpaired). 
Calculated mean values (SD) for Kelcort in healthy subjects and asthmatic patients were 0.09 
hr-1 (0.87) and 1.6 *10-4 hr-1 (0.11), respectively. 
   The calculated data of PRED, DEXA and cortisol are represented in Figure 4.1. Mean of all 
fitted data from the healthy and the asthmatic men are presented in panel A and B, while 
panels C and D show the results in 1 subject representative for respectively healthy subjects 
and asthmatic men. The decline of the slope of mean plasma cortisol concentrations was 
steeper with DEXA (––) than with PRED (–––) in both healthy and asthmatic men (p<0.01, 
student t-test, 2 sided, paired). The switch-on of the endogenous cortisol production (Inf3) 
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after PRED can be identified in healthy men (panel A and C). This switch-on of Inf3 can be 
identified after both DEXA and PRED in asthmatic men (panel B and D).  
   It should be noted that for cortisol in Figure 4.1 the time of onset of Inf2 was arbitrarily 
assumed to be 4 a.m. (t-4 = 4 a.m.), four hours before administration of the exogenous GC but 
that only the last part (from 7 to 8 a.m.) of the endogenous cortisol estimations resulting from 
Inf2 are depicted. 
   Already at this point it has to be emphasized that for the other effect variables in all Figures 
t0 was 8 a.m., the time of administration of the exogenous GC. Because the start of Inf2 
happened before the administration of the GCs, it was decided to use clock time for the X-
axis, while the real time counting was continued until 33 hours (i.e. 9 a.m. clock time the 
following day). 
   Table 4.3 lists the pharmacodynamic parameters of the effects on lymphocyte count, OC, 
and ECP after administration of DEXA and PRED, and the influence on these parameters by 
endogenous cortisol. 
   The relative effectiveness of DEXA and PRED were compared by calculating areas under 
the curve (AUCs) for cortisol, lymphocyte counts, OC and ECP (Table 4.4). AUCs ratios for 
each effect between DEXA and PRED were calculated. 
   The calculated time courses of lymphocyte counts, OC and ECP are demonstrated in 
Figures 4.2, 4.3, and 4.4. Mean data of all healthy and asthmatic men were plotted in these 
figures in panels A and B respectively and data for healthy subject 1 and asthmatic patient 5 
in panels C and D, respectively. Figure 4.4 shows the mean ECP data obtained from 7 
healthy and 4 asthmatic men; data from one healthy and two asthmatic men could not be 
described by our applied mathematical model. 
 
Discussion 
 
In the current study, pharmacokinetic–pharmacodynamic (PK–PD) modelling was applied to 
compare the in vivo effects of dexamethasone (DEXA) and prednisolone (PRED), in 
combination with endogenous cortisol. Effects on lymphocyte counts, osteocalcin (OC) and 
eosinophilic cationic protein (ECP) after in vivo stimulation by granulocyte colony 
stimulating factor (G-CSF) were compared in healthy and asthmatic men, who had refrained 
from their regular inhaled corticosteroid (ICS) therapy for at least one week prior to each 
study session. 
DEXA and PRED 
   The study was performed to compare DEXA and PRED, in assumed equipotent IV bolus  
doses of 2.0 and 12.5mg1. In order to look at the effects of cortisol in these combinations, 
changes in the concentration-time course of endogenous cortisol after the administration of 
DEXA or PRED were quantified. Plasma PK concentrations and effect variables were 
serially determined. The DEXA and PRED PK-parameters, i.e. volume of distribution and 
half- life, summarized in Table 4.1, were in concordance with data from earlier studies from 
our laboratory26,33. The concentration-time data of DEXA and PRED (Table 4.1) were best 
fitted to a two- and one-compartment model, respectively. The effects of both DEXA and 
PRED showed a considerable delay in comparison to the corresponding steroid plasma 
concentrations, which justified the use of an effect compartment model. 
   Using a non- linear model which has already been described8,26,33,36, effects of DEXA and 
PRED on cortisol were compared. In this model the concentration-time course of the 
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(endogenous) cortisol after administration of an exogenous GC was described as a 
combination of three infusions. PK/PD modelling, by means of a competitive interaction 
model, was subsequently adopted to study the effects of DEXA, PRED, and cortisol on 
lymphocyte counts, OC and ECP. This model has been used before to describe exogenous 
steroid effect on lymphocyte counts26,33. 
 
Cortisol 
The calculated cortisol infusion rates responsible for the concentration-time course of 
(endogenous) cortisol after administration of an exogenous GC are given in Table 4.2. As 
mentioned the V for cortisol (Vcortisol) was set at 1 litre since no experimental data were 
available for estimation. Assuming a Vcortisol as reported in literature
1 of 0.3 litre per kg and 
the body weights of the healthy and the asthmatic men being 77.3 and 78.9 kg respectively 
Vcortisol would be approximately 23 and 24 liters, leading to a more precise estimation of the 
different infusion rate constants by dividing the outcomes by these volumes, e.g. in healthy 
men for DEXA: Inf1 Inf2 and Inf3 : 1.2, 37.1 and 0 ng*hr -1and for PRED: 1.2, 41.6 and 21.7 
ng*hr -1, respectively; in asthmatic men for DEXA: Inf1, Inf2, and Inf3 were: 0.45, 28.8, and 0 
ng*hr -1 and for PRED 0.45, 39.8 and 20.8 ng*hr -1, respectively.  
   With regards to cortisol, we found a clear difference in adrenal suppression between DEXA 
and PRED in healthy and asthmatic men, while these results between the two groups were 
also dissimilar.  
   The DEXA and PRED PK-parameters, i.e. volume of distribution and half- life, 
summarized in Table 4.1, were in concordance with data from earlier studies from our 
laboratory and showed no differences between healthy and asthmatic subjects26,33,36. The 
modelled effects of DEXA on cortisol were also in accordance with previous results33,36. 
   Theoretically, the elimination rate constant of cortisol (Kelcort ) should not be influenced by 
exogenous glucocorticoid. However, we found the elimination rate constant of cortisol after 
DEXA to be apparently higher than after PRED (p<0.01). This difference in elimination is 
also illustrated in Figure 4.1. In order to improve the goodness of fit in the model, we 
allowed for two separate elimination rate constants: after DEXA: KelcortD and after PRED: 
KelcortP (Table 4.2). Based on the current data on KelcortD, which appeared to be equivalent to 
Kelcort , as has been described previously33, it was concluded that the part of the production of 
cortisol that was susceptible to exogenous GC administration (Inf2) was totally stopped. 
Derived from these observations, the concentration-time course of the (endogenous) cortisol 
after administration of an exogenous GC was described as a combination of three infusions 
(Table 4.2). Notably, between 4 a.m. and 8 a.m. the only time point available to estimate the 
nocturnal nadir of this diurnal cortisol production (Inf2) was at 8 a.m. This may have led to 
an under-estimation of Kelcort and an over-estimation of Inf2. 
   After administration of PRED, the decrease in cortisol production (Inf2) was evident but 
with a lower t½ as was described for exogenous administered hydrocortisone
36. Apparently, 
PRED was not able to block Inf2 completely (Figure 4.1). In the asthmatic patients, 
significantly lower baseline cortisol levels (p<0.01) were found as well as a remarkably 
lower continuous basal cortisol production (Inf1) (p<0.05). As mentioned before, Inf1 was 
assumed not to be affected by exogenous GC (Figure 4.1). This could indicate an essential 
difference between single bolus administration of exogenous GCs and chronic exogenous GC 
regimens and underlines that extrapolation from data obtained from single bolus studies to 
prospective influences of chronic GC regimens on HPA-axis is perilous. Another possibility 
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could be that exogenous GC insensitive cortisol production (Inf1) and baseline cortisol levels 
in patients with asthma are lower, independent of the use of exogenous GCs. The patterns of 
the concentration-time curves of cortisol after DEXA and PRED were similar in healthy and 
asthmatic men (Figure 4.1): in both groups a restart of the cortisol production (Inf3) within 
the observed time was only seen after the administration of PRED. The precision of the 
estimation of the time of onset and the rate of infusion of Inf3 is limited, due to the limited 
number of samples beyond 20 hours, describing this part of the plasma cortisol curve. 
 
Lymphocyte count  
Table 4.3 illustrates that in healthy and asthmatic subjects the estimated E0 values for the 
lymphocyte count were similar on the two study sessions. 
   The modelled effects on lymphocytes, as found for the healthy subjects, are in agreement 
with previous results from our laboratory26,33. As such, these data suggest that DEXA and 
PRED act as full agonists with respect to lymphocyte count, reaching an Emax of nearly 
100%. In contrast, cortisol appeared to be a partial agonist. However, the results show that 
the efficacy (Emax) of cortisol for the lymphocyte count is higher in asthmatic patients than in 
the healthy subjects (p<0.02). In healthy subjects, the EC50 values of cortisol and PRED 
towards lymphocyte count were significantly higher than the EC50 of DEXA (p<0.01); in 
asthmatic subjects, DEXA had a similar EC50 while the EC50 of cortisol and PRED indicated 
a higher potency (p<0.05). The EC50 ratio of cortisol, DEXA, and PRED for the effects on 
lymphocyte count (Table 4.3) is approximately 80:4:23 in healthy subjects, approaching the 
classical paradigm of the potency ratio1of cortisol versus DEXA versus PRED being 
100:4:25. In asthmatic patients this ratio was somewhat different, being 32:4:10 (p<0.05). 
 
Osteocalcin (OC) 
The OC responses after PRED and DEXA in healthy and asthmatic subjects (Table 4.3) are 
congruent with those observed for lymphocyte counts. The Emax values for OC indicate again 
that cortisol is a partial agonist whereas DEXA and PRED are full agonists.  
   However, the potencies of the three GCs are different also for this effect: cortisol versus 
DEXA versus PRED show an EC50 ratio in healthy subjects of approximately 66:4:14. These 
findings are again somewhat in the range of those found for the effects on lymphocyte 
counts, and to some extent in accordance with the classical paradigm1. In asthmatic subjects 
the potency ratio was approximately 570:4:50, indicating a much lower potency of cortisol 
(p<0.01) and a lower potency of PRED (p<0.05). Thus, compared to DEXA, the potency of 
PRED was weaker (p<0.05) and this was most prominent in asthmatic subjects. 
 
Eosinophilic Cationic Protein (ECP) 
Table 4.3 illustrates that in healthy and asthmatic subjects E0 values for ECP were not 
different on the two study sessions. It has to be realized that our approach of modelling the 
effects on ECP cannot be considered as being more than a rough approximation. In actual 
fact, these effects are the resultant of the administration of one stimulant: i.e. granulocyte 
colony stimulating factor (G-CSF), intervening with two inhibitors (probably non-
competitive antagonists): cortisol with either DEXA or PRED, while these two inhibitors 
actually are competing with each other. To circumvent the complexities of the model that 
would be needed to describe such a situation, the individual data were transformed to 
calculated DECP values as described in the methods section. An additional advantage of this 
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approach was that variability could thus be reduced. However, as a consequence of this 
simplification the interpretation of especially the Emax values for this effect has considerable 
limitations. 
  Nevertheless, it is clear that the efficacy (Emax) of endogenous cortisol is significantly less in 
comparison to DEXA and PRED. In fact the cortisol Emax is so low, both in healthy and in 
asthmatic subjects, that this endogenous GC in presence of a full agonist acts as an antagonist 
and will antagonize the effects of any other, more potent GC present. In the competitive 
model that was chosen, it can thus fully block any effects of the exogenous GCs on ECP. 
This interaction between cortisol and the exogenous GCs might be an explanation for the low 
DECP values that were found in healthy subjects (Table 4.4, Figure 4.4) in the presence of 
relatively high Emax estimations (Table 4.3) for DEXA. The interpretation of statistical 
significant difference found between healthy and asthmatic subjects is not directly clear. The 
EC50 values showed a similar rank order in potencies as was found with lymphocyte counts 
and OC; for healthy subjects the ratio was approximately 54:4:29 and for asthmatic 357:4:38. 
 
Comparison to effects expressed as AUCs 
Table 4.4 and Figures 2, 3, and 4 allow comparisons between effects as AUCs and between 
the parameters for efficacy and potency (Table 4.3). For cortisol a lower AUC after DEXA 
compared to after PRED was noted, which is in accordance with the finding that DEXA has a 
higher potency than PRED, whilst the efficacy is comparable. Similar findings could be 
described for lymphocyte counts, with a slight difference between AUCs after DEXA 
between healthy and asthmatic subjects (p<0.05). Also, for OC similar findings were 
confirmed, albeit that those AUCs for OC were relatively lower in asthmatic subjects. One 
may speculate that chronic asthma, i.e. inflammation, exerts a suppressive effect on 
osteocalcin levels, as has been described for other chronic inflammations37,38. For ECP in the 
healthy subjects, it seems apparent that the results in Table 4.4 support the illustration (Figure 
4.4 panel A and C) that PRED exerts more suppression of induced ECP in comparison to 
DEXA (p<0.05). However, this is not supported by the estimated parameter values for 
efficacy and potency. The distinction between AUC values of DECP (Table 4.4) and the Emax 
and EC50 of DEXA and PRED towards ECP in healthy subjects (Table 4.3) indicates that 
simply looking at values of dynamic parameters when a competitive interaction model is 
being applied, may fail to predict the effects on ECP as expressed in AUC39. In asthmatic 
men, this distinction is even more difficult to interpret, due to more scattered raw data on 
ECP plasma concentrations, possibly as a result of the asthma itself 40,41. 
 
Comparisons between healthy and asthmatic men 
As was described baseline values of lymphocyte counts and ECP were similar but baseline 
values of cortisol and osteocalcin differed significantly between these two groups; with 
respect to potencies only EC50’s for PRED towards lymphocyte counts and for cortisol 
towards OC differed significantly. However, we have to emphasize that comparing potencies 
in healthy and asthmatic men poses special problems, since it can not be excluded that 
asthma itself may influence OC and ECP data40,41 and we expect that calculated potencies in 
healthy men can not be extrapolated to asthmatic men.  
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In summary 
The current study critically addressed a classical paradigm in GC research and found that, 
although a similar ranking order could be identified (Table 4.3), assumed equipotent doses of 
2.0mg DEXA and 12.5mg PRED do not exert equal activity towards different effect 
parameters and this activity also differs per target tissue. Moreover, distinct outcomes were 
also found when healthy and asthmatic subjects were compared. In healthy subjects, as 
reported before, data suggest DEXA to have a greater influence on bone metabolism and 
PRED to have a greater influence on inflammation22. 
PK/PD relationships were sustained for cortisol lymphocyte counts and OC, but not for 
DECP. Systemic effects of ICS have been reported42,43 and - even after cessation for one 
week - our data suggest a difference between matched asthmatic and healthy men, thereby 
possibly hampering the interpretation of estimated effects of different GCs in the asthmatic 
patients. This will make determination of potencies of GCs cumbersome in asthmatic 
patients. 
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 Pharmacokinetic data in healthy and asthmatic men after 2 mg 
DEXA or 12.5 mg PRED 
 
 
Healthy men VD DEXA 
(l) 
t1/2 DEXA 
(hr) 
VD PRED 
(l) 
t1/2 PRED 
(hr) 
1 143.2 7.70 40.1 3.15 
2 120.9 4.95 58.2 3.85 
3 304.5 3.46 55.6 3.01 
4 277.0 3.85 40.6 2.10 
5 221.7 4.33 50.7 2.77 
6 184.9 1.73 46.7 4.62 
7 217.2 3.85 58.9 4.33 
8 226.6 2.66 45.2 4.33 
Mean 212.0 4.06 49.5 3.52 
SD 61.9 1.66 7.5 0.84 
Asthmatic men 
1 274.6 4.62 57.7 3.15 
2 147.5 4.62 55.5 4.95 
3 267.0 4.62 62.2 3.01 
4 145.8 5.77 61.5 4.33 
5 462.6 3.30 62.0 4.07 
6 139.9 4.95 69.7 3.30 
Mean 239.6 4.65 61.4 3.80 
SD 125.6 0.73 4.9 0.70 
Phealthy/asthma ns ns <0.02 ns 
 
Table 4.1.  Abbreviations: VD DEXA and VD PRED : volume of distribution for DEXA 
and PRED, pdexa/pred: p-value for Wilcoxon rank test between DEXA and PRED, 
phealthy/astma: p-value for Wilcoxon rank between healthy and asthmatic men.  
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Table 4.2. Abbreviations: Inf1: basal infusion not influenced by exogenous GC, 
Inf2: endogenous cortisol production between 4 and 8 a.m., Inf3: the restart of the 
endogenous cortisol production after its inhibition by exogenous GC has stopped, 
Kelcort,  KelcortD and KelcortP: elimination rate constant for cortisol, unaffected or 
changed after DEXA and PRED, respectively, ton: time of onset of Inf3, pdexa/pred 
healthy and asthma: p-value for Wilcoxon paired test between DEXA and PRED for 
healthy and asthmatic subjects, respectively, phealthy/\asthma: p-values for Wilcoxon 
unpaired test, between healthy and asthmatic men.  
  
· In two asthmatic patients cortisol production (Inf3) started 18 and 23 hours after  
    DEXA administration, in the other patients cortisol production did not restart. 
* The Inf1 after PRED was assumed to be the same as after DEXA administration. 
 
 
 
 
Cortisol kinetic data after DEXA 2 mg and PRED 12.5 mg IV 
In healthy and asthmatic men  
 
                                                         DEXA 
 
 
Healthy men                                               
Inf1  
(ng.h-1) 
Inf2 
(ng.h-1) 
Inf3 
(ng.h-1) 
KelcortD 
(h-1) 
 
Ton 
(h) 
 
Mean 27.3 853.2 - 0.46 
 
- 
SD 39.6 239.7 - 0.08 
 
- 
Asthmatic men  
Mean 10.8 691.1 · 0.39 · 
SD 16.9 159.3 - 0.04 - 
Phealthy/asthma ns ns  <0.05  
                                                           PRED 
Healthy men Inf1 Inf2 Inf3 KelcortP  Ton 
Mean * 956.6 499 0.33 26.9 
SD * 280 146 0.04 2.8 
Asthmatic men  
Mean 10.8 817.9 457.6 0.29 25.3 
SD 16.9 364.2 265.7 0.06 0.8 
Phealthy/asthma ns ns ns ns ns 
Pdexa/pred healthy  - <0.05 - <0.01 - 
Pdexa/pred asthma - ns - <0.05 - 
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Pharmacodynamic parameters of the effects on lymphocyte count, OC, and ECP after 
DEXA 2 mg and PRED 12.5 mg IV in 8 healthy and 6 asthmatic men 
 
                                                                          Lymphocyte count 
 
 
Healthy 
men 
 E0 
DEXA  
108*.l -1 
E0 
PRED  
108*.l -1 
Emax  
cortisol 
fraction 
Emax  
DEXA 
fraction 
Emax  
PRED  
fraction 
EC50 
cortisol 
ng.ml-1 
EC50 
DEXA 
ng.ml-1 
EC50 
PRED  
ng.ml-1 
Ke0 
cortisol 
h-1 
Ke0 
DEXA 
h-1 
Ke0 
PRED  
h-1 
Mean 8.5 5.9 0.62 0.98 0.97 76.3 3.86 22.5 9.08 0.31 0.68 
SD 9.1 9.1 0.16 0.02 0.03 63.5 3.6 10.5 20.61 0.10 0.30 
pGC ns ns <0.01* ns ns <0.01* <0.01 <0.01 <0.01* ns ns 
Asthmatic men 
Mean 1.0 2.3 0.86 0.99 0.95 32.3  3.60 10.1 4.79 0.51 1.63 
SD 7.0 6.0 0.13 0.02 0.04 27.6 7.64 6.9 8.52 0.62 2.14 
pGC ns ns ns* ns ns <0.05* <0.05 <0.05 <0.01* ns ns 
phealthy/asthma ns ns <0.02 ns ns ns ns <0.05 ns ns ns 
                                                                          OC 
 
 
Healthy 
men 
 E0 
DEXA 
ng.ml-1 
E0 
PRED  
 ng.ml-1 
Emax  
cortisol 
fraction 
Emax  
DEXA 
fraction  
Emax  
PRED  
fraction 
EC50 
cortisol 
ng.ml-1 
EC50 
DEXA 
ng.ml-1 
EC50 
PRED  
ng.ml-1 
Ke0 
cortisol 
h-1 
Ke0 
DEXA 
h-1 
Ke0 
PRED  
h-1 
Mean 0.98 1.71 0.64 0.99 0.89 65.82 4.01 13.91 3.13 0.05 0.59 
SD 2.60 3.94 0.29 0.02 0.18 44.17 4.91 9.00 4.99 0.02 0.95 
pdexa/pred ns ns <0.05* ns ns <0.01* <0.05 <0.05 <0.05* <0.05* <0.05* 
Asthmatic men 
Mean 0.15 1.60 0.83 1.00 0.97 285.4 1.89 24.8 4.73 0.04 0.86 
SD 2.67 3.35 0.24 0.003 0.07 147.7 1.57 18.2 9.99 0.02 1.82 
pGC ns ns ns* ns ns <0.01* <0.05 <0.05 <0.01* <0.05* <0.05* 
phealthy/asthma ns ns ns ns ns <0.01 ns ns ns ns ns 
                                                                          DECP 
 
 
Healthy 
men 
E0 
DEXA 
ng.ml-1 
E0 
PRED  
 ng.ml-1) 
Emax  
cortisol 
ng.ml-1
 
Emax  
DEXA 
ng.ml-1 
Emax  
PRED  
ng.ml-1 
EC50 
cortisol 
ng.ml-1 
EC50 
DEXA 
ng.ml-1 
EC50 
PRED  
ng.ml-1 
Ke0 
cortisol 
h-1 
Ke0 
DEXA 
h-1 
Ke0 
PRED  
h-1 
Mean 1.2 3.9 3.3 65.5 50.3 134.1 10.4 73.7 14.1 0.65 0.37 
SD 5.3 3.9 4.4 114.7 70.1 255.4 14.1 74.2 33.3 0.95 0.72 
pGC ns ns <0.01* ns ns ns <0.05 <0.05 ns ns ns 
Asthmatic men 
Mean 1.3 2.0 0 34.9 30.9 147.4 1.65 15.51 50.27 0.03 0.24 
SD 7.7 5.5 0 6.2 3.5 158.1 2.5 19.5 99.8 0.005 0.34 
pGC ns ns <0.05* ns ns ns* ns ns ns ns ns 
phealthy/asthma ns ns ns <0.02 ns ns ns ns ns ns ns 
Table 4.3.  Abbreviations E0: the effect value in the hypothetical situation that neither exogenous nor endogenous 
GC is present. Emax cortisol, Emax DEXA and Emax PRED: maximal possible effects of cortisol, DEXA and PRED, 
respectively. For lymphocytes and OC, these are expressed as fraction of E0. EC50 cortisol, EC50 PRED, and EC50 DEXA: 
steady-state plasma concentration leading to 50% of Emax cortisol, Emax DEXA, and Emax PRED, respectively , Ke0cort, 
Ke0dexa and Ke0pred: elimination rate constant after cortisol, DEXA and PRED, respectively, pGC: p-value Wilcoxon 
rank between DEXA and PRED or * a value Friedman’s non-parametric test comparing cortisol, DEXA and PRED. 
For DECP absolute values are given, phealthy/asthma: p-value Wilcoxon rank, between healthy and asthmatic men. E0 
values as given in this table are calculated from the raw data. 
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Table 4.4.  Abbreviations: AUCcort D, AUCcort P, AUCLY D, AUC LY P, AUCOC D, AUCOC P, AUCECP D, 
AUCECP P: area under curve of cortisol, lymphocyte counts, OC and ECP after DEXA and PRED,  
DPratiocortisol, DPratiolymphocytes, DPratioOC, DPratioECP: AUCcort D/AUCcort P, AUCLY D/AUC LY P,  
AUCOC D/AUCOC P, AUCECP D/AUCECP P respectively  , HA ratio’s: AUCcort D /AUCcort D,  
AUCcort p/AUCcort P, AUCLY D/AUC LY D, AUCLY P/AUCLY P, AUCOC D/AUCOC D, AUCOC P/AUCOC P, 
AUCECP D/AUCECP D, AUCECP P/AUCECP P in healthy and asthmatic men, respectively.  
 
Average AUCs of calculated data for cortisol, lymphocyte counts, OC and ECP 
after DEXA 2 mg and PRED 12.5 mg IV in healthy and asthmatic men. 
 
 healthy men asthmatic men  
 mean SD mean SD HA ratio phealthy/asthma 
AUCcortD  (ng/ml.hr) 2012.6 390.3 1758.8 789.6 1.14 ns 
AUCcortP   (ng/ml.hr) 3951.5 867.1 3025.6 1215.8 1.31 ns 
DP ratiocortisol 0.51  0.58    
pdexa.pred <0.01  <0.05    
       
AUCLY D   (ng/ml.hr) 399.0 129.0 521.9 124.0 0.76 <0.05 
AUCLY P   (ng/ml.hr) 458.3 156.3 589.3 268.7 0.78 ns 
DP ratiolymphocytes  0.87  0.88    
pdexa.pred ns  ns    
       
AUCOC D   (ng/ml.hr) 170.7 49.5 91.7 23.3 1.86 <0.01 
AUCOC P   (ng/ml.hr) 213.6 82.1 95.2 20.0 2.24 <0.001 
DP ratioOC 0.80  0.96    
pdexa.pred  <0.01  ns    
       
AUCD ECP D   (ng/ml.hr) 39.1 47.9 265.1 116.7 0.14 <0.01 
AUCD ECP P   (ng/ml.hr) 128.6 134.0 175.3 199.1 0.73 ns 
DP ratioECP 0.30  1.51    
pdexa.pred <0.05  ns    
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Figure 4.1. Abbreviations  (panel A, B, C, and D): CORTc D: calculated concentration-time course (cctc) of 
cortisol after DEXA, CORTc P: cctc of cortisol after PRED, DEXAc: cctc of DEXA, PREDc: cctc of PRED, 
H1-8: healthy subject 1 to 8, P1-6: asthmatic patient 1 to 6. Abbreviations: (panel C and D): CORT D: 
measured concentration-time points (mctp) of cortisol after DEXA, CORT P: mctp of cortisol after PRED, 
DEXA: mctp of DEXA, PRED: mctp of PRED, H1: healthy subject 1, P5: asthmatic patient 5.
 
Average calculated concentration-time courses of DEXA, PRED and cortisol after 
two GCs (DEXA and PRED) in healthy (panel A) and asthmatic men (panel B) and 
the concentration-time courses of DEXA, PRED and cortisol in healthy subject nr 1 
(panel C) and asthmatic subject nr 5 (panel D). 
A 
 
 
B 
 
C 
 
 
 
D 
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Figure 4.2.  Abbreviations (panel A, B, C, and D): LYMPHOC D and LYMPHOC P mean calculated 
lymphocyte count-time course after the administration of DEXA and PRED, respectively, (panel C and D) 
LYMPHO D and LYMPHO P: measured lymphocyte counts. H1-8: healthy subject 1 to 8, H1: healthy 
subject 1, P1-6: asthmatic subject 1 to 6, P5: asthmatic subject 5. 
 
Average calculated concentration-time courses of lymphocyte counts after two 
GCs (DEXA and PRED) in healthy (panel A) and asthmatic men (panel B) and the 
concentration-time courses of lymphocyte counts in healthy subject nr 1(panel C) 
and asthmatic subject nr 5 (panel D).  
 
A 
 
B 
 
C 
 
D 
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Figure 4.3.  Abbreviations (panel A, B, C, and D): OCC D and OCC P: mean calculated concentration-time 
course of OC after DEXA and PRED, respectively, (panel C and D) OC D and OC P: measured plasma 
concentrations of OC after DEXA and PRED, respectively. H1-8: healthy subject 1 to 8, H1: healthy subject 
1, P1-6: asthmatic subject 1 to 6, P5: asthmatic subject 5. 
 
Average calculated concentration-time courses of osteocalcin (OC) after two GCs 
(DEXA and PRED) in healthy (panel A) and asthmatic men (panel B) and the 
concentration-time courses of OC in healthy subject nr 1 (panel C) and asthmatic 
subject nr 5 (panel D).  
 
A 
 
B 
 
C 
 
D 
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Figure 4.4.  Abbreviations (panel A, B, C, and D): dECPC D and, dECPC P: calculated decrement in plasma 
concentrations of stimulated ECP with DEXA and PRED in healthy (H1-8) and asthmatic (P1-6) men, 
respectively; (panel C and D): Abbreviations: dECP D and dECP P: measured decrement in plasma 
concentrations of ECP after DEXA and PRED in healthy subject nr 1 (H1) and asthmatic subject nr 5 (P5), 
respectively.  
 
Average calculated decrement of G-CSF stimulated ECP concentration-time courses 
after administration of DEXA 2 mg or PRED 12.5 mg IV, in healthy (panel A) and 
asthmatic men (panel B) and the calculated and measured decrement in healthy 
subject nr 1 (panel C) and asthmatic subject nr 5 (panel D). 
 
A 
 
B 
 
C 
 
D 
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Abstract 
 
Objective: The medical use of glucocorticoids (GCs) is related to low bone mineral density 
(BMD). In the current study we tested the hypothesis that the cumulative GC dose is not 
related to BMD outcome.  
Design and methods: A cross-sectional study, including healthy individuals with chronic low 
back pain, resistant against conventional treatments. In two steroid-naive subjects, cortisol 
and methylprednisolone (MP) concentrations were serially assessed after a single MP depot 
(160mg epidurally). Furthermore, in 14 men and 14 postmenopausal women, previously 
treated with multiple epidural MP depots, endocrine parameters in relation to BMD outcomes 
were analysed. The minimal cumulative MP dose received by all 28 included subjects was 3 
gram.  
Results: In the two steroid-naive subjects, cortisol concentrations were completely suppressed 
for at least 6 days, and recovered partly in the course of 30 days. During this period, MP 
concentrations remained detectable in plasma. In the 28 subjects, the cumulative MP dose 
received was (mean±1SD): 7.76±4.23g in the men and 8.50±3.13g in the women. None of the 
men had osteoporosis while osteopenia was prevalent in 78.5% according to WHO criteria 
extrapolated to men. Half of the women had osteoporosis and half of them had osteopenia. 
The body mass index (BMI) and endogenous oestradiol levels of the men were not related 
towards BMD outcomes. Univariate linear relationships in women were found between BMI, 
towards spinal (r:0.62; p=0.02) and total hip BMD (r:0.61; p=0.03), but not towards femoral 
neck BMD. In women, relationships were also found between the total and, for protein 
binding corrected oestradiol levels, towards spinal BMD (r:0.70; p=0.01 and r:0.72; p=0.01, 
respectively) and total hip BMD (r:0.53; p=0.08 and r:0.56; p=0.05, respectively). No 
significance was observed between endogenous oestradiol levels and the BMD of the femoral 
neck. 
Conclusions: The administration of a single MP depot (160mg) resembled a systemic low 
peak dose GC exposition. The administration of multiple MP depots in men and women with 
chronic low back pain, revealed no relationship of cumulative GC dose towards BMD. In 
women, however, BMI and oestradiol were related toward spinal and total hip BMD 
outcomes. These findings support the hypothesis of a non-existing relationship between 
cumulative GC dose and BMD outcomes in healthy men and women providing a prior GC 
administration of at least three grams. 
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Introduction 
 
Low back pain is recognised as a disabling condition with serious consequences for the 
quality of life1. Non-steroid anti- inflammatory drugs are usually prescribed as first choice 
agents, but with limited efficacy in a number of patients2. Consequently, a number of 
invasive techniques are used in the clinic aiming at focal tissue destruction and temporarily 
pain relief3. Apart from these techniques, epidural and spinal administration of steroids in 
depots is commonly used4. In fact, these therapies are commonly used in specialised ‘pain 
clinics’. 
   Glucocorticoids (GCs) are clearly efficacious in the suppression of inflammation and 
oedema, which play a role in the origin of radicular pain syndromes5. Despite of a clear 
advantageous effect on pain, the therapeutic window of GCs is narrow due to frequent 
adverse effects. GC therapies are frequently initiated in high doses, while doses are tapered 
when disease activity diminishes. Rapid bone loss occurs particularly at the onset of 
treatment with GCs, and is caused by the initial high GCs dose and/or the activity of the 
disease6-8. Skeletal adverse effects of epidurally administered methylprednisolone (MP) 
depots against bone mineral density (BMD) were never previously reported. It should be 
emphasised that these depots are commonly used in case of intractable low back pain. Apart 
from their pain, often originating from benign vertebral or disc pathologies, many subjects 
are otherwise healthy.  
   It is conceivable, that BMD outcomes are more likely associated to the exposure of GCs 
peak doses than to cumulative GCs doses, previously received. This hypothesis is supported 
by a large epidemiological study conducted in the UK9. Based on this notion, we studied 
BMD outcomes from subjects who had received multiple MP depots for their chronic low 
back pain. We assumed this form of administration to resemble the bio-availability of a daily 
continuous low GC peak dose exposition. Hence, we measured plasma MP and cortisol 
concentrations after a single depot in two healthy steroid-naive subjects. To investigate our 
hypothesis, we further measured some metabolic/laboratory parameters in relation to BMD 
outcomes, in 28 other subjects exposed to multiple MP depots.  
 
Subjects and methods  
 
Subjects 
In two steroid-naive subjects with chronic low back pain, plasma methylprednisolone (MP) 
and cortisol concentrations were determined after a single epidural depot. One man of 42 and 
one women of 36 years old consented to undergo serially venous blood sampling 1, 3, 7 and 
30 days after receiving one MP depot.  
   Furthermore, a group of 28 subjects with intractable chronic low back pain treated with a 
minimal cumulative MP dose of 3g were invited for a clinical study. Recruitment included a 
letter of announcement, which was send to all patients who were still actively treated with 
multiple MP injections. The letter comprised detailed information about the study and an 
invitation to discuss further details with one of the physicians. The Medical Ethical 
Committee of Hospital Reinier De Graaf Groep approved the study.  
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   Forty-two subjects responded and informed consent was obtained in all of them. At 
inclusion, medical histories were taken and physical examinations performed. From the 42 
subjects initially invited, 36 were eligible. From these subjects, 2 men and 6 women 
withdraw their informed consent, leaving 14 men and 14 women to evaluate. These 28 
subjects had received several conventional therapies, directed against chronic low back pain, 
without substantial effect. Due to the current glucocorticoid therapy (GC) all subjects 
reported pain relief and improvement of mobility and were motivated to continue this form of 
treatment. The use of analgesics was only sparsely reported. No one was using drugs that 
could affect calcium metabolism including bisphosphonates, hormonal replacement therapy, 
calcium, and vitamin D formulations. None of the subjects took medication against diabetes 
mellitus at the time of epidural GCs therapy. The use of tobacco and alcohol was only sparse 
in some of them. All subjects were treated with 6 weekly epidural injections containing MP 
depots, 160mg each dose. 
 
Laboratory and Dual X-Ray Absorptiometry (DXA) measurements 
In the 28 subjects, blood samples were drawn between 8 and 9 a.m. With exception for a 
modified High Performance Liquid Chromatography (HPLC) analysis of cortisol and MP in 
two steroid-naive subjects, all hormonal assessments were performed with commercial 
assays. LH reference values in men were: 1-8 U/l and in postmenopausal women: >15 U/l, 
interassay coefficient of variation (CV): 6%; FSH: 1-10 U/l and in postmenopausal women :> 
25 U/l, CV: 9%; Cortisol between 8 and 9 a.m.: 110-730nmol/l, CV: 9%; all these assays 
were from Advia Centaur®, Bayer. Oestradiol reference values in men were: <0.20nmol/l 
and in postmenopausal women: <0.10nmol/l, CV:19%; Total Testosterone (T): in men: 9.0-
35.0nmol/l and in postmenopausal women: 0.5-3.5nmol/l, CV:14%; Sex Hormone Binding 
Globulin (SHBG): in men: 10-70nmol/l and in postmenopausal women: 20-140nmol/l, 
CV:11%; call these assays were from Immulite®, DPC. Oestradiol was adjusted for SHBG 
and expressed as bio-available oestradiol. The reference values of fasting glucose were 3.5-
6.0mmol/l. Adrenal sufficiency was defined if serum cortisol concentrations were less than 
520nmol/l, or a cortisol rise was less than 190nmol/l, 30 minutes after 250mg ACTH1-24 IV 
bolus. MP was analysed with a HPLC with UV detection. Analytical methods followed were 
previously reported by Rose and Jusko10 and modified later by Oosterhuis et al 11. The CV of 
the detection method was approximately 7%. The lower limit of detection in serum was 20 
ng/ml. 
   Bone Mineral Density (BMD) was measured by Dual Energy X-ray Absorptiometry (DXA) 
using a LUNAR Expert-XL densitometer (Madison, WI, USA). Each subject was measured 
at the lumbar spine (L2-4), total hip and femoral neck. Calibration procedures were 
performed every day and after series of eight scans using appropriate phantoms provided by 
the manufacturer. The CV for BMD measurements was 1.3% at the lumbar spine and 1.6% at 
the total hip and femoral neck. Individual values of spinal, total hip and femoral neck BMD 
were expressed in absolute values (g/cm2). BMD values of the spine, total hip, and femoral 
neck regions were expressed in absolute values (g/cm2) and according to the definitions 
‘normal, osteopenia and osteoporosis’ proposed in 1994 by the WHO for women12. We used 
the same definitions also for men. Osteopenia (-2.5 SD < BMD T-score < -1.0 SD) and 
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osteoporosis (BMD T-score £ -2.5 SD) were studied with reference to a database of 
Caucasian males and females provided by Lunar Inc. The absolute BMD values 
corresponding with T = -1.0 SD and -2.5 SD in males were 1.121 and 0.941 at the lumbar 
spine, 0.975 and 0.780 at the total hip and 0.968 and 0.773g/cm2 at the femoral neck. 
Absolute BMD values in females were 1.080 and 0.900g/cm2 at the lumbar spine, 0.887 and 
0.707g/cm2 at the total hip, and 0.878 and 0.698g/cm2 at the femoral neck.  
 
Statistical analysis 
Comparisons between laboratory and BMD outcomes of men and women, and of 
overweighed and non-overweighed individuals, were performed with Wilcoxon Rank tests. 
Associations between laboratory parameters and BMD outcomes were performed with 
Spearman Rank correlation’s, expressed as r; p<0.05 was considered as statistically 
significant. 
 
Results 
 
Clinical aspects 
Plasma cortisol and methylprednisolone (MP) concentrations obtained from two steroid-naive 
subjects are listed in Table 5.1. As depicted, the MP concentrations were detectable at day 1, 
3, 7 and 30, while cortisol concentrations recovered to 22% in the male and 67% in the 
female subject. 
   Demographic data of the 28 subjects, 14 men and 14 women, treated with multiple GCs 
depots are demonstrated in Table 5.2. None of these subjects had clinical features of overt 
hypercortisolism i.e. moon facies or buffalo hump. Eleven subjects, 3 men and 8 women, 
used either medical therapy against hypertension and/or had systolic blood pressures 
³160mmHg and/or diastolic pressure ³95mmHg (at 2 consecutive measurements). The men 
were younger than the women and they had a higher body mass index (BMI). Both genders 
had received similar cumulative MP doses.  
   Using the criteria for glucose intolerance issued by the American Diabetes Association 
(ADA)13, we found fasting plasma glucose concentrations of <6.1 (normal), 6.1-7.0 
(carbohydrate intolerance), and ³7.0 mmol/l (diabetes mellitus) in 17, 4, and 8 subjects, 
respectively. Their mean fasting glucose concentrations were (SD): 4.9 (0.5), 6.3 (0.3), and 
8.3mmol/l (1.4) with a BMI of 24.9 (2.4), 27.8 (4.7), and 27.4kg/m2 (4.4), respectively.  
   One man and one woman had adrenal insufficiency according to aforementioned criteria 
(not listed in Table 5.2). The men had higher endogenous total oestradiol levels as well as 
levels corrected for protein binding (oestradiol/SHBG*100 = bio-oestradiol), and lower 
SHBG concentrations, compared to the women. Furthermore, their BMD outcomes of the 
spine, total hip and femoral neck regions were higher.  
   Overweight and normal weight was categorised using accepted clinical guidelines in 
adults14. As listed in Table 5.3 the men with and without overweight had different fasting 
glucose and SHBG concentrations, but similar BMD outcomes. Table 5.3 also illustrates that 
the women with and without overweight had a different spinal and total hip BMD. Both 
groups of women had similar fasting glucose, oestradiol and bio-oestradiol levels.  
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BMD outcomes of the spine, total hip and femoral neck regions in the men and women are 
listed in Table 5.4. None of the men had osteoporosis and 11 had osteopenia (of at least one 
skeletal region). Half of all women had osteoporosis, while the others had osteopenia (of at 
least one skeletal region). The analysis was also performed after correction for age (Z-scores) 
and listed in Table 5.5.  
 
Correlation’s 
No significant relationships were found, either in the men or in the women, between the 
cumulative MP dose and the BMD of the spine, total hip, and femoral neck. Considering 
relationships of BMI towards oestradiol levels in the men, correlation’s were found between 
BMI and oestradiol (r:0.47; p=0.08) and bio-oestradiol (r:0.64; p=0.02). Considering 
relationships of carbohydrate metabolism towards BMI and oestradiol levels, correlation’s 
were found between fasting glucose and BMI (r:0.60; p=0.03), between fasting glucose and 
oestradiol (r:0.55; p=0.04) and between fasting glucose and bio-oestradiol (r:0.66; p=0.02). 
Fasting glucose, oestradiol or bio-oestradiol bore no relationships towards spinal, total hip 
and femoral neck BMD outcomes. Finally, no relationships were observed between BMI and 
BMD outcomes at any skeletal site measured. 
   A different picture emerged in the women studied. Considering relationships of BMI 
towards endogenous oestradiol levels, correlation’s were found between BMI and oestradiol 
(r:0.49; p=0.07) and between BMI and bio-oestradiol (r:0.60; p=0.03). Considering 
relationships of carbohydrate metabolism towards BMI, oestradiol levels and BMD, no 
correlation’s were observed. Significant relationships were found between BMI towards 
spinal BMD (r:0.62; p=0.02) and towards total hip BMD (r:0.61; p=0.03), but not towards 
femoral neck BMD. Relationships were also existent between the endogenous levels of 
oestradiol and bio-oestradiol towards the outcome of spinal BMD (r:0.70; p=0.01 and r:0.72; 
p=0.01, respectively). There was a trend to significance between the levels of oestradiol and 
bio-oestradiol towards the BMD outcome of the total hip (r:0.53; p=0.08 and r:0.56; p=0.05, 
respectively). Finally, no significance was observed between oestradiol levels towards the 
BMD of the femoral neck. 
 
Discussion 
 
In this cross-sectional study, we investigated the hypothesis that the cumulative 
glucocorticoid (GC) dose received over lifetime did not bear any relationship towards bone 
mineral density (BMD) outcomes of the spine, total hip and femoral neck regions. This 
hypothesis emerged from the results of a formerly performed study by our group, in men with 
Chronic Obstructive Pulmonary Disease (COPD)15. In this cross-sectional analysis, we found 
no associations between cumulative GCs doses, either as prednisone tablets daily or as short 
courses, towards BMD outcomes. The lowest BMD outcomes were observed in men who 
received the GCs therapy in courses, while men taking prednisone daily had far higher BMD 
outcomes despite of at least ten fold higher cumulative GC doses previously received. The 
BMD differences were observed at the region of the lumbar spine and persisted after 
adjusting for age, disease severity and smoking habits. 
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In order to test our hypothesis, we included subjects treated with multiple MP depots up to 
high cumulative doses. We assumed that these subjects were exposed to low GC peak doses, 
continuously released from the methylprednisolone (MP) depots. The two steroid-naïve 
subjects, who underwent serially blood sampling after their first epidural MP administration, 
confirmed this assumption. After their first depot, complete cortisol suppression in both 
subjects was observed, which lasted for at least 6 days, and which was followed by 
incomplete cortisol suppression during several weeks thereafter. These findings strengthen 
the assumption, that the bioavailability of an MP depot resembles that of a daily continuous 
low peak dose infusion.  
   Increased bone loss is regarded as one of the most important adverse effects of systemically 
administered GCs. As expected, we found a higher osteopenia prevalence in the men (78.5%) 
and higher osteoporosis prevalence in the women (50%), compared to what has been 
observed in the general population. In a Canadian prospective cohort study among men over 
fifty years of age, an osteoporosis prevalence was observed in 2.9% at the lumbar spine and 
4.8% at the femoral neck. Osteopenia was prevalent in a third if, like in the current study, 
men’s reference standards were used16. In women who were older than 50 years, an 
osteoporosis prevalence of 12.1% was observed at the lumbar spine and of 7.9% at the 
femoral neck. Osteopenia at the femoral neck was prevalent in 50%. Osteoporosis at the 
lumbar spine and femoral neck, in a cohort of 60 to 69-year-old women, was found in 15 and 
10%, respectively.  
   We speculate that the non-existent relationship of cumulative GCs doses towards BMD 
outcomes can be ascribed to the bio-availability of MP depots, i.e. a continuous daily low GC 
dose. Apart from osteopenia, we did not observe any male with osteoporosis even though 
they were exposed to large cumulative GCs doses. This finding supports our hypothesis that 
the relationship between high cumulative GC doses and one of the typical adverse effects of 
GCs reported after high peak dose regimens, i.e. rapid bone loss6-8,17-19, is lacking. A 
mechanism that could explain this type of rapid bone loss is the observed GC-induced 
extension of the osteoclast life span20. Enhanced bone loss, probably elicited by other 
mechanisms, was recently demonstrated during regular GC use. For example, longitudinal 
studies have shown that regular inhaled GCs use will affect the bone of COPD patients21,22. 
The current observations were made in subjects with chronic low back pain without systemic 
illness or life threatening COPD exacerbation’s, thereby excluding factors interfering with 
bone loss. The present observations that GC cumulative dose and BMD behaved 
independently confirmed our former findings in men with COPD15. 
   Considering the independence of cumulative GCs dose and BMD, we also questioned 
whether endogenous oestradiol levels and BMD were related since the latter relationship has 
been reported previously23,24. This relationship was confirmed by our study, although only in 
postmenopausal women. Our findings were further in agreement with the literature i.e. that 
postmenopausal women with overweight had the highest oestradiol levels, independently of 
glucose concentrations25,26. A different picture emerged in men, who had higher oestradiol 
levels than postmenopausal women as previously reported27. Endogenous oestradiol levels in 
these men were related to their overweight and carbohydrate metabolism, but bore no 
relationship towards BMD outcomes. In men with overweight, we also found a higher non-
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bound oestradiol fraction and, as older studies already have pointed, we had clear indications 
that the adipose tissues serve as source for oestradiol production28,29.  
   Our study has several limitations. In the first place, the number of included individuals was 
small and all subjects had already received a minimum cumulative MP dose of 3g. MP dose 
(160mg) and dose interval (once per six weeks) implied a treatment period of at least 2.3 
years prior to inclusion. It is conceivable that, during this period, critical loss of BMD had 
taken place. Secondly, the cumulative MP dose distribution appeared to be rather small and 
this could have been responsible for the lack of association between cumulative MP dose and 
BMD. Thirdly, multiple epidural administrations of GCs may interfere with spinal BMD 
outcomes assessed with Dual X-Ray Absorptiometry (DXA). However, the GCs depots were 
equally distributed among subgroups. Fourthly, our reported osteoporosis/osteopenia 
prevalence data definitely were subtracted from small groups allowing interference of 
confounding factors. To minimise selection bias we only included subjects who were 
regularly treated in one pain clinic. Regardless of their chronic low back pain, all study 
participants were otherwise healthy. They were completely mobile, analgesics were 
sporadically used and none of the included subjects had vertebral fractures on X-rays, which 
were performed shortly before inclusion. Finally, a large number of statistical tests were 
performed on a sample size of n=28. No Bonferroni correction was applied, which implicates 
that, in case of finding statistical significant correlations, these results should be regarded as 
hypothesis generating rather than hypothesis confirming. However, in this study we did not 
find a correlation between possible side effects and cumulative MP dose, which implicates 
that by not applying the Bonferroni correction, even hypothetical side effects could not be 
assumed. 
 
In summary 
BMD outcomes in 14 men treated with multiple MP depots revealed no osteoporosis and 
osteopenia in 78.5%. BMD outcomes in 14 postmenopausal women, who received a similar 
therapy, revealed osteoporosis in 50% and osteopenia in the remainder half of the group. The 
cumulative GCs dose received had no relationship with BMD outcomes, either in men or in 
women. Being a female with overweight correlated positively with spinal and total hip BMD 
outcomes, while no such associations were observed in men. Interrelationships of BMI, 
fasting glucose and oestradiol levels (total as well as corrected for protein binding) were 
exclusively observed in men. The results of the current study indicate that the cumulative GC 
dose, which started at a minimum cumulative dose of 3g MP in depots, appeared to be 
independently from BMD.  
 
Acknowledgements 
We are indebted to Mr. Oscar LH van Hemel, MD, for advice during the performance of the 
study and to Mrs. Ineke Bosman and Mrs. Els Portier for excellent laboratory support. 
Chapter V: Cumulative methylprednisolone depots bear no relationship towards BMD outcomes. 
 
 92 
 
      t = 0 t =2 days t = 3days t = 6days t = 30days 
male 
 
cortisol (nmol/l) 320 7 9 7 70 
MP (ng/ml) 0 23.5 13.2 7.7 4.0 
female 
cortisol (nmol/l) 468 10 3 214 322 
MP (ng/ml) 0 20.2 12.8 5.1 3.1 
 
Table 5.1. Cortisol and methylprednisolone concentrations in two steroid-naive subjects treated with a 
single 160mg depot epidurally. Cortisol and methylprednisolone (MP) concentrations were serially 
determined in plasma by high performance liquid chromatography (HPLC). 
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Table 5.2. Clinical characteristics, laboratory findings and BMD outcomes in 28 men and 
women treated with multiple methylprednisolone depots. Abbr. BMI: body mass index, MP: 
methylprednisolone, bio-oestradiol = oestradiol/SHBG*100, T: total testosterone, SHBG: sex 
hormone binding globulin, FSH: follicle stimulating hormone, LH: luteinizing hormone, BMD: 
bone mineral density. p-value <0.05 is considered as significant. 
clinical characteristics male female p-value 
N 14 14  
age (year) 54 ± 9 68 ± 9 <0.05 
body weight (kg) 83 ± 9 68 ± 10 <0.05 
BMI (Kg/m2) 27.3 ± 2.8 24.9 ± 3.7 ns 
MP (cumulative dose) (gram) 7.76 ± 4.23 8.50 ± 3.13 ns 
laboratory findings    
glucose (mmol/l) 6.4 ± 2.0 5.6 ± 1.3 ns 
oestradiol (nmol/l) 0.09 ± 0.04 0.05 ± 0.01 ns 
bio-oestradiol  0.23 ± 0.18 0.05 ± 0.07 <0.001 
T (nmol/l) 15.8 ± 5.4 0.7 ± 0.7 <0.001 
SHBG (nmol/l) 46 ± 16 72 ± 45 <0.05 
FSH (U/l) 4.4 ± 3.4 60.2 ± 21.6 <0.001 
LH (U/l) 4.9 ± 1.5 28.2 ± 12.9 <0.001 
BMD outcomes 
lumbar spine  (g/cm2) 1.23±0.20 1.00±0.19 <0.01 
total hip (g/cm2) 0.98±0.12 0.79±0.14 <0.001 
femoral neck (g/cm2) 0.92±0.12 0.74±0.14 <0.01 
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normal weight overweight 
 
p-values 
normal vs. overweight 
clinical characteristics men women men women men women 
N 7 7 7 7   
age (year) 55±12 67±8 54±10 66±11 ns ns 
laboratory findings       
glucose (mmol/l) 5.3±1.1 5.5±1.4 7.5±2.1 5.8±0.98 0.04 ns 
bio-oestradiol 0.15±0.16 0.03±0.02 0.33±0.17 0.09±0.11 0.02 ns 
T (nmol/l) 15.7±4.2 0.36±0.44 15.8±6.9 0.69±0.82 ns ns 
SHBG (nmol/l) 54.5±16.3 94.3±50.5 36.5±12.2 42.6±16.9 0.003 0.01 
MPcumulative dose (g) 7.71±4.25 8.21±2.96 7.81±4.55 8.08±3.89 ns ns 
BMD outcomes 
lumbar spine (g/cm2) 1.16±0.10 0.94±0.21 1.30±0.25 1.09±0.13 ns 0.03 
total hip (g/cm2) 1.00±0.10 0.73±0.12 0.97±0.12 0.90±0.12 ns 0.02 
femoral neck (g/cm2) 0.93±0.08 0.72±0.15 0.91±0.16 0.81±0.13 ns ns 
 
Table 5.3.  Clinical characteristics, laboratory findings and BMD outcomes of the lumbar spine total hip and 
femoral neck in 14 men and 14 women treated with multiple methylprednisolone depots. Normal weight is 
defined as a BMI <25 Kg/m2, overweight is defined as a BMI >25 Kg/m2. Abbr. BMI: body mass index, Bio-
oestradiol = oestradiol/SHBG*100, T: total testosterone, SHBG: sex hormone binding globulin, MP: 
methylprednisolone, BMD: bone mineral density.  
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normal {0} osteopenia {-1.0 SD} osteoporosis {-2.5 SD} 
 
T-scores 
men women men women men women 
BMD (g/cm2) >1.121 > 1.080 >0.941 >0.900 £0.941 £0.900 
N 8 3 6 6  5 
lumbar 
spine 
% 57 21 43 43 0 36 
BMD (g/cm2) 0.975 >0.887 >0.780 >0.707 £0.780 £0.707 
N 7 3 7 6  5 
total hip 
% 50 21 50 43 0 36 
BMD (g/cm2) >0.968 >0.878 >0.773 >0.698 £0.773 £0.698 
N 3 3 11 4  6 
femoral 
neck 
% 21% 21% 79% 29% 0% 43% 
 
Table 5.4.  BMD outcomes of the lumbar spine, total hip and femoral neck regions in 14 men and 14 women 
treated with multiple methylprednisolone depots. Bone mineral density (BMD) outcomes (g/cm2) at the spine, 
total hip and femoral neck are cited with reference to normative data derived as T-scores (Lunar Inc). BMD 
values (g/m2) correspond with T-scores of 0,-1.0, and -2.5 SD {between parenthesis} derived from US Caucasian 
men and US Caucasian women. 
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Z-scores ³ 0 -1 £ Z < 0 -2 £ Z < -1 -3 £ Z < -2 
 men women men women men women men women 
lumbar spine 
5/14   
 (36%) 
4/14 
(29%) 
5/14 
(36 %) 
6 /14 
(43%) 
4/14 
(29%) 
4/14 
(29%) 
- - 
total hip 
4/14   
(29%) 
7/14 
 (50%) 
6/14 
(43%) 
3/14 
(21%)  
4/14 
(29%) 
4/14 
(29%) 
- - 
femoral neck 
2/14 
(14%) 
5/14 
(36%) 
7/14 
(50%) 
4/14 
(29%) 
4/14 
(29%) 
5/14 
(36%) 
1/14 
(7%) 
- 
 
Tabel 5.5.  BMD outcomes (Z-scores) of the lumbar spine, total hip and femoral neck in 14 men and 14 women 
treated with multiple methylprednisolone depots. Bone mineral density (BMD) Z-scores at the spine, total hip 
and femoral neck per gender with reference to normative data provided by Lunar Inc.  
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Abstract 
 
Background: Quantitative Ultrasound (QUS) has been claimed as an alternative technique for risk 
assessment of hip fractures associated with osteoporosis. However, reports concerning modest 
correlations between QUS parameters and dual energy X-ray absorptiometry (DXA) in women 
raise questions about the reliability of QUS technology to predict bone mineral density (BMD). 
Partially the lack of stronger correlations may be due to heterogeneity in bone architecture 
deterioration which may be more pronounced in older than in younger women. Therefore, it was 
thought important to study QUS / DXA interrelationships in subgroups of premenopausal and 
postmenopausal women. 
Methods: We studied 217 pre- and postmenopausal women between the age of 25 to 75 years, 
who were referred for a BMD measurement because of osteoporosis in at least one family member 
either in the first or in the second degree. All women had a calcaneal QUS and a DXA measurement 
at the lumbar spine, total hip and femoral neck. 
Results: The linear regression coefficients between the QUS parameters, broadband ultra-sound 
attenuation (BUA) and speed of sound (SOS) and DXA at the various sites in the group as a whole 
were 0.53 to 0.54 (p<0.0001). Significantly lower regression coefficients between BUA and DXA 
at the total hip and the femoral neck were found in premenopausal women (r=0.31 and 0.38, 
p<0.0001) compared to postmenopausal women (r=0.56 and 0.53; p<0.0001). For SOS there 
was no significant difference between the regression coefficients in the pre- and postmenopausal 
group. The overall prevalence of osteoporosis as assessed by DXA in the total group was 25% (6% 
in the pre- and 36% in the postmenopausal group). BUA failed to detect osteoporosis in all 5 
premenopausal women but also in twenty out of fifty postmenopausal women with osteoporosis 
according to DXA measurements. SOS measurements were even worse in this respect. 
Conclusions: Linear regression coefficients between calcaneal QUS parameters and DXA are only 
modest considering a group of 25–75 year old Dutch women. In the subgroup of premenopausal 
women correlations between BUA and BMD at the hip and femoral neck are worse compared to 
those in postmenopausal women. The predictive value of QUS parameters for BMD is limited; 
therefore it is not appropriate to use QUS as a surrogate for DXA. 
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Introduction 
 
Osteoporosis is a major cause of morbidity because of its association with fragility fractures. It is 
characterised by both low bone mass and deterioration of the bone micro-architecture. Osteoporosis 
is diagnosed in terms of bone mineral density (BMD) as measured by dual energy x-ray 
absorptiometry (DXA) according to criteria formulated by the WHO1. A new technique to measure 
bone quality is quantitative ultrasound (QUS)2-6. Most of the commercially available ultrasound 
devices have been developed for measurements at the calcaneus, as this bone contains a high 
percentage of trabecular bone mimicking that of the spine and the hip4,7. For measurements of the 
calcaneus, the QUS parameters broadband ultrasound attenuation (BUA) and velocity or speed of 
sound (SOS) are the two most commonly used. 
   In two large clinical studies, QUS measurements at the os calcis predicted hip fractures equally 
well as DXA measured at the spine or hip in elderly women8,9. However, this promising finding 
seems to be in contrast to earlier reported modest correlations between QUS measurements at the 
calcaneus and BMD measurements of the spine or the femoral neck in postmenopausal women 
(r=0.37 to 0.68)10-16. Besides by the fact that QUS and DXA measurements were performed at 
different skeletal sites, this discrepancy may also be explained by the fact that QUS measures other 
mechanical properties of bone than BMD and in vitro there is evidence, that QUS parameters are 
structure related17-23. 
   Therefore, QUS and DXA may show different results due to differences in the assessment of 
mechanical properties of bone. In postmenopausal osteoporosis, there is not only a decrease of 
BMD, but also a deterioration of the trabecular architecture. A decrease of trabecular number and 
increased trabecular spacing has been reported in the calcaneus and distal radius of postmenopausal 
women with osteoporosis compared to postmenopausal women without osteoporosis and 
premenopausal women24,25. Therefore, when QUS parameters are structure related the correlations 
between QUS parameters and BMD may be worse for premenopausal compared to 
postmenopausal women. Remarkably, data concerning correlation coefficients between QUS 
parameters and DXA in premenopausal women as compared to postmenopausal women are sparse. 
   In the present study we compared linear regressions of QUS parameters and BMD measured at 
the lumbar spine, total hip and femoral neck in premenopausal and postmenopausal women. 
Moreover, we assessed the predictive values of QUS for BMD defined osteoporosis in both groups.  
 
Subjects and Methods  
 
Subjects 
A total of 217 women aged 54 (14) years (mean (1SD)), range 25–75 years, was studied. In the 
premenopausal group there, were 28 women between 25 and 35 years, 34 between 35 and 45 
years and 18 between 45 and 55 years. In the postmenopausal group, there were 36 women 
between 45 and 55 years, 46 between 55 and 65 years and 55 between 65 and 75 years. All 
subjects were referred for a DXA measurement by their general practitioner. The reason for their 
referral was the presence of osteoporosis in at least one family member either in the first or in the 
second degree. All subjects reported to be healthy without other conditions that could affect their 
bone and mineral metabolism. No elementary calcium, vitamin D analogues, glucocorticoids or 
bisphosphonates were taken. Women who were amenorrhoeic for at least 12 months were defined 
as postmenopausal, all other women as premenopausal. Based on these definitions, 80 women were 
premenopausal and 137 postmenopausal. After informed consent was obtained a DXA 
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measurement and a QUS measurement was performed in all participants. The study was approved 
by the Medical Ethical Committee of the Reinier de Graaf Groep in the Netherlands. 
   QUS measurements of the right heel were performed with a Sahara ultrasound device (Hologic 
Inc, Waltham, MA, USA). The acoustic properties broadband ultrasound attenuation (BUA, 
dB/MHz) and speed of sound (SOS, m/s) were assessed and calculated by the software provided 
by the manufacturer. Acoustic phantoms were scanned daily and the results showed no drift over the 
time period of the study. The same operator performed all measurements in order to minimise 
operator and technical intervariability. The heel of each patient was measured thrice with complete 
interim repositioning between the measurements. The calculated coefficient of variation (CV) for 
BUA measurements was 4.6% and for SOS 0.9%. 
   BMD was measured by DXA using a LUNAR Expert-XL densitometer (Madison, WI, USA). 
Each subject was measured at the lumbar spine (L2-4), total hip and femoral neck. Calibration 
procedures were performed every day and after series of eight scans using appropriate phantoms 
provided by the manufacturer. The CV for BMD measurements was 1.3% at the lumbar spine and 
1.6% at the total hip and femoral neck. Individual values of vertebral and femoral BMD were 
expressed in absolute values (g/cm2) and in T-scores according to the database delivered by Lunar 
Inc. 
 
Data and statistical analysis 
WHO definitions of osteopenia (-2.5 SD < BMD T-score < -1.0 SD) and osteoporosis (BMD T-
score < -2.5 SD) were used for the analysis. The absolute BMD values corresponding with T = -1.0 
SD and -2.5 SD were obtained from the manufacturers database. These values were 1.080 and 
0.900g/cm2 at the lumbar spine, 0.887 and 0.707g/cm2 at the total hip, and 0.878 and 0.698g/cm2 
at the femoral neck, respectively. Linear regression coefficients (r) between BUA, SOS and BMD 
were calculated and compared with covariance analysis.  
   Discriminant analysis with leave-one-out cross validation was performed to calculate the pre-test 
sensitivity and specificity of BUA and SOS to diagnose or to rule out osteoporosis. With Receiver 
Operator Characteristics (ROC) analyses the optimal sensitivity and specificity for BUA and SOS 
were calculated. Differences between ROC curves were compared with the McNemar test. Cut-off 
values for BUA and SOS corresponding to either 90% sensitivity or 90% specificity were 
determined non-parametrically. The positive and negative predictive value of BUA and SOS to 
predict the chance of osteoporosis, based on a 0-100% osteoporosis prevalence range in the 
population were calculated using Bayes law.  
 
Results 
 
The demographic data of the 80 premenopausal and 137 postmenopausal women are presented in 
Table 6.1. The diagnosis osteopenia or osteoporosis was established when the WHO criteria were 
fulfilled at any site measured (lumbar spine, total hip and femoral neck). Of the total group of 217 
women, 83 had osteopenia (38%) and 55 had osteoporosis (25%). Of the women with osteopenia, 
23 were premenopausal (28%) and 60 postmenopausal (72%). Of the women with osteoporosis, 5 
were premenopausal (9%) and 50 postmenopausal (91%). Hence we found osteoporosis in 6% of 
80 premenopausal women and in 36% of the 137 postmenopausal women.  
   Linear regression coefficients between the QUS parameters BUA and SOS on the one hand and 
BMD on the other were not significantly different (Figure 6.1). For the whole group of women these 
were 0.53 at the lumbar spine and 0.54 at the total hip and femoral neck for both BUA and SOS 
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(p<0.0001). In the subgroup of premenopausal women linear regression coefficients between BUA 
and BMD were 0.51 at the lumbar spine, 0.31 at the total hip and 0.38 at the femoral neck (all 
p<0.001). In the postmenopausal women the regression coefficients between BUA and BMD were 
0.47, 0.56 and 0.53 for the lumbar spine, total hip and femoral neck respectively, all p<0.001 
(Figure 6.2). There was no statistical significant difference between the regression coefficients of pre- 
and postmenopausal women at the lumbar spine. However, the regression coefficients between BUA 
an BMD at the total hip and femoral neck were significantly lower in the premenopausal group 
(p<0.01). The linear regression coefficients between SOS and BMD in premenopausal women were 
0.56 at the lumbar spine, 0.42 at the total hip and 0.45 at the femoral neck (all p<0.001). In 
postmenopausal women these regression coefficients were 0.47, 0.50 and 0.45, respectively (all 
p<0.001). There was no statistically significant difference between the regression coefficients 
between SOS and BMD of pre- and postmenopausal women.  
   With ROC analysis, optimal cut-off values of BUA and SOS were calculated for osteoporosis, 
defined as BMD T-score < -2.5 SD at either the lumbar spine or the total hip or the femoral neck 
(corresponding with absolute BMD values of <0.900, <0.707 and <0.698g/cm2, respectively). The 
sensitivity of BUA and SOS ranged between 70% and 79%, and the specificity between 69% and 
79% (Table 6.2). There was no statistically significant difference between the ROC curves for BUA 
and SOS, neither for the single sites nor for three sites together.  
   The positive and negative predictive values of BUA and SOS to predict the chance of BMD 
defined osteoporosis, using optimal sensitivity and specificity values as a function of osteoporosis 
prevalence, are graphically demonstrated in Figure 6.2. In case of an osteoporosis prevalence of 
25%, as found in the total group of 217 women in the current study, the positive predictive value of 
BUA was 54% and the negative predictive value 91%. For SOS these percentages were 43 and 
95%, respectively. Nevertheless, all 5 premenopausal women with BMD defined osteoporosis were 
missed both with BUA and SOS. In any of the 75 premenopausal women without osteoporosis the 
prediction with both QUS parameters was truly negative, which corresponds with a positive 
predictive value of 0% and a negative predictive value of 94%. Of the 50 postmenopausal women 
with osteoporosis, only 30 were detected with BUA (sensitivity: 60%) and 24 with SOS (sensitivity: 
48%). Of 87 postmenopausal women without osteoporosis, 74 were accurately diagnosed with 
BUA (specificity: 85%) and 79 with SOS (specificity: 91%). These results are presented in Table 
6.3. The positive and negative predictive values for BUA were 70% and 79%, for SOS both 75%.  
   When assuming a pre-test sensitivity of 90% for the whole group (corresponding to a BUA cut-off 
value of 88.3dB/MHz and a SOS cut-off value of 1583m/s), specificity was only 53%. When 
assuming a pre-test specificity for the whole group of 90% (corresponding to a BUA cut-off value of 
70dB/MHz and a SOS cut-off value of 1546m/s), sensitivity was only 44%. 
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Discussion 
 
The purpose of the current study was to compare regression coefficients between QUS parameters 
and BMD measured with DXA and to analyse the predictive values of QUS determinations for the 
diagnosis of osteoporosis. The study was performed in a selected group of 217 Dutch women with 
osteoporosis in the first or second degree and the analysis was focussed on the group as a whole as 
well as on subgroups of premenopausal and postmenopausal women. Studies as such are of 
importance since implementation of QUS technology may become a part of future clinical decision 
making. The equipment is of low cost and radiation free, which makes it attractive for use in daily 
clinical practice. Furthermore, its ability for independent prediction of hip fractures has been shown 
previously in large clinical prospective studies8,9. Those studies included only women of at least 65 
years old, whereas fracture risk assessment studies with QUS in younger women are lacking. Since 
the outcome of BMD measurements is accepted by the WHO as gold standard for the diagnosis of 
osteoporosis, it is useful to compare QUS with BMD. 
   We found statistically significant but rather weak regression coefficients between the QUS 
parameters BUA and SOS on the one hand and DXA at the lumbar spine, total hip and femoral 
neck on the other. This is in agreement with earlier studies10-16. These earlier studies were performed 
either in a group of postmenopausal women only or in a mixed group of pre- and postmenopausal 
women, but so far the relationship between the results obtained with both techniques was not 
separately assessed for the premenopausal group. In the present study, we found significantly lower 
linear regression coefficients between BUA and total hip and femoral neck BMD coefficients in 
premenopausal women, as compared to postmenopausal women. For SOS we did not find different 
regression coefficients between the pre- and postmenopausal groups. 
   The rather weak regression coefficients between QUS parameters and BMD may be due to 
differences in the measurement sites, bone geometry and the impact of soft tissue composition. In 
addition, there is substantial evidence from in vitro studies, that QUS parameters are not only related 
to bone density, but also to the bone microarchitecture17-23. As QUS parameters and BMD show 
independent associations with fracture risk8,9, it is likely that both techniques measure different 
properties related to bone strength. Hence moderate correlations between both techniques may be 
expected. 
   The correlations that were found between BUA and BMD at the total hip and femoral neck were 
significantly weaker in premenopausal than in postmenopausal women. Accelerated bone loss starts 
around menopause and in addition to a decrease in density, it is reported that bone structure is also 
deteriorated: a decrease of trabecular number and trabecular spacing in the calcaneus and distal 
radius is present in bone of osteoporotic postmenopausal women as compared to premenopausal 
and not osteoporotic postmenopausal women24,25. Furthermore, in vitro there is evidence that SOS 
is linearly correlated with BMD, while the correlation of BUA and BMD is non-linear26-29. Based on 
the considerably weaker correlation coefficients between BUA and total hip and femoral neck BMD 
in premenopausal as compared to postmenopausal women, we speculate that BUA is relatively 
insensitive to detect low BMD when the micro architecture is still intact. When bone loss proceeds, 
the lowering of BMD will eventually be accompanied with loss of trabeculae. It is likely that the 
correlation between BMD and QUS parameters is improved in this situation. The correlations 
between BUA and BMD at the lumbar spine are not different between the pre- and postmenopausal 
group, but BMD data of the lumbar spine should be interpreted with caution because of arthritic 
changes in later life. Lumbar spine BMD of elderly people may therefore be inaccurate30,31, and this 
may influence the correlations with QUS.  
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   In the present study, the positive and negative predictive values of BUA for BMD outcome were 
54% and 91% respectively. For SOS these percentages were 43% and 95%. Although these 
negative predictive values are high one must realise that, especially in the premenopausal group, 
osteoporosis prevalence is relatively low. Therefore, in our study there was a considerable number of 
false negative QUS results. BUA and SOS failed to detect BMD defined osteoporosis in all of 5 
premenopausal women and in 20 (for BUA) and 26 (for SOS) of 50 postmenopausal women. 
Referring to the earlier mentioned hypothesis we speculate that in these latter cases the micro 
architecture was still intact despite extensive bone loss, which resulted in relatively high QUS values 
and low BMD outcomes. Based on these results it is not appropriate to use QUS parameters as 
predictors for BMD. 
   We found an osteoporosis prevalence of 6% in the premenopausal group and 36% in the 
postmenopausal group. Compared with previous population-based Dutch studies32,33, osteoporosis 
prevalence is high particularly in the postmenopausal group. The present study however was not 
designed to analyse the prevalence of osteoporosis in the Netherlands. The main reason for referral 
was the familiar occurrence of osteoporosis either in the first or in the second degree. Therefore a 
substantial selection bias should be taken into account when comparing our data with those from 
population-based studies. We accepted such a selection bias for the present study, since it mimics 
daily practice in referral for a DXA measurement. The combination of these kinds of analyses and 
population-based prevalence studies are necessary to provide sufficient information to design 
diagnostic strategies in the near future. 
   QUS is not implemented in the diagnostic work-up of patients suspected of osteoporosis in the 
Netherlands34,35. Despite large clinical studies showing adequate risk assessment of hip fractures, 
there are valid arguments against implementation of QUS in daily practice. First, there are no strictly 
defined cross-calibration procedures for the different devices available on the market. Furthermore, 
there is no uniform reference database and factors like ankle oedema and foot positioning influence 
the results and reproducibility of the measurements. Treatment follow-up is hampered by these 
factors6. The results of the current study add arguments against the use of QUS as an estimate for 
BMD on a routine basis. The technique itself is however promising for evaluation of bone quality and 
prospective studies are encouraged to further explore the value of QUS for fracture risk assessment. 
 
In summary 
Linear regression coefficients between calcaneal QUS parameters and DXA are only modest 
considering a group of 25–75 year old Dutch women. In premenopausal women, correlations 
between BUA and BMD at the hip and femoral neck are worse compared to those in 
postmenopausal women. The predictive value of QUS parameters for the outcome of BMD is 
limited; therefore it is not appropriate to use QUS as a surrogate for DXA. 
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Table 6.1. Demographic data of 80 premenopausal and 137 postmenopausal women. Data are expressed as 
mean±SD. *=p<0.001 versus premenopausal women (ANOVA).  
 Premenopausal women (N=80) Postmenopausal women (N=137) 
Age (years)  39 ± 9 63 ± 8* 
Weight (Kg) 67 ± 14 66 ± 10 
BMI (kg/m2) 24 ± 4 25 ± 4 
BUA (dB/MHz) 70 ± 15 61 ± 15* 
SOS (m/s) 1553 ± 27 1534 ± 25* 
BMD lumbar spine (g/cm2)
  
1.20 ± 0.17 1.02 ± 0.19* 
BMD femoral neck (g/cm2) 0.97 ± 0.14 0.81 ± 0.15* 
BMD total hip (g/cm2) 0.98 ± 0.15 0.84 ± 0.15* 
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BUA SOS 
BMD Cut-off 
(dB/MHz) 
Sensitivity 
(%) 
Specificity 
(%) 
Cut-off 
(m/s) 
Sensitivity 
(%) 
Specificity 
(%) 
lumbar spine  57 70 73 1530 73 73 
total hip  54 79 78 1525 79 79 
femoral neck  57 71 73 1531 71 71 
combination  58 74 75 1533 70 69 
 
Table 6.2.  Sensitivity and specificity of BUA (dB/MHz) and SOS (m/s) based on optimal cut-off values for the 
diagnosis of BMD-defined osteoporosis (T-score < -2.5 SD). Osteoporosis based on combination BMD is 
defined as a T-score < -2.5 SD at one or more of the measured skeletal sites (either lumbar spine or total hip or 
femoral neck). Positive and negative predictive values of quantitative ultrasound parameters (BUA and SOS) 
to predict BMD-dependent osteoporosis against a prevalence scale of 0-100%. 
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Premenopausal women (n=80) 
  BUA  SOS 
  + –  + – 
BMD + 0 5  0 5 
 – 0 75  0 75 
 
Postmenopausal women (n=137) 
  + –  + – 
BMD + 30 20  24 26 
 – 13 74  8 79 
 
Table 6.3.  Number of premenopausal and postmenopausal women with a positive or negative 
BUA or SOS outcome for BMD defined osteoporosis based on optimal cut-off values for both 
ultrasound parameters. 
+ or – for BMD means the presence or absence of osteoporosis based on a T-score < -2.5 SD 
+ or – for BUA and SOS means a value above or below the optimal cut-off value. 
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Postmenopausal women 
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Figure 6.1.   Regression coefficients between BUA (dB/MHz) on the x-axis and BMD (g/cm2) at the lumbar 
spine, total hip and femoral neck on the y-axis in 80 premenopausal women (diamonds, upper panel) and 137 
postmenopausal women (closed circles, lower panel). All regression coefficients were statistically significant 
(p<0.001).  
r = 0.51 r = 0.31 
r = 0.47 r = 0.53 
r = 0.38 
r = 0.56 
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Figure 6.2.   Positive (upper lines) and negative (lower lines) predictive value of the ultrasound parameters 
BUA and SOS (based on optimal cutt-off values) for the occurrence of BMD defined osteoporosis (Y-axis), as 
a function of osteoporosis prevalence (x-axis). 
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Abstract  
 
Study objectives: To compare Bone Mineral Density (BMD) outcomes of patients who received 
continuous oral systemic glucocorticoids (GCs) with BMD results of patients who received 
multiple GCs courses, oral or IV. 
Design: Cross-sectional study. 
Participants: Eighty-six Caucasian males with Chronic Obstructive Pulmonary Disease (COPD) 
selected from the outpatient clinic for pulmonary diseases.  
Intervention: Data analysis from medical records, bone densitometry and pulmonary function 
tests of consecutive selected patients. Inclusion period into the study was exactly one year.  
Measurements and results: Ten patients were treated with oral prednisolone daily (Group 1). 
Eleven patients were treated for several exacerbations with multiple systemic prednisolone 
courses, up to a period of two weeks per course, with a cumulative dose of more than 1000mg 
(Group 2). Likewise, 28 patients were treated with multiple systemic prednisolone courses, but 
with a cumulative dose of less than 1000mg (Group 3). Thirty-seven patients were never treated 
with systemic prednisolone, and partly with inhaled corticosteroids (Group 4). All groups were 
balanced for age and pack years of smoking. In Group 2, body mass index (BMI) and forced 
expiratory volume in one second (FEV1) were lowest and hyperinflation was highest. The 
cumulative systemic prednisolone dose was highest in Group 1, irrespective of the additional 
ICS treatments. DXA scanning of the lumbar spine, total hip and femoral neck regions revealed a 
T-score £ 2.5 SD in 27 (31%), 31 (36%) and in 34 (40%) patients respectively. BMD outcomes 
at any site were lower in patients receiving multiple systemic prednisolone courses higher than 
1000 mg, cumulatively (Group 2), compared to the other groups, and these values were (mean 
(1SD)) 0.759 (0.238), 0.683 (0.115), and 0.686g/cm2 (0.125), respectively (p<0.0001). 
Multivariate regression analysis revealed a correlation between the cumulative dose of 
prednisolone in Group 2 and BMD of the lumbar spine (adjusted r=0.48; p<0.01). At the total 
hip and femoral neck regions, only a correlation between BMI and BMD was observed (adjusted 
r=0.65 and 0.58; p<0.0001 for both sites).  
Conclusions: Despite of a far lower cumulative GC dose in comparison with patients treated with 
systemic corticosteroids continuously, after adjusting for BMI and lung function, osteoporosis of 
the lumbar spine was most frequent in patients receiving more than 1000mg prednisolone 
cumulatively, administered in multiple courses for the treatment of exacerbations of COPD.  
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Introduction 
 
Glucocorticoids (GCs) are frequently prescribed in patients with chronic obstructive pulmonary 
disease (COPD). Although the efficacy is small, these patients are frequently treated with a 
regular course of inhaled corticosteroids (ICS)1. In addition, many receive courses of systemic 
GC during the treatment of exacerbations. Besides ICS and courses of systemic GCs, a subgroup 
of COPD patients will also receive daily, low-dose oral prednisolone due to glucocorticoid (GC) 
dependency.  
   Fractures, as a result of osteoporosis, are one of the most serious complications of patients 
receiving GCs. The loss of bone mass and the associated risk of fracture appears to be strongly 
related to the magnitude of the GC dose, received daily, and much less to the cumulative dose of 
GC that the patients received previously2. In an older landmark study among asthma patients 
who were treated with at least 15mg prednisolone orally per day for a minimum of one year, it 
was shown that the incidence of rib and vertebral fractures increased3. Furthermore, the patients 
who received long-term GCs had significantly lower bone mineral densities (BMD) at the distal 
and proximal radius3. Similar outcomes were reported in older male COPD patients taking either 
inhaled or systemic GCs. The incidence of vertebral fractures rose compared to non-GC users 
(odds ratios; 1.38 and 2.15, respectively)4. Studies focusing on the safety of long-term inhaled 
GC regarding the skeleton are difficult to interpret due to many confounding variables. In a 
recent study, however, evidence of a negative relationship between the total cumulative dose of 
inhaled GCs and BMD was demonstrated in patients with asthma5. A doubling of the dose of 
inhaled GSs was associated with a decrease in spinal BMD at a rate of 0.16SD per year. 
   The effects of different treatment regimens (continuous versus courses) on the amount of bone 
loss have not been studied extensively in humans. Biphasic loss of bone due to systemic GC 
treatment is comprised of a rapid initial bone loss of approximately 12% during the first few 
months, followed by a slower loss of about 2-5% annually6. After initiation of high doses (3 
times 200 mg dexamethasone IV in eight days for patients with rheumatoid arthritis and 1g 
methylprednisolone IV for 10 days for those with multiple sclerosis), systemic GC-induced bone 
loss can be detected within a week. Most of the adverse effects of GCs occur in primarily 
trabecular bone, which is dominantly present in vertebrae7,8.  
   Treating acute airway inflammation in COPD patients with short GC courses, usually lasting 
up to two weeks is well accepted. Based upon the pattern of GC-induced bone resorption, we 
hypothesize that treatment with repeated courses of systemic GCs leads to exceedingly high bone 
loss, probably as a result of repetitive, early phase, osteoclast-mediated bone resorption. In the 
present study with COPD patients, we compared BMD outcomes in different treatment groups 
and hypothesized, that BMD values were lowest in those patients, who received multiple 
systemic GC courses. 
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Patients and methods  
 
Study design 
Previous uses of systemic GCs and ICS in a cohort of Caucasian male COPD patients were 
carefully assessed from hospital patient records, taken from the Pulmonary Diseases outpatient 
clinic of the Reinier de Graaf Groep, in Delft and Voorburg, the Netherlands. 
   Patients included in the study, consulted one lung physician consecutively. Every new patient 
with COPD and all those previously diagnosed with COPD, were invited to participate in the 
study. Informed consent was obtained from each patient to anonymously use their medical 
history in further research and to perform Dual X-Ray Absorptiometry (DXA) measurements. 
The Medical Ethical Committee of Hospital Reinier De Graaf Groep approved the study. 
 
Subjects 
Eighty-six men with documented COPD for at least 5 years were included in the study. The 
recruitment period lasted exactly 12 months. All patients were classified into one of 4 groups, 
according to their GC treatment history. Patient characteristics are listed in Table 7.1. 
   Group 1 consisted of 10 patients who received prednisolone orally in a daily dose of at least 
10mg. Six of these patients also received additional systemic prednisolone courses (250mg per 
course), of which the mean dose administered did not exceed 1000mg, cumulatively.  
   Group 2 consisted of 11 patients treated with multiple courses of oral or IV prednisolone, 
lasting up to fourteen days, because of recurrent exacerbations. These patients had received at 
least 1000mg prednisolone, in total and were not taking GC medication continuously.  
   Group 3 consisted of 28 patients treated with multiple courses of oral or IV prednisolone. 
These patients had received less than 1000mg prednisolone cumulatively, and were also not on 
continuous GCs. 
   Group 4 consisted of 37 patients with mild to moderate COPD, never treated with systemic GC 
therapies. Fifteen of these patients were daily ICS users, when included in the study. These 
patients were considered as the control group.  
   Smoking habits were expressed in pack years. ICS, prescribed in the study were 
beclomethasone and budesonide. These compounds were considered equivalent for the purpose 
of the study in terms of BMD impact9. Estimates were drawn from the medical hospital records 
and expressed as “prescription years”; one prescription year with either ICS normalized to 800mg 
per day during one year. 
 
Pulmonary Function Tests 
Pulmonary function test (PFT) data were obtained from the medical records and were all 
measured within one year prior to inclusion into the study. Function tests were established using 
Jaeger Masterlab® and the (included) normal values were based on the European Respiratory 
Society (ERS) standards10. Total Lung Capacity (TLC), Residual Volume (RV) and Forced 
Expiratory Volume in 1 second (FEV1), in absolute values and in percentages of predicted 
values, were recorded. 
 
Measurement of Bone Mineral Density  
Bone mineral density was measured by DXA using a LUNAR Expert-XL densitometer 
(Madison, WI; USA). The lumbar spine (L2-4), total hip and femoral neck of each subject was 
evaluated. Calibration procedures were performed at least every day and again after each series 
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of eight scans using the appropriate phantoms provided by the manufacturer. The coefficient of 
variation (CV) for BMD measurements was 1.3% at the lumbar spine and 1.6% at the total hip 
and femoral neck. Individual measurements for spinal, total hip and femoral neck BMD were 
expressed as absolute values (g/cm2) as is shown in Figure 7.1. 
 
Data and statistical analysis 
Osteopenia (-2.5 SD < BMD T-score < -1.0 SD) and osteoporosis (BMD T-score £ -2.5 SD) 
were studied with reference to a database of Caucasian males provided by Lunar Inc. The 
absolute BMD values corresponding with T = -1.0 SD and -2.5 SD were, respectively, 1.121 and 
0.941 at the lumbar spine, 0.975 and 0.780 at the total hip and 0.968 and 0.773g/cm2 at the 
femoral neck. 
   Demographics, PFT, and BMD results were compared between groups using ANOVA and the 
post-hoc LSD procedure. Correlations between BMI and PFT with BMD were analyzed and 
expressed using Pearson's correlation coefficients. Relations between these variables were 
further analyzed using stepwise regression analysis; p-values<0.05 were considered to be 
statistically significant.  
 
Results 
 
Patient characteristics  
As demonstrated in Table 7.1, the mean age of patients in the 4 groups were similar, but Body 
Mass Index (BMI) was lower in Group 2. Group 4 consisted of 22 non-ICS and 15 ICS users 
(60±14 vs. 69±11 years; p<0.05). In these two subgroups, spinal BMD outcomes were similar 
(mean (SD)) (1.17 (0.17) vs. 1.12g/cm2 (0.22); p=0.44) but total hip and femoral neck BMD 
values were lower in the ICS users (0.98 (0.12) vs. 0.88g/cm2 (0.16) and 0.92 (0.12) vs. 
0.82g/cm2 (0.17), respectively; p<0.05). After adjusting for age, however, these differences 
disappeared . 
   Smoking habits expressed as pack years, were (mean (SD)) 21 (19); 30 (18); 20 (15) and 21 
(15) in Group 1 through 4, respectively. These values did not differ significantly, but a trend for 
higher cigarette consumption was noted in Group 2 (p=0.09).  
 
Pulmonary function tests 
PFT data are summarized in Table 7.2. There were significant differences between patients in 
Groups 1 and 4 compared to patients in Groups 2 and 3. Patients in Group 2 had the lowest FEV1 
values. Compared to patients in Group 3, their FEV1 outcomes were also lower (p<0.01). 
Regarding TLC and RV, patients in Groups 2 and 3 had a marked hyperinflation, which was 
most severe in Group 2. 
 
Bone Mineral Density Measurements 
The percentages of patients meeting the criteria for osteopenia and osteoporosis are shown in 
Table 7.3. Of all 86 patients, the prevalence of osteopenia and osteoporosis was 27 and 21 at 
lumbar spine, 31 and 22 at the total hip and 34 and 28 at the femoral neck, respectively. In Group 
1, at the lumbar spine and the total hip regions, although respectively 40 and 60% osteopenia 
was prevalent, no osteoporosis was observed. At the femoral neck, the prevalence of 
osteoporosis was 20%. 
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   BMD outcomes assessed at the three skeletal sites are listed in Table 7.4 and plotted in Figure 
7.1. Patients included in Group 2 had the lowest BMD at any site compared to other groups 
(p<0.0001). 
 
Interrelationships 
   Pearson’s correlation coefficients (r) between BMI and BMD for all Groups were 0.40 at the 
lumbar spine, 0.60 at the total hip and 0.51 at the femoral neck (p<0.0001 for all sites). There 
were no significant correlations between PFT and BMD outcomes at any site. The relationships 
between the cumulative prednisolone dose received and BMD at any site before and after 
adjustment for BMI and PFT are demonstrated in Table 7.5. 
   In Group 2, a relationship was found between the cumulative GC dose and spinal BMD. After 
adjustment for BMI and PFT, this relationship persisted. In the same group, the non-adjusted 
correlations between GC dose and total hip BMD as well as that at the femoral neck disappeared 
after adjusting for BMI and PFT.   
   Multivariate regression analysis was also used to study correlations between BMI, PFT, Group 
number (GC dose per treatment group) and BMD per skeletal site. Spinal BMD was associated 
with Group number (adjusted r=0.48; p<0.001), whereas BMD at total hip and femoral neck 
were associated with BMI (adjusted r=0.65 and 0.58, respectively; p<0.0001).  
 
Discussion 
 
In this cross-sectional study we tested the hypothesis that administration of multiple courses of 
GCs, would elicit more harmful effects to bone than continuous GC treatment regimens. In the 
analysis, we calculated cumulative GCs usage throughout lifetime and it was found that, when 
adjusted for BMI and PFT, lowest spinal BMD was observed in patients receiving GC in 
multiple courses, lasting up to two weeks per course, exceeding 1000mg prednisolone 
cumulatively. Osteoporosis of the lumbar spine was prevalent in 0, 82, 21, and 16 % of Groups 1 
to 4, respectively. Of all the patients studied, 39.5% fulfilled the World Health Organization’s 
(WHO) criteria for osteopenia and 32.5% for osteoporosis. In another study of 16 asthmatic men, 
1 smoker, who had difficulty weaning off GCs (11 Caucasians, 43 to 80 years of age, and all, but 
1, with documented atopia), osteoporosis was prevalent in 38%, at the lumbar spine and 19% at 
the femoral hip11. The total GC dose range administered to these patients was 4 to 41g.  
   In the current study, it was observed that the majority of patients in Group 2 had osteoporosis 
(82%). We wondered, whether this could be attributed primarily to the regimen of GC 
administration. It is of note, that the BMI of the patients in Group 2 was lowest and PFT revealed 
a marked hyperinflation and a significantly lower FEV1. After including these factors in a 
multivariate regression model, we found no independent association between these parameters 
and spinal BMD. Low spinal BMD appeared to be confined to multiple GC courses >1000mg, 
cumulatively. The finding of GC use and associated spinal bone loss is in agreement with other 
earlier reports12, 13. In other studies, however, GC associated bone loss at the hip was shown to be 
similar or even worse, compared to that of the spine14,15,16,17. 
   The mechanism of GC-induced bone loss is thought to be mediated through the induction of 
apoptosis of osteoblasts and osteocytes, leading to a reduction of bone formation and associated 
bone loss6. The initial rapid onset of bone loss is caused by osteoclast-mediated bone resorption, 
probably as the result of extended osteoclast lifespan6. Looking at effects due to GCs for at least 
one year, reveals an initial substantial bone loss, which later on attenuates and plateaus. In a 
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longitudinal study, using biopsied bone, treatment with intermediate doses of oral prednisolone 
resulted in 27% decrease in trabecular bone in 6 months, without any evidence of further bone 
loss later on18. Other bone density studies revealed a similar pattern of bone loss within the first 
12 months of treatment, and then also reaching a plateau following a longer duration of 
treatment19,20. On the basis of these observations, we speculate that multiple courses of systemic 
prednisolone are correspondingly associated with multiple episodes of rapid bone loss. This 
hypothesis requires further study with prospective analyses of biochemical markers of bone 
turnover.  
   In the current study, Groups were similar with respect to age, gender and smoking habits. 
There are limitations, however, some of which are related to the cross-sectional study design. 
Firstly, while there were no differences in PFTs in Groups 1 and 4, these were lower in Groups 2 
and 3. Secondly, all PFTs were measured in patients with stable disease and not during 
exacerbations. Thirdly, measurements of the production of pro- inflammatory cytokines were not 
available from the medical records. Fourthly, patient numbers particularly those of Groups 1 and 
2, were small. Alternatively, it should be emphasized that, since only one consulting lung 
physician saw all patients, and therewith practicing uniform care, we believed that maximal 
homogeneity in the treatment of patients could be achieved.  
   It was decided to include all male COPD patients, consecutively seen by one pulmonary 
physician, during exactly 12 months, into the study. Patients in Group 4, “the controls”, were not 
subdivided despite of daily ICS use in 15 of the 37. Doing so, Group 4 remained balanced for 
age, BMI and smoking habits. Sub-analysis in this group was performed, although the design of 
the current study was inappropriate for detecting any small differences in BMD between ICS 
users and non-users. The ICS users in Group 4 appeared to be older than the non-users. In this 
respect, the similar spinal BMD outcomes can be explained by age-related degenerative 
changes22. The BMD outcomes of total hip and femoral neck in ICS users were lower, but 
similar after adjusting for age. There are no data in the literature indicating that ICS can cause 
extra bone loss in elderly men. Several reports, particularly in women, have shown contradictory 
results with respect to ICS use and BMD21. Effects of inhaled budesonide and beclomethasone 
were studied in a large French multi-center study, revealing no differences in BMD outcomes9. 
In contrast with this study, two recent longitudinal studies in premenopausal and early 
postmenopausal women with asthma have shown that ICS use lead to a dose-related bone 
loss23,24.  
   Even though a minority of COPD patients will experience improvements in pulmonary 
function25, systemic GCs are preferentially used for exacerbations of COPD. The Veterans 
Affairs Cooperative Study Group showed fewer treatment failures for patients who received 
different regimens of high-dose GCs compared to controls26. A prospective study of severe 
COPD patients showed a benefit of systemic GC use at the onset of exacerbations13. Based on 
these findings, the current practice of administering a course of GCs for exacerbations in COPD 
is widely believed to be justified.  
   Information about GC prescription patterns was obtained from a large database in the United 
Kingdom, revealing that respiratory disease was the most frequent indication (i.e. 40%). 
Compared to patients with chronic pain syndromes, long-term daily oral GC treatment of COPD 
patients was less likely to occur. Furthermore, it was shown that cessation of chronic GCs 
exposure was advantageous to fracture risk2. Results of several other studies focusing on GC-
induced bone loss indicates that bone recovery occurs after cessation of GCs treatments27-34. In 
contrast with these results, current data provide evidence against reversible bone loss. This 
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discrepant finding can be explained, firstly, by the repetitive administration of prednisolone 
courses and secondly, by the interaction of non-stable disease activity on bone loss. Prospective 
studies involving this category of patients may help to resolve these controversies. 
   In COPD patients, several variables are thought to affect bone, but due to patient’s 
heterogeneity, their relevance remains unclear. Most data on cigarette smoking and other risk 
factors, like body weight and vitamin D status, comes from healthy women. For example, after 
adjusting for body weight, a negative association between tobacco smoking on total body and 
femoral neck BMD was demonstrated in a large controlled cohort study of healthy 
premenopausal Danish women35. In this particular study, there was only a small, but negative, 
effect of current smoking or vitamin D status in a subpopulation. This was also shown in another 
study among elderly men36. These studies indicate that these risk factors contribute to bone loss, 
particularly when abundantly present like in COPD patients.  
   Frequent usage of GCs is inevitable in the course of COPD, particularly during severe 
exacerbations, which are occasionally life threatening conditions throughout the course of the 
disease. The present, cross-sectional study supports the hypothesis that administration of 
multiple GC courses would bring forth more harmful effects against bone, compared to 
continuous GC treatment regimens. Whether the loss of bone is mainly caused by “multiple GC 
interventions” and/or by “illness with all its negative biological effects and risk factors”, should 
be confirmed with longitudinal studies in healthy subjects or laboratory animals. Longitudinal 
studies comparing bone loss either caused by continuous or multiple GC courses may confirm 
our findings and may lead to new recommendations for future clinical management of COPD 
patients treated with different GC regimes. 
   Since it remains difficult to predict which COPD patient will lose critical amounts of bone, 
when exposed to multiple courses of GCs, care and vigilance by the physician remains a 
prerequisite for treating this category of patients. An average GC course consists approximately 
of 250mg prednisolone equivalent. The data, reported in our study, indicate a cumulative dose 
threshold of 1000mg prednisolone above which alarming bone loss can be expected. Based on 
this, we would stress that patients receiving multiple GC courses should have their BMD 
measured in an early phase of the management of these patients. 
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  Age 
 
(years) 
BMI 
 
(kg/m2) 
Cumulative dose 
systemic GCs 
(mg) 
Cumulative dose 
ICS 
 (mg) 
 
                           [Group] 
N mean SD mean SD mean SD mean SD 
continuous             [1] 10 63.6 12.2 26.4 2.9 23457 16566 2210 1887 
course >1000mg    [2] 11 69.5 10.9 20.5* 3.6 2276 1095 3686 2416 
course <1000mg    [3] 28 64.8 13.5 24.6 3.5 400 208 1650
# 1280 
control                    [4] 37 63.2 13.0 26.1 3.9 - - 321
# 549 
  
Table 7.1.  Demographic data of 86 male patients with chronic obstructive pulmonary disease, cumulative systemic 
glucocorticoids and inhaled corticosteroids doses received. Demographic data, cumulative prednisolone doses and 
cumulative ICS doses in 86 patients, grouped according to GC regimen and compared for age and body mass index 
(BMI). * p-value <0.001 (lower BMI values than Groups 1,3 and 4) # p-value <0,0001 (lower cumulative ICS doses 
than Groups 1 and 2). 
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TLC%pred                                           [Group] N mean  SD p–value 
continuous                          [1] 10 1.050 0.224 ns 
course > 1000mg               [2] 11 1.211 0.200 < 0.001 
course < 1000mg              [3] 28 1.080 0.188 < 0.05 
control                             [4] 37 1.007 0.103 ns 
     
RV%pred      
continuous                          [1] 10 1.045 0.347 ns 
course > 1000mg               [2] 11 1.459 0.278 < 0.0001 
course < 1000mg              [3] 28 1.269 0.227 < 0.01 
control                             [4] 37 1.104 0.207 ns 
     
FEV1%pred      
continuous                          [1] 10 0.682 0.274 ns 
course > 1000mg               [2] 11 0.370 0.159 < 0.0001 
course < 1000mg              [3] 28 0.582 0.234 < 0.01 
control                             [4] 37 0.797 0.268 ns 
  
Table 7.2. Pulmonary Function Tests in 86 Male COPD Patients.Pulmonary function tests (PFT) 
measured per group: Total Lung Capacity (TLC), Residual Volume (RV) and Forced Expiratory 
Volume one second (FEV1). Data are expressed as percentage of the predicted values and standard 
deviation (SD). 
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  Lumbar spine Total hip Femoral Neck 
                  
                               [Group]             
N Osteopenia 
(%) 
Osteoporosis  
(%) 
Osteopenia 
(%) 
Osteoporosis  
(%) 
Osteopenia 
(%) 
Osteoporosis  
(%) 
continuous            [1] 10 40 0 60 0 30 20 
course >1000mg   [2] 11 18 82 18 82 18 82 
course <1000mg   [3] 28 29 21 35 25 39 25 
control                   [4] 37 35 16 35 16 48 27 
 
Table 7.3. The prevalence of osteopenia and osteoporosis in 86 male patients with COPD. Osteopenia was defined 
as: -2.5 SD < BMD T-score < -1.0 SD and Osteoporosis as: BMD T-score £ 2.5 SD. 
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BMD (g/cm2)        N mean SD p-value 
 
lumbar spine                 [Group]                
    
continuous                             [1] 10 1.168 0.156 ns 
course > 1000mg                  [2] 11 0.759 0.238 < 0.001 
course < 1000mg                 [3] 28 1.121 0.207 ns 
control                               [4] 37 1.118 0.190 ns 
 
total hip 
    
continuous                             [1] 10 0.991 0.175 ns 
course > 1000mg                  [2] 11 0.683 0.115 < 0.0001 
course < 1000mg                 [3] 28 0.928 0.176 ns 
control                               [4] 37 0.939 0.145 ns 
 
femoral neck 
    
continuous                             [1] 10 0.922 0.149 ns 
course > 1000mg                  [2] 11 0.686 0.125 < 0.0001 
course < 1000mg                 [3] 28 0.881 0.167 ns 
control                               [4] 37 0.882 0.126 ns 
  
Table 7.4.   Bone mineral density (BMD) (g/cm2)  in 86 male COPD patients measured per group 
at three different sites: lumbar spine, total hip and femoral neck. Values are expressed as mean ± 
1SD. 
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Table 7.5.  Multivariate Regression Analysis in 86 Male COPD Patients. Multiple regression analysis 
expressed as mean BMD of controls (Group 4) subtracted from mean BMD per group, before and after 
correction for BMI (correction 1) PFT parameters: TLC, RV, and FEV1 (correction 2 ) and the combination of 
BMI and PFT (correction 3). * p<0.05; ** p<0.01, *** p<0.001.  
 
 
BMD (g/m2) 
 
Group 1 
Continuous 
Group 2 
Course >  1000mg 
Group 3 
Course < 1000mg 
lumbar spine +0.05 -0.36** 0 
correction 1 (BMI) +0.05 -0.29*** +0.02 
correction 2 (PFT) +0.05 -0.31*** -0,01 
correction 3 (both) +0.05 -0.25*** +0.01 
    
total hip +0.05 -0.26** +0,01 
correction 1 (BMI) +0.05 -0.14* +0.02 
correction 2 (PFT) +0.05 -0.16* +0.02 
correction 3 (both) +0.05 -0.05 +0.05 
    
femoral neck +0.04 -0.19* +0.00 
correction 1 (BMI) +0.04 -0.10 +0.02 
correction 2 (PFT) +0.04 -0.11 +0.03 
correction 3 (both) +0.04 -0.02 +0.05 
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A 
 
 
 
 
 
           
        1             2   3          4      
(group) 
B 
 
 
 
 
 
         1            2   3        4      
(group) 
C 
 
 
 
 
      1         2               3     4      
(group) 
      1         2              3                4      
(group) 
 
Figure 7.1. Scatter plots of BMD data per group (1,2,3 and 4) obtained  
at lumbar spine (top, A), total hip (center, B), and femoral neck (bottom, C). 
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Summary and conclusions  
 
Glucocorticoids (GC’s) are widely administered in the treatment of inflammatory diseases, 
including bronchial asthma and exacerbations of chronic obstructive pulmonary disease 
(COPD). Treatment regimens are still based on clinical expertise. Since 75 years, many 
indirect approaches to calculate the potency of GCs have been suggested, but many questions 
still need clear answers. 
 
In Chapter II, the influence of hydrocortisone (HC) is described on two parameters, i.e. 
plasma tyrosine and lymphocyte count, demonstrating its genomic and nongenomic actions, 
respectively. After HC therapy, plasma tyrosine concentrations decrease as a result of 
induction of tyrosine amino transferase, a genomic (in-direct) effect. A decrease in 
lymphocyte count is considered to be a nongenomic (direct) effect. The objective of this study 
was to test the hypothesis that both genomic and nongenomic effects of HC can be described 
by essentially the same pharmacokinetic-pharmacodynamic (PK/PD) model. Seven healthy 
subjects were studied for two 24-hours periods during which they received either no drug 
(control day) or 300mg HC orally (test day). Plasma tyrosine concentration decreased by a 
mean maximum 15% on the control day and by 50% on the test day. Lymphocyte counts 
decreased by a mean maximum of 30% on the control day and by 75% on the test day. 
Tyrosine nadirs were observed on average two hours later than nadirs of lymphocyte counts. 
The mean HC concentration for 50% maximal drug effect (EC50) was 378±186mg/L for 
plasma tyrosine levels. The mean estimated lymphocyte inhibition (IC50) was 142±42mg/L. It 
was concluded that diurnal variations in tyrosine and lymphocytes can be described by 
fluctuations in levels of endogenous cortisol. The effects of endogenous cortisol and of 
exogenous HC on tyrosine and lymphocyte counts could be fitted to the same PK/PD model 
with identical parameters. This model may be used to describe concentration-dependent 
genomic and nongenomic actions of a variety of GCs.  
 
In Chapter III, dexamethasone (DEXA) and prednisolone (PRED) were compared in 
assumed clinically equivalent doses with respect to the suppressive effect on the adrenal gland 
(cortisol). Induced effects towards cortisol, osteocalcin (OC), a parameter of bone metabolism 
and eosinophilic cationic protein (ECP), a parameter of inflammation, were simultaneously 
assessed. In four random sessions of 25 hours each, 8 healthy subjects received saline IV 
alone, Granulocyte-Colony Stimulating Factor (G-CSF) SC alone, or G-CSF in combination 
with either DEXA 2.0mg IV or PRED 12.5mg IV. A similar decrease in plasma cortisol 
concentration was observed up to 10 hours after DEXA and PRED administration; thereafter, 
a sustained suppression of plasma cortisol at 25 hours existed only after administration of 
DEXA. The AUC of OC was 24.4 and 2.3% lower than the AUC of OC without exogenous 
GC administration between 4 to 10 hours after DEXA and PRED administration. This 
suppression of OC also persisted at 25 hours, only after DEXA. The AUC  of the G-CSF-
stimulated ECP response decreased on average by 23.2% of baseline between 5 and 10 hours 
after administration of PRED, while no suppression was observed after DEXA (p<0.02). This 
suppression of ECP was no longer apparent at 25 hours. It was concluded that DEXA and 
PRED in formerly assumed clinically equivalent doses were equally suppressive towards 
cortisol within the first 10 hours after administration and exerted differential actions towards 
cortisol at 25 hours, OC and G-CSF-stimulated ECP. 
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In Chapter IV the previous study was extended to PK/PD modelling studies to explain the 
clinical observations in healthy and asthmatic men. At three random sessions of 25 hours 
each, 8 healthy and 6 asthmatic men received G-CSF SC alone, or G-CSF in combination 
with either DEXA 2.0mg IV or PRED 12.5mg IV. Induced effects towards cortisol, 
lymphocyte counts, OC and ECP were simultaneously studied. For each individual, all effect 
parameters could be fitted to a PK/PD model although for ECP adequate fitting was only 
possible in 7 healthy and 4 asthmatic men. Predicted endogenous cortisol reappeared in all 
healthy men within the observational period after PRED and in the asthmatic men after PRED 
and DEXA. Asthmatic men, who had stopped their regular ICS since a week, showed a 
predicted basal cortisol production of approximately 60% compared with healthy men. DEXA 
elicited a stronger maximal effect (Emax) towards all effect parameters except for ECP. Emax of 
DEXA to suppress in suppressing ECP was higher in men with asthma compared with healthy 
individuals. The rank order of potencies (EC50) was DEXA>PRED>cortisol for all effect 
parameters, regardless of differential clinical effects of each GC towards each parameter. 
PK/PD modelling revealed a higher Emax of DEXA towards cortisol, lymphocyte counts and 
OC compared with that of PRED. Oppositely, Emax of PRED towards ECP was higher than 
that of DEXA. Healthy and asthmatic men differed for each pharmacokinetic parameter 
studied. The AUC calculations for cortisol, lymphocyte counts and OC were in accordance 
with the estimated EC50 values of PRED and DEXA. However, this was not the case for ECP, 
illustrating herein the paradoxical hindering effect of an agonist with a low activity (cortisol) 
in the presence of a relatively much stronger agonist (DEXA or PRED). The differences 
observed between healthy and asthmatic men cannot unequivocally be ascribed to prior ICS 
use, since asthma itself may play a role. Without further understanding, caution should be 
taken to determine potencies of GCs in asthmatic patients. It was concluded that DEXA and 
PRED in formerly assumed clinically equivalent doses were not equally potent towards 
different effect parameters although the ranking order of potencies were in agreement with the 
classical paradigm. Notably, pharmacokinetic outcomes were also different between healthy 
men and men with asthma who had stopped ICS for a week.  
 
In Chapter V clinical outcomes of patients were described who received multiple epidural 
administrations of methylprednisolone depots (MP). This cross-sectional study included 14 
male and 14 post-menopausal female individuals with chronic low back pain who were 
resistant against conventional treatments, but who were otherwise healthy. In two other 
subjects, who were steroid-naive, cortisol and MP concentrations were serially assessed after 
a single MP depot (160mg epidurally). In both subjects, cortisol concentrations were 
completely suppressed for more than 6 days, with only a partial recovery after 30 days. 
Throughout this period, plasma MP concentrations remained detectable. In the 14 men and the 
14 women, endocrine parameters were also analysed in relation to Bone Mineral Density 
(BMD). The cumulative MP dose received by all 28 patients was at least 3g, e.g. (mean ±  
1SD) 7.76 ± 4.23 in the men and 8.50±3.13g in the women. None of the men had osteoporosis 
although osteopenia was prevalent in 78.5% (WHO criteria for women extrapolated to men). 
Half of the women had osteoporosis and the others had osteopenia. In men, body mass index 
(BMI) and endogenous oestradiol levels were not related with BMD. In women, univariate 
linear relationships were found between BMI and both spinal BMD (r:0.62; p=0.02) and total 
hip BMD (r:0.62; p=0.02), but not between BMI and BMD at the femoral neck. In women, 
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relationships were also found between the total and - for protein binding- corrected free 
oestradiol levels and both spinal BMD (r:0.70; p=0.01 and r:0.72; p=0.01, respectively) and 
total hip BMD (r:0.53; p=0.08 and r:0.56; p=0.05, respectively). No significant relationship 
was observed between endogenous oestradiol and BMD of the femoral neck. Administration 
of a single MP depot (160mg) resembled a continuous low dose infusion. A relationship 
between cumulative GC dose and BMD could not be revealed after administration of multiple 
MP depots. In women, BMI and oestradiol were related to spinal and total hip BMD 
outcomes. It was concluded, that in healthy men and post-menopausal women no relationship 
existed between cumulative exogenous GC dose and BMD outcomes.  
 
In Chapter VI an alternative screening method for osteoporosis, Quantitative Ultra Sound 
(QUS), was evaluated and described. 217 pre- and post-menopausal women between the age 
of 25 to 75 years, who were referred for a BMD measurement because of osteoporosis in at 
least one family member, either in the first or in the second degree were studied. All women 
underwent a calcaneal QUS and a DXA measurement at the lumbar spine, total hip and 
femoral neck. The linear regression coefficients between the two QUS parameters - 
broadband ultrasound attenuation (BUA) and speed of sound (SOS)- and DXA at the various 
sites were 0.53 to 0.54 (p<0.0001). Significantly lower regression coefficients between BUA 
and DXA at the total hip and the femoral neck were found in pre-menopausal women (n=80) 
(r=0.31 and 0.38; p<0.0001) compared to post-menopausal women (n=137) (r=0.56 and 0.53; 
p<0.0001). For SOS there was no significant difference between the regression coefficients in 
the pre- and post-menopausal group. The prevalence of osteoporosis as assessed by DXA in 
the whole group was 25% (6% in the pre- and 36% in the post-menopausal group). BUA 
failed to detect all cases (5) of osteoporosis that were detected by DXA measurements in the 
pre-menopausal women (80), but also in 20 out of 50 cases of osteoporosis in the post-
menopausal women (137). SOS measurements were even worse in this respect. It was 
concluded that the predictive value of QUS parameters for BMD is limited. Therefore, it is 
not appropriate to use QUS as a surrogate for DXA. 
 
In Chapter VII, BMD outcomes of different GCs regimen were studied. DXA measurements 
of COPD patients were compared who either had received continuous oral systemic GCs, 
multiple oral or IV courses of GCs, or no systemic GCs. In this cross-sectional study, 86 
Caucasian males with COPD were consecutively recruited from the outpatient clinic for 
pulmonary diseases and included into the study. Of this group, 10 patients were treated with 
oral prednisolone daily (Group 1). Eleven patients were treated for several exacerbations with 
multiple systemic prednisolone courses, up to a period of two weeks per course, with a 
cumulative dose of more than 1000mg (Group 2). Likewise, 28 patients were treated with 
multiple systemic prednisolone courses, but with a cumulative dose of less than 1000mg 
(Group 3). Thirty-seven patients were never treated with systemic prednisolone, and partly 
with inhaled corticosteroids (Group 4). All groups were balanced for age and pack years of 
smoking. In Group 2, body mass index (BMI) and forced expiratory volume in one second 
(FEV1) were lowest and hyperinflation was highest. The cumulative systemic prednisolone 
dose was highest in Group 1, irrespective of the additional ICS treatments. DXA scanning of 
the lumbar spine, total hip and femoral neck regions revealed a T-score £ 2.5 SD in 27 (31%), 
31 (36%) and in 34 (40%) patients respectively. BMD outcomes at any site were lower in 
patients receiving multiple systemic prednisolone courses higher than 1000mg, cumulatively 
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(Group 2), compared to the other groups, and these values were (mean ± 1SD) 0.759 ± 0.238, 
0.683 ± 0.115, and 0.686 ± 0.125g/cm2, respectively (p<0.0001). Multivariate regression 
analysis revealed a correlation between the cumulative dose of prednisolone in Group 2 and 
BMD of the lumbar spine (adjusted r=0.48; p<0.01). At the total hip and femoral neck 
regions, only a correlation between BMI and BMD was observed (adjusted r=0.65 and 0.58; 
p<0.0001 for both sites). It was concluded that in spite of a far lower cumulative GC dose in 
comparison with patients treated with systemic corticosteroids continuously, after adjusting 
for BMI and lung function, osteoporosis of the lumbar spine was most frequent in patients 
receiving more than 1000mg prednisolone cumulatively, administered in multiple courses for 
the treatment of exacerbations of COPD.   
 
Conclusions  
 
Several glucocorticoids (GCs) exerted different actions towards various targets using the 
outcome parameters cortisol, lymphocyte counts, tyrosine, osteocalcine (OC), and 
eosinophilic cationic protein (ECP). The results confirmed the hypothesis that the older 
bioassays, which led to the classical paradigm of differential clinical efficacies of GCs, are 
inadequate for further studies. Moreover, studies on potencies of GCs should always direct 
towards PK/PD modelling of at least more than one biological target. Notably, more relevant 
clinical information was gained by studying a pro-inflammation marker (ECP) rather than 
classical outcome parameters of GC’s action alone. For this purpose, a new model was 
developed i.e. ECP stimulation after Granulocyte Colony Stimulating Factor (G-CSF) SC.  
In clinical studies different effects of GC’s were demonstrated as a result of continuous or 
course applications. Long lasting low peak GCs dose regimes, even in 10-fold higher 
cumulative doses, appeared to be less harmful towards mineralized bone tissue. These 
findings support the hypothesis that GC’s affect bone by different mechanisms which clearly 
depends on peak versus continuous low dose regimens. 
 
Directions for future investigations  
 
Differential clinical effects and potencies of GCs were studied after systemic administration, 
orally or IV. Similar studies are needed in the field of inhaled corticosteroids (ICS) use in 
healthy individuals as well as in patients with pulmonary disease. To emphasize, these studies 
need to direct towards clinical outcome parameters as well as PK/PD modelling of various 
biological targets, thus describing a spectrum of potencie s rather than potency. 
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Samenvatting en conclusies 
 
Glucocorticoiden (GCs) worden bij verschillende ontstekingen toegepast, bijvoorbeeld bij 
exacerbaties van astma bronchiale en COPD. Met betrekking tot de wijze van toepassen, die 
veelal is gebaseerd op empirie, zijn er vele stud ies geweest die de argumenten hiervan 
getracht hebben te onderbouwen. Vele manieren om de potentie van GCs vast te stellen zijn 
onderzocht in bijna 75 jaar, waarin GCs worden toegepast. Desondanks blijft er nog veel 
onopgehelderd. 
 
In Hoofdstuk II wordt de invloed van hydrocortison (HC) op twee effectparameters 
beschreven, namelijk op de plasmatyrosineconcentratie en het lymfocyten aantal. Tyrosine 
wordt bij gebruik van exogeen HC verlaagd door inductie van tyrosine-aminotransferase, en 
berust op een genomisch (indirect) effect. Verlaging van de lymfocytenaantallen daarentegen 
wordt beschouwd als een nongenomisch (direct) effect.  Het doel van deze studie is om aan te 
tonen dat zowel genomische als nongenomische effecten door HC door het zelfde PK/PD 
model kunnen worden beschreven. Hiervoor werden 7 gezonde vrijwilligers gedurende 2 
sessies van 24 uur bestudeerd. Zij kregen op de controledag geen farmacon en op de testdag 
300mg HC per os. De gemiddelde maximale daling van tyrosine was op de controle dag 15% 
en op de test dag 50%. Lymfocytenaantallen daalden maximaal met 30% op de controle dag 
en met 75% op de test dag. De gemiddelde nadir (laagste waarde) voor tyrosine viel ongeveer 
twee uur later dan de nadir voor de lymfocytendaling. De concentratie van HC leidend tot 
50% van het maximaal te bereiken effect (EC50) bedroeg voor plasma tyrosine 378±186mg/L 
en voor lymfocyten 142±42mg/L. Het diurnale ritme van zowel lymfocyten als tyrosine kon 
uit de endogene cortisolfluctuaties voorspeld worden. De effecten van endogeen cortisol en 
exogeen HC op lymfocytenaantallen en tyrosine konden worden voorspeld met behulp van 
het zelfde fysiologische door PK/PD beschreven model, gebruik makend van identieke 
parameters. Concluderend kan dit model worden gebruikt om concentratie-afhankelijke 
genomische en nongenomische werkzaamheid van exogene GCs te beschrijven. 
 
In Hoofdstuk III wordt een onderzoek beschreven waarbij dexamethason (DEXA) en 
prednisolon (PRED) worden vergeleken in verondersteld  klinisch overeenkomende doses met 
betrekking tot hun bijnierschors-onderdrukkend effect (cortisol). De effecten ten opzichte van 
cortisol, osteocalcine (OC), een parameter van botmetabolisme en eosinophilic cationic 
protein (ECP) een ontstekingsparameter, werden gelijktijdig nagegaan. Gedurende 4 
gerandomiseerde sessies van elk 25 uur, kregen 8 gezonde mannen NaCl 0.9% IV, 
granulocyte colony stimulating factor (G-CSF) SC alleen, of samen met 2mg DEXA IV dan 
wel 12.5mg PRED IV. Tien uur na de toediening van DEXA of PRED werd een vergelijkbare 
verlaging van het cortisol waargenomen; na 25 uur bleek slechts nog een verlaging na DEXA. 
Tussen 4 en 10 uur na DEXA of PRED toediening daalde de AUC  van OC ten opzichte van 
de AUC van OC zonder exogeen GCs met respectievelijk 24.4 en 2.3%. Evenals bij cortisol 
bleek dit effect 25 uur na DEXA nog aanwezig. De AUC van ECP tussen 5 en 10 uur na 
PRED toediening werd 23.2 % lager (p<0.02) terwijl effect na DEXA uitbleef. Dit effect na 
PRED bleek na 25 uur verdwenen. De conclusie van de studie was, dat DEXA en PRED in 
veronderstelde klinisch overeenkomende doses alleen gedurende de eerste 10 uur een 
vergelijkbare verlaging van het endogeen cortisol geven terwijl de effecten ten opzichte van 
OC en ECP hiervan afweken. 
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In Hoofdstuk IV wordt het onderzoek uit  hoofdstuk III uitgebreid met een PK/PD model om 
de vastgestelde klinische effecten van GCs in gezonde en astmatische mannen verder te 
verklaren. Gedurende 3 gerandomiseerde sessies van 25 uur werd aan 8 gezonde en 6 
astmatische mannen G-CSF SC alleen, of in combinatie met 2mg DEXA IV of 12.5mg PRED 
IV toegediend. Effecten ten opzichte van cortisol, lymfocytenaantallen, OC en ECP werden 
simultaan gemeten. Alle effectparameters konden met behulp van een mathematisch model 
worden beschreven, echter bij ECP gold dit voor 7 gezonde en 4 astmatische mannen. De 
voorspelde endogene cortisol productie herstelde zich binnen de observatie periode alleen na 
PRED bij de gezonde mannen terwijl dit herstel zowel na DEXA als PRED optrad bij de 
astmatische mannen. Bij de astmatische mannen die hun ICS gedurende een week hadden 
gestopt, was de gemiddelde ochtend cortisol concentratie ca 60% van de concentratie bij 
gezonde mannen. DEXA had de sterkste ‘efficacy’ (Emax) met betrekking tot alle effect 
parameters met ECP als uitzondering. De Emax van DEXA t.a.v. ECP was bij astmatici hoger 
dan bij gezonde mannen. Voor alle effectparameters gold dat de rangorde van de potenties 
(EC50) identiek was: DEXA>PRED>cortisol. Ondanks deze overeenkomstige rangorde, 
bleken EC50’s echter wel per effect parameter te verschillen. Met behulp van PK/PD 
modelling bleek het mogelijk relatieve potenties ten opzichte van cortisol, lymfocyten 
aantallen, OC en ECP te bepalen. De Emax van DEXA ten opzichte van cortisol, lymfocyten 
aantallen en OC bleken hoger dan die ten opzichte van ECP. Omgekeerd bleek de Emax van 
PRED ten opzichte van ECP hoger dan die van DEXA. De Emax’s ten opzichte van 
bovengenoemde effectparameters bleken tussen gezonde en astmatische mannen verschillend. 
De berekende AUC’s voor cortisol, lymfocyten aantal en OC waren in overeenstemming met 
de geschatte EC50 waarden voor DEXA en PRED. De EC50’s voor DEXA en PRED ten 
opzichte van ECP bleken niet overeenkomstig de berekende AUC’s. Dit laatste illustreert de 
paradoxale remming van een nauwelijks actieve agonist (cortisol) in aanwezigheid van een 
relatief veel sterkere agonist (DEXA of PRED). Het kan niet uitgesloten worden dat deze 
verschillen tussen gezonde en astmatische mannen niet alleen zijn toe te schrijven aan 
recentelijk ICS gebruik, aangezien astma ook hierin een rol zou kunnen spelen. Zonder dat 
hierover meer duidelijkheid bestaat moet men voorzichtig zijn met het bepalen van potenties 
van GCs in astmatici. De conclusie van de studie was dat DEXA en PRED, in verondersteld 
klinisch overeenkomstige doses, per effectparameter een andere potentie bleken te hebben, 
terwijl de rangordes van de potenties wel overeenkwamen met de klassieke opvattingen. 
 
In Hoofdstuk V worden de klinische gevolgen beschreven van patiënten, die langdurig 
epiduraal methylprednisolon (MP) toegediend hadden gekregen. De aandacht werd hierbij 
speciaal gericht op de botdichtheid (BMD). In een transversaal onderzoek werden 14 mannen 
en 14 post-menopauzale vrouwen, met moeilijk behandelbare lage rugpijn onderzocht. Bij 
twee nooit met GCs behandelde personen, 1 man en 1 vrouw, werden MP en cortisol 
bepalingen verricht, voorafgaande aan en na het eerste epidurale MP depot (160mg). De 
cortisolconcentraties waren gedurende 6 dagen volledig onderdrukt en herstel trad ten dele op 
in de loop van 30 dagen. Het MP bleef meetbaar gedurende deze gehele periode. Bij de 28 
personen, die allen cumulatief met minstens 3 gram MP waren behandeld, werden endocriene 
parameters in relatie tot de BMD meetresultaten onderzocht. De cumulatieve MP dosis 
bedroeg (gemiddeld±1SD) 7.76±4.23g bij de mannen en 8.50±3.13g bij de vrouwen. Bij de 
mannen werd geen osteoporose vastgesteld maar wel osteopenie in 78.5%. De helft van de 
vrouwen had osteoporose en de andere helft osteopenie. De BMI en de endogene oestradiol 
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concentraties bij de mannen bleken niet gerelateerd te zijn met BMD. Univariate lineaire 
relaties werden bij de vrouwen echter wel gevonden namelijk tussen BMI en BMD van de 
lumbale wervel kolom (LWK) (r:0.62; p=0.02) en de totale heup(r:0.62; p=0.02), echter niet 
met het collum femoris. Verder werden er bij vrouwen relaties gevonden tussen - zowel het 
totaal als de voor eiwit gecorrigeerde - oestradiol concentraties en BMD van de LWK (r:0.70; 
p=0.01 en r:0.72; p=0.01) en de totale heup (r:0.53; p=0.08  en r:0.56; p=0.05). Er bestond 
geen relatie tussen beide oestradiolfracties en de BMD van het collum femoris. Een eenmalig 
MP depot leek farmacokinetisch op een continu infuus met een lage piekconcentratie. De 
toediening van meerdere MP depots liet geen relatie zien tussen de cumulatieve dosis en 
BMD, wel bestond er bij vrouwen een relatie tussen de BMD van lumbale wervelkolom en de 
totale heup met BMI en oestradiol. De conclusie van deze studie ondersteunt de hypothese dat 
er bij overigens gezonde mannen en post-menopauzale vrouwen geen cumulatieve GC dosis-
effect relatie bestaat met BMD, gegeven een langdurige continue GCs belasting met lage piek 
dosis. 
 
In Hoofdstuk VI wordt, Quantitative Ultra Sound (QUS), een alternatieve opsporings-
methode voor osteoporose, geëvalueerd en beschreven. 217 pre- en post-menopausale 
vrouwen tussen 25 en 75 jaar werden geïncludeerd, die verwezen waren voor een BMD 
bepaling, omdat er osteoporose was geconstateerd bij tenminste één eerste of tweedegraads 
familielid. Een QUS meting van de calcaneus en een DXA meting van de LWK, de totale 
heup en het collum femoris werd verricht. Lineaire regressie van twee QUS parameters - 
‘broadband ultrasound attenuation’ (BUA) en ‘speed of sound’ (SOS)- met DXA op de 
verschillende niveau’s lieten in de groep als geheel een correlatie zien van respectievelijk 0.53 
en 0.54 (p<0.0001). Deze correlaties waren significant lager wanneer BUA en DXA van de 
totale heup en het collum femoris van de premenopausale groep: (n=80) r=0.31 en 0.38  
(p<0.0001) werden vergeleken met die van de postmenopausale groep: (n=137) r=0.56 en 
0.53 (p<0.0001). Er bestonden geen significante verschillen tussen de regressie coëfficiënten 
met SOS tussen deze groepen. De prevalentie van osteoporose in de totale groep was 25% 
(6% in de pre- en 36% in de post-menopausale groep). BUA miste alle 5 casus met DXA 
gediagnosticeerde osteoporose onder de 80 premenopausale vrouwen en 20 van de 50 met 
DXA gediagnosticeerde osteoporose casus onder de 137 postmenopausale vrouwen. SOS 
metingen correleerden nog slechter. De conclusie van het onderzoek was dat de positief 
voorspellende waarde van QUS parameters voor het voorspellen van de met DXA gemeten 
osteoporose laag is en daarom niet afdoende om een DXA meting te vervangen. 
 
In Hoofdstuk VII worden verschillende wijzen van toediening van GCs in relatie tot BMD 
bestudeerd. DXA metingen werden vergeleken bij 4 groepen COPD patiënten, behandeld met 
continu orale systemische GCs, meerdere z.g. GCs stootkuren (oraal of IV) en COPD 
patiënten die nooit met een systemische GCs therapie waren behandeld. Aan dit transversale 
onderzoek  namen 86 Caukasische mannen met COPD deel. Tien patiënten werden behandeld 
met dagelijks oraal prednisolon (Groep 1); 11 patiënten met meerdere prednisolon 
‘stootkuren’, van maximaal 2 weken per kuur daarbij een cumulatieve dosis van 1000mg 
overschrijdend (Groep 2); 28 patiënten met stootkuren tot een cumulatieve dosis van 1000mg 
(Groep 3); 37 patiënten die nooit behandeld waren met systemische GCs (Groep 4). Alle 
groepen bleken in evenwicht voor leeftijd en rookgedrag. In Groep 2 werd een lagere BMI, 
een lagere FEV1 en een hogere mate van hyperinflatie gevonden. De cumulatieve systemische 
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prednisolon dosis was het hoogst in Groep 1. DXA-metingen van de LWK, de totale heup en 
het collum femoris toonden voor alle patiënten osteoporose aan (T-score £ 2.5 SD) bij 27 
(31%), 31 (36%) en 34 (40%) patiënten. Bij patiënten uit Groep 2 werden voor LWK, totale 
heup en collum femoris de laagste BMD-waarden gemeten: (gemiddeld±1SD) 0.759±0.238, 
0.683±0.115, and 0.686±0.125g/cm2, (p<0.0001). Na multivariate regressie analyse bleef 
alleen een correlatie over tussen de cumulatieve dosis van prednisolon en de BMD van de 
LWK (gecorrigeerde r=0.48; p<0.01), terwijl op het niveau van de totale heup en het collum 
femoris slechts een correlatie werd gevonden met BMI (respectievelijk gecorrigeerde r=0.65 
and 0.58; p<0.0001). De conclusie van het onderzoek was, dat er ondanks een in vergelijking 
met Groep 1 veel geringere cumulatieve prednisolon dosis, na correctie voor BMI en 
longfunctie, een gemiddeld veel lagere BMD van de LWK werd vastgesteld in Groep 2 
(stootkuren >1000mg). 
 
Conclusies 
 
De onderzochte GCs bleken in verschillende mate effectief te zijn ten aanzien van een aantal 
onderzochte uitkomstparameters; cortisol, lymfocyten aantallen, tyrosine, osteocalcine (OC) 
en eosinophilic cationic protein (ECP). De onderzoeksresultaten bevestigden de hypothese dat 
de oudere bio-assays, welke tot de klassieke aannames van differentiële klinische effectiviteit 
hebben geleid, onvoldoende bruikbaar zijn voor verder onderzoek. Bovendien geldt dat 
PK/PD modelling aangewezen is als instrument om potenties van verschillende GCs na te 
gaan, bij voorkeur aan de hand van meerdere biologische parameters. Van belang daarbij is 
dat relevante klinische informatie werd verkregen uit de bestudering van een 
ontstekingsparameter (ECP) toegevoegd aan de al eerder beschreven uitkomstparameters van 
GCs. Om die reden werd een nieuw model ontwikkeld, namelijk ECP stimulatie na toediening 
van granulocyten colony stimulating factor (G-CSF). 
 
Richting voor toekomstig onderzoek 
 
Verschillende klinische effecten en potenties van GCs werden na systemische toediening 
(oraal en IV) tot nu toe bestudeerd. Toekomstige onderzoeken op het gebied van inhalatie 
corticosteroïden vormen een nieuwe uitdaging, waarbij naast klinische effecten eveneens 
aandacht moet worden gegeven aan het spectrum van potenties in plaats van te spreken van 
één potentie.  
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Dankwoord 
 
Aan het einde van de periode die ik aan dit proefschrift heb besteed, denk ik met veel plezier 
terug aan een belangrijke episode in mijn loopbaan, waarin het resultaat haast kan worden 
omschreven als: ‘liber amicorum’, zij het dat dit boek is geschreven mèt in plaats van dóór 
goede vrienden, welke ik jaren geleden heb ontmoet. Allen, die de afgelopen periode hebben 
bij gedragen aan het ontstaan van dit proefschrift dank ik dan ook ‘vriendelijk’. In het 
bijzonder zou ik willen bedanken: 
 
Prof. Dr. P.N.R. Dekhuijzen. 
Hooggeleerde heer, beste Richard, onze opleidingstijd in het Onze Lieve Vrouwe Gasthuis te 
Amsterdam, nu zo’n 20 jaar geleden, werd naast het leerproces met name gekenmerkt door je 
uitstekende gevoel voor humor. Nadien scheidden zich onze wegen, maar bleef onze 
vriendschap, ook van onze gezinnen, bestaan. Het was voor mij heel bijzonder om jouw 
promovendus te zijn geweest. Naast je vriendschap, waren je objectiviteit, je scherpe visie en 
commentaren gecombineerd met je uiterst snelle revisie van de manuscripten zeer inspirerend. 
 
Prof. Dr. C.J. van Boxtel. 
Hooggeleerde heer, beste Chris, als ‘dictaatschrijver’ van je colleges klinische farmacologie 
ontmoette ik je in 1976. 20 jaar later tijdens een congres, ontmoeten wij elkaar opnieuw. 
Onze hernieuwde samenwerking kreeg wel een ander karakter. Na eerst deel te nemen in het 
wetenschappelijk onderzoek van één van je promovendi, kwam later dit proefschrift, 
waarvan jij de initiator bent geweest, tot stand. Ik dank jou voor alle zeer noodzakelijke 
ondersteuning op klinisch farmacologisch gebied, want ondanks alle gevolgde colleges 
(uiteraard om dictaat te schrijven) bleef dit toch een vakgebied waar ik als klinische longarts 
weinig parate kennis van had. 
 
Dr. D.H. Schweitzer. 
Zeergeleerde heer, beste Dave, na ons eerste co-schap interne verloren wij elkaar jarenlang 
uit het oog. Onze vriendschap hernieuwde zich in 1995, toen jij specialist werd in het zelfde 
ziekenhuis. Wanneer we alle momenten die jij me - als goede vriend en copromotor - hebt 
bijgestaan hier zouden beschrijven, zou dit een te dik proefschrift worden, met hoog 
vriendschappelijk- maar te laag wetenschappelijk gehalte. Het ene na het andere “stukje” - 
zoals we een manuscript noemden - verscheen van onze “handen en laptops”, waarbij steeds 
onze complementaire krachten zich bundelden. Dit proefschrift heeft onze vriendschap 
letterlijk op de proef gesteld en verdiept. In het bijzonder zou ik hier ook Myra en de 
kinderen zeer hartelijk willen bedanken. Onze ‘stukjes’ hebben ongetwijfe ld veel van jouw 
aandacht en tijd voor hen ontnomen, ik hoop dat in de komende tijd enigszins goed te kunnen 
maken. 
 
Dr. M.G.M. Derks 
Zeergeleerde heer, beste Michiel, jij was de promovendus van Prof. Dr. van Boxtel, waarmee 
de samenwerking met de afdeling klinische farmacologie begon. Na het voltooien van je 
eigen proefschrift bleef onze samenwerking doorgaan en nam je enthousiast deel in een 
aantal van de ‘modelling’studies. Je waardevolle kennis en kunde op dit gebied heb ik naast 
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je vriendschap zeer gewaardeerd en ik ben dan ook zeer verheugd dat je optreedt als één van 
mijn paranimfen.  
 
Drs. E. Röder 
Lieve Esther, vanaf het begin van mijn praktijk in Voorburg ben je betrokken geweest bij 
verschillende wetenschappelijke onderzoeken. Ook bij diverse onderzoeken in dit 
proefschrift heb je een grote ondersteunende rol gespeeld in de klinische uitvoering en deel 
van het status onderzoek en recent nog, in het doorlezen van het manuscript op punten en 
komma’s samen met je Mr Drs Ewald, die ik uiteraard ook vriendelijk dank. Buiten dit ben je 
als een dochter in ons gezin en ben ik zeer blij dat jij ook de rol van paranimf op je wilt 
nemen.  
 
Dr. M.G.M. Wagemans 
Zeergeleerde heer, beste Michel, jou wil ik hartelijk bedanken en met jou je collega’s voor de 
medewerking die we kregen bij het onderzoeken van de pijn-polikliniek patiënten. 
 
Dr. J.P.M. Wagenaar. 
Zeergeleerde heer, beste Jan, met zeer veel plezier denk ik terug aan mijn tijd bij jou als 
assistent in opleiding in het Onze Lieve Vrouwe Gasthuis. Ook nadien hebben jij en Wil mij 
met raad en daad bijgestaan, vooral ook in de begin periode van de praktijk in Voorburg. 
 
Prof. Dr. A.H. Zwinderman 
Hooggeleerde heer, beste Koos, bedankt voor jouw waardevolle en niet alleen statistisch 
significante ondersteuning. 
  
Mevrouw I. Bosman 
Beste Ineke, jou wil ik hartelijk danken voor het coördineren, behandelen en bewaren van 
alle bloedmonsters door de jaren heen bij alle onderzoeken in de Reinier de Graaf Groep.  
 
Mevrouw E. Portier 
Beste Els, jou wil ik hartelijk bedanken voor je zorgvuldigheid en ondersteuning bij het 
bepalen van de vele glucocorticoid monsters. 
 
De heer M. Batelaan 
Beste Martin, jou wil ik hartelijk bedanken voor het verzorgen van alle immuno-assay 
bepalingen en de hulp bij het inrichten van een ‘ambulante laboratorium faciliteit’. 
 
Alle patiënten en arts assistenten, die hebben deelgenomen aan deze onderzoeken, wil ik bij 
deze hartelijk bedanken. 
 
Mijn collega’s in de Reinier de Graaf Groep dank ik voor de morele ondersteuning door de 
jaren heen. 
 
De Wetenschappelijke Advies Commissie van de Reinier de Graaf Groep dank ik hartelijk 
voor de financiële ondersteuning, met welke de kosten van het gebruik van materialen van 
het ziekenhuis ten behoeve van enkele onderzoeken konden worden gedekt. 
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De Medisch Ethische Commissie  van de Reinier de Graaf Groep dank ik hartelijk voor het 
beoordelen van de protocollen en de waardevolle adviezen. 
 
 
Lieve Alain en Guy, dit proefschrift was als een berg die ik met vrienden heb beklommen, de 
volgende berg beklim ik met jullie! 
 
Lieve Albertine, zoals bij velen te lezen valt, vormt de echtgenote vaak het fundament voor 
een karwei zoals dit, het schrijven van een proefschrift, dat meestal enige jaren kost. 
Ondanks dat jij voor mij heel bijzonder bent, vorm ook jij hierop geen uitzondering. Je liefde 
en zorgzaamheid voor ons gezin en de vrijheid, die je mij liet om de nodige tijd aan dit 
proefschrift te besteden, stelde mij in staat dit te volbrengen. 
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 Stellingen 
 
behorend bij het proefschrift:  
Pharmacological and clinical aspects of treatment 
with glucocorticoids.  
E.F.L. Dubois, Nijmegen, 22-04-2004 
 
1. Relatieve potenties van verschillende glucocorticoiden ten opzichte van elkaar kunnen 
niet worden voorspeld vanuit hun relatieve bijnierschors-remmende effect, maar 
verschillen per orgaansysteem. (Dit proefschrift) 
 
2. Vergeleken met continue systemische glucocorticoid therapie, geeft het behandelen 
met ‘korte stootkuren’ bij veel lagere cumulatieve dosering een veel hoger risico op 
het ontstaan van osteoporose. (Dit proefschrift) 
 
3. Er zijn aanwijzingen dat glucocorticoid-geïnduceerde osteoporose (GIOP) bij 
stootkuren gerelateerd is aan de cumulatieve dosis. (Dit proefschrift)  
 
4. Door Granulocyte Colony Stimulating Factor (GCSF) gestimuleerd Eosinophilic 
Cationic Protein (ECP) is bruikbaar als een ontstekingsmodel bij onderzoek naar de 
klinische potenties van glucocorticoiden. (Dit proefschrift) 
 
5. ‘Bij het kinderasthma (bronchitis asthmatica) komen andere aetiologische momenten 
in aanmerking dan bij het asthma bronchiale der volwassenen.’ (Stelling V, Uit: thesis 
Universiteit van Amsterdam, Dr. F.G.J. Dubois, 5 juni 1923) 
 
6. Quantitative Ultra Sound (Q.U.S) is geen goed alternatief voor Dual X-ray 
Absorptiometry (D.X.A.) bij de opsporing van osteoporose. (Dit proefschrift) 
 
7. Bij farmaco-dynamisch onderzoek van glucocorticoiden zijn uitkomsten bij gezonde 
vrijwilligers niet zonder meer te extrapoleren naar patiënten. (Dit proefschrift) 
 
8. Voor het bepalen van klinische potenties van glucocorticoiden zijn farmaco-kinetische 
en farmacodynamische bepalingen waarschijnlijk even belangrijk als klinische 
uitkomsten. (Dit proefschrift) 
 
9. Glucocorticoiden toegediend als epiduraal depot preparaat, gedragen zich 
farmacokinetisch als een continu infuus. (Dit proefschrift) 
 
10. Artsen ‘zonder grenzen’ nemen grote risico’s. 
 
11. Van alle (drog-)redenen om te blijven roken krijgt een longarts op den duur tabak. 
 
12.  “Tobacco smoking” wordt in de Angelsaksische literatuur afgekort met “T.S.”, 
hetgeen niet tot misverstanden hoeft te leiden. 
